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EXECUTIVE SUMMARY
This summary presents the main results of a European collaborative work on
how to identify and understand early changes in drug use or new drugs more 
quickly than by using standard monitoring systems. It gives a general and theore-
tical overview of the dynamic process of an Early information function (EIF) for
Emerging Drug Phenomena (EDP). This document is structured in three parts: firs-
tly, a presentation of the context, objective and methods of the project; secondly,
a synthesis of the results: the structure and operation of an Early Information 
Function for Emerging Drug Phenomena; and thirdly, the prospects for this issue.
I THE PROJECT CONTEXT, OBJECTIVE AND METHOD
In Europe, drug use is considered a high priority concern. In order to deal with
the various issues related to drug use, consideration has been given to the imple-
mentation, development and improvement of monitoring systems (Drug Informa-
tion Systems) as a means of obtaining operational knowledge on drugs and drug
use. The creation in 1993 and subsequent development of the European Monito-
ring Centre on Drugs and Drug Addiction (EMCDDA), which is based on the deve-
lopment of a network of National Focal Points (REITOX), enabled the operation
and linking of national Drug Information Systems (DISs) and an improvement in
their compatibility. The information produced by a dis must allow a better unders-
tanding of certain drug-related phenomena and facilitate decision-making at the
policy-maker, professional and individual level. 
At present, various models of dis exist in European countries. Frequently, these
are rooted in standard sources which provide interesting data but which often have
a considerable time lag behind any actual changes in the drugs field. This lack of
sensitivity is harmful to the early identification of changes or new phenomena rela-
ted to drugs and drug use. Moreover, the fast circulation of new drugs and new pat-
terns of use within Europe highlights the high probability of rapid changes in the
drugs field. The need to identify these changes more quickly was perceived by
various actors working in drug monitoring systems and led to the Euro-TREND pro-
ject being promoted in 2000.
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Main Lines, Areas of Interest and Indicators
In order to work properly, an EIF needs first to focus on selected topics. To
address this concern, a three-tier information structure was defined. This includes
three main lines of inquiry (users, substances and settings). Each of these cor-
responds to different Areas of Interest which help to draw together the points that
are considered most interesting (e.g. for the “user” main line of inquiry, the areas
of interest include demographic characteristics, patterns of use and health conse-
quences). Indicators are chosen for each area of interest. During the operational
process of the EIF, information on these indicators will be collected and analysed.
Operational steps of an EIF
In order to make the EIF operational, a five-step dynamic model was develo-
ped. The steps identified are: data collection, identification, assessment, dissemi-
nation, and follow-up and feedback (see the following figure).
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The main objective of Euro-TREND project was to define and describe a pos-
sible common model of an Early Information Function (EIF) for Emerging Drug
Phenomena (EDP) in order to make the Drug Information Systems in the partici-
pating countries more sensitive to EDP and more compatible with each other.
Within this context, several European countries (namely, France, Germany,
Greece, Netherlands, Portugal, Spain, and Sweden1) decided to participate in the
Euro-TREND project which started at the beginning of 2002. The project was co-
funded by the European Union and the participating countries. Two European agen-
cies, the EMCDDA and the European Agency for the Evaluation of Medicinal Pro-
ducts (EMEA), contributed by following the process and participating in the general
meetings. 
The project was structured in six work phases. For each of these, except the
last (drafting of the manual), the work was divided into three steps. First, a Euro-
pean Proposal was produced by a working party consisting of the coordination
team and some of the coordinators from the participating countries. Secondly, this
European Proposal was critically discussed at national level by experts who also
had to put together a synthesis of their national situation in respect of the phase
topic. Finally, a synthesis taking into account all the national reports was drawn
up by the project coordination team and validated at the European level by all the
participating countries and European agencies. 
The manual produced, drawn up mainly on the basis of synthesis documents,
tries to provide information on the description and working outline of what is 
called an Early Information Function (EIF) for Emerging Drug Phenomena (EDP),
within a national or local/regional DIS. 
II PROJECT RESULTS
It was considered that a Drug Information System had to fulfil various functions.
One of these, regarded as the central point of this project, is the Early information
function for Emerging Drug Phenomena (EIF for EDP). This function needs 
quickly to identify, assess and categorize Emerging Drug Phenomena in order to
allow the production of relevant information and its timely dissemination to target
audiences.
12
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1. The corresponding institutions were: OFDT, IFT, UMHRI, Trimbos Institute, IDT, Valladolid University/DGPND,
NIPH.
The Early Information Function for Emerging Drug Phenomena:
An outline of the operational steps
Data collection
Identification
Assessment
Dissemination
Follow-up and feedback
and its dissemination to different target audiences must be carefully considered.
This process implies definition of the purposes of the information dissemination
(what do we want to do?), selection of the target audiences (who do we want to
inform?) and selection of the dissemination methods (how do we want to disse-
minate?). Target audiences may belong to different sub-groups, such as policy-
makers, professionals, information specialists and specific groups, or the general
population. In general, the EIF has to provide an appropriate information format.
The EIF team should be responsible for the production of recommendations on the
purposes, target audiences and dissemination methods. Recommendations should
be validated by a group of people appropriate to the national context. The results
of the actual dissemination to the target audiences should permit the early reduc-
tion of a potentially harmful phenomenon.
Feedback and follow-up
To end the cycle and to begin a new one, feedback information will be sent by
the EIF team to all those participating in the data collection, and a follow-up pro-
cess will be carried out for all interesting topics. This implies that the new data
collection period will have to continue to gather data on all topics of interest from
the previous cycle.
The manual
The project outcomes have been laid down in the manual. In addition, this pro-
vides a description of concrete examples of national solutions for an EIF and a
detailed overview on the sources and methods for data collection and dissemina-
tion. The national situation in the participating countries is described in an annex.
III PROSPECTS
The development of an EIF within a Drug Information System complements the
traditional monitoring of indicators and trends. A properly functioning EIF will be
able to inform the target audiences in a shorter period of time, in order to promote
actions aimed at reducing harm for users and the general population. The produc-
tion of this information will be of less interest if it is not is linked to actions. 
The heterogeneity of the DISs in the countries that participated in this project
implies that the proposed model is sufficiently adaptable to cope with different
national realities. Even though it is rooted in the previous experiences of the par-
ticipating countries, this work remains a theoretical model of a possible EIF for
EDP. It should be read critically and adapted in the light of national/local contexts
and experiences. It is aimed at helping people who already participate in an EIF and
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Data collection
Co-ordination of the data collection seems essential in order to make it fully ope-
rational. It has to address two key points: the elusive nature of drug use and the avai-
lability of resources. Data collection includes collecting, describing and storing as much
relevant data as possible with as much detail as possible. It is a process that requires
a variety of information sources (i.e., drug users, low-threshold facilities, health ser-
vices, criminal justice settings, recreational nightlife settings, etc.), data collection
professionals, data collection methods (i.e., population surveys, observations, inter-
views, focus groups, etc.) and instruments (i.e., questionnaires, interview guidelines,
etc.). The many and varied data collection tools will allow the EIF to obtain infor-
mation from different sources and by different methods which will facilitate the iden-
tification step. Pre-existing general data collection tools that deal with the EIF’s main
lines of inquiry should be included and optimised to make them as functional as pos-
sible for EIF purposes. Where necessary, specific EIF tools will be developed. These
tools will have to be robust and flexible and produce valid and reliable data. 
Identification
The next step in the process leads to the identification of an Emerging drug
phenomenon (EDP). Various analyses of the data previously collected are neces-
sary for the identification of an EDP. At the end of these analyses, all the availa-
ble information for each chosen indicator is compared to discover any significant
changes and possibly to identify an EDP.
Assessment
When an EDP is identified, it has to be described in as much detail as possi-
ble. It has to go through a standard assessment process which will use all the
information already available on this EDP. Some EDP will be considered of high
concern and thus meriting a specific assessment. Within this framework, four
criteria are considered helpful for categorizing the EDP as a candidate for a spe-
cific assessment: diffusion potential, health consequences, social consequences
and economic consequences. This categorization, along with other aspects (e.g.,
available resources, decision-maker interest, etc.), will help in deciding whether
or not to undertake a specific assessment. It implies a more in-depth analysis and
sometimes additional data collection, enabling a detailed description of the cho-
sen EDP to be produced in a short time-span. All standard and specific assess-
ments will end with a written report.
Dissemination
Once EDP are identified and assessed, a dissemination strategy must be desi-
gned. A great deal of information is available in the assessment reports produced
14
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INTRODUCTION
In Europe, drug use is considered a high priority concern. In order to deal with
the various issues related to drug use, consideration has been given to the imple-
mentation, development and improvement of monitoring systems as a way of obtai-
ning knowledge on drugs and drug use. The creation and development of the Euro-
pean Monitoring Centre on Drugs and Drug Addiction (EMCDDA), which is based
on the development of a network of National Focal Points (REITOX), enabled the
operation and linking of national monitoring systems and an improvement in their
compatibility.
The general purpose of a national/regional Drug Information System (DIS) is
to produce reliable information on drugs and drug use. The information produced
allows a better understanding of certain drug-related phenomena and facilitates
decision-making at the policy-maker, professional and individual level. 
In European countries, various models of DIS exist. Frequently, these are roo-
ted in standard sources (i.e. data derived from law-enforcement activity statistics,
specialized care services, and general population surveys, etc.), which provide
interesting data but which frequently have a considerable time lag behind any actual
changes in the drugs field. In general, this time lag is linked to at least two factors:
(i) the production of activity statistics may not be aimed at a monitoring strategy
but may be used primarily for administrative purposes, and (ii) early changes in
drug use are not seen by these sources because of the elusive nature of the popu-
lation. This lack of sensitivity is prejudicial to the early identification of changes
or new phenomena related to drugs and drug use. Moreover, the fast circulation of
new drugs and new patterns of use within Europe highlights the high probability
of rapid changes. The need to identify these changes more quickly was perceived
by various actors working in monitoring structures and led to the Euro-TREND
project being promoted. Many aspects of this problem had been already studied in
a project funded by the EMCDDA and coordinated by Griffith (Griffiths et al.,
1999).
Within this context, several European countries (France, Germany, Greece,
Netherlands, Portugal, Spain, and Sweden), which were interested in the idea of
promptly receiving relevant information on Emerging Drug Phenomena (EDP),
participated in the Euro-TREND project. Two European agencies, the EMCDDA
and the European Agency for the Evaluation of Medicinal Products (EMEA), contri-
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people who are willing to implement and/or develop an EIF in their own country.
Available information sources will vary from country to country. Available resour-
ces for an EIF will also vary and, thus, the volume of work will also change. The
political structure of a country (federal or centralized) will certainly have an influence
on the final design of a national EIF as well. In any case, the implementation of such
a function is not a short-term process and it is necessary to have the time to be able
to build a function that works properly.
It is worth stating that organising our work at two levels (national and European)
allowed us to develop and strengthen the national groups of experts committed to
this problem within the participating countries. It appears that this sort of group
can be a firm cornerstone in the construction of an EIF.
The expected results should merit the investment. With the development of the
European community and the acceleration of exchanges of people and knowledge,
a collaboration between European countries is very necessary. A commonly sha-
red model for an EIF will obviously facilitate the exchange of information on iden-
tified and assessed Emerging Drug Phenomena and collection, analysis and disse-
mination techniques. New developing drugs, emerging patterns of use and emerging
harms will be identified much earlier than with a standard monitoring system. It will
allow earlier intervention and avoidance of the significant burden of suffering and
expenditure in the care and law-enforcement fields.
The next stage in this work is due to address a variety of aspects:
- Adaptation of the EIF model to the different national realities in the partici-
pating countries and other interested European countries.
- Development of the process of exchanging information on EDP and on the
technical aspects (data collection tools, analysis methods, dissemination
methods) of the EIF among interested countries.
- The development of a European EIF for EDP, which implies not only exchan-
ges of information but also the analysis and dissemination of information at
the European level. 
- Improvement and refinement of this model is obviously necessary. Although
the practical experiences of the countries are an efficient way of improving the
model, periodic discussion of the more theoretical aspects should help to refine
it.
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dered in developing the dissemination strategy and deals with how to develop this
dissemination strategy. Finally, chapter 5 deals with follow-up and feedback, which
are closely related to the use of the information produced by the EIF. From 
chapter 2 to chapter 5, practical issues are provided for promoting a pragmatic
implementation of the EIF. In addition, national examples are presented in order
to illustrate certain theoretical elements.
A glossary is available at the end of the manual. The glossary includes opera-
tional definitions of key concepts (indicated with a red fount), as well as definitions
from reference books/authors for other concepts related to public health in gene-
ral. 
The appendix contains a summary of what already exists at national level in
the participating countries which may contribute to the implementation of an EIF.
This appendix volume presents, for each participating country, what is already
available at national level and the prospects for implementing the EIF. The content
of the appendix volume is derived from the meetings of national experts which
took place in each country during each work phase of the project.
Although the content of the manual is based to a large extent on the practical
experiences of the participating countries, it remains a theoretical document and
needs to be refined in order to fit the daily reality of our Drug Information Sys-
tems. We hope that this document will be of help to those involved in improving
monitoring systems on drug abuse and thus in improving the situation of people 
suffering as a result of drug use. Naturally, any comments and experiences relating
to this problem are welcome. 
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buted by following the process and participating in the general meetings. The aim
of the project was to define and describe a possible common model of an Early
Information Function (EIF) for Emerging Drug Phenomena (EDP). The imple-
mentation of the model within the existing national Drug Information Systems
(diss) in the participating countries should make these systems more sensitive to
Emerging Drug Phenomena (EDP). 
This manual is based on the results of the work produced during the Euro-
TREND Project from January 2002 until December 2003. The project was struc-
tured in six work phases and for each of these, except the last one which corresponds
to the drafting of this manual, the work was divided into three steps. Firstly, a Euro-
pean proposal was produced by a working party of European experts. Secondly, this
European proposal was critically discussed at national level by experts who also
had to produce a synthesis of their national situation in respect of the phase topic.
Finally, a synthesis taking into account all the national reports was drawn up by the
project coordination team and validated at the European level by all the participa-
ting countries and European agencies. Drawn up primarily on the basis of synthe-
sis documents agreed during each phase of the project, this manual therefore pro-
vides an initial view of the methods, and the organizational and practical means for
quickly identifying and assessing changes related to drugs and drug use. The theo-
retical model of the EIF for EDP presented in this manual should therefore be read
critically and adapted in the light of national/local contexts and experiences. 
The objective of this manual is to share with those countries that did not parti-
cipate in the development of the project, and/or with people within the participa-
ting countries, the main results of the work carried out during this project. It tries
to provide description information and a working outline of what is called an Early
information function (EIF) for Emerging Drug Phenomena (EDP), within a natio-
nal or local/regional DIS. It should help people already participating in an EIF and
people intending to implement and/or develop an EIF in their own country.
The manual has been drafted in English and will be available in other langua-
ges.
An overall presentation of the main objective of the EIF and the characteristics
of the EIF for achieving this objective is given in the first chapter. This presents the
dynamic ongoing process of the EIF, which is structured in five operational steps,
and the information structure adopted. 
The following chapters give a further description of the operational steps of the
EIF. After presenting key data collection elements (information sources, data col-
lection methods), chapter 2 provides some organizational and practical explana-
tions for operating the data collection step. chapter 3 deals with the data analysis
process, including both the identification step and the assessment step. It defines
and describes the objective of each analysis level and then explains how to operate
them. chapter 4 deals with dissemination. It presents the key elements to be consi-
18
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1 - OBJECTIVE AND CHARACTERISTICS OF THE EARLY 
INFORMATION FUNCTION
Summary
Chapter 1 gives a general presentation and a basic description of an Early
Information Function (EIF) for Emerging Drug Phénomena (EDP).The EIF
should not be seen as a new information system but rather as a way of making
existing systems more sensitive. Firstly, chapter 1 is aimed at presenting the
main objective of the function. Secondly, it provides a description of the dyna-
mic process and briefly presents how to make the EIF operational. Finally, the
EIF information structure is presented.
An Early Information Function is intended quickly to identify, assess and
categorize Emerging Drug Phénomena in order to allow the production of rele-
vant Information and its timely dissemination to target audiences.To achieve its
objective, the EIF should be a dynamic model structured in five operational steps.
These steps are linked in an ongoing process.The first step is to collect as much
relevant data as possible about drugs and drug use.Then the data, which may
reveal new phenomena, is identified (second step).This data is subjected to an
assessment (third step) in order to provide a more detailed description and a bet-
ter understanding of the Emerging Drug Phénomena.After assessing the phe-
nomena, the strategy for disseminating the results is drawn up (fourth step).The
information produced by the EIF should be appropriately disseminated with the
aim of undertaking effective actions to deal with the EDP. Finally, it is important
to carry out and promote follow-up and feedback of the information produced
by the EIF (fifth step).
A three-tier information structure has been adopted: this is a means of
defining what types of information should be produced by the EIF. Firstly, three
main lines of inquiry (users, substances and setting), which are broad fields of
interest related to drug use, are identified and defined.Then, relevant areas of
interest are proposed for guiding the data collection and analysis of each main
lines of inquiry. Finally, these areas of interest are characterized by EIF indicators.
Particular focus is given to the EIF indicators that are most relevant to the
identification of an EDP - here called "EIF core indicators" 
Dissemination does not mean systematically spreading all available informa-
tion to everybody. The information has to be appropriately disseminated to target
audiences and should have credibility among them. Depending on the type of infor-
mation, different target audiences should be addressed (see 4.2.3). 
1.3. OPERATIONAL STEPS
In order to work properly, the EIF needs a defined information structure (see
1.4). A three-tier structure has been adopted. This includes main lines of inquiry
which are split into areas of interest. Each area of interest is described with selec-
ted EIF indicators. Once this structure is defined, the EIF will be able to focus on
priority information. 
The working outline of the Early Information Function is structured in a five-
step operational model (see figure 1). This model emphasizes that the EIF is a
continuous process. 
- data collection step 
- identification step: identification of EDP
- assessment step: standard and/or specific assessment of identified EDP
- dissemination step: selection and realization of a strategy for dissemina-
ting the information produced
- follow-up/feedback step.
Each step is described briefly in this chapter and in more detail in the follo-
wing chapters. 
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1.1. INTRODUCTION
Chapter 1 gives a description of the main objective of an Early Information
Function (EIF) for Emerging Drug Phenomena (EDP) and a general overview of
the different operational steps that have been identified. Within a Drug Information
System (DIS), an Early Information Function has to be able to deal with phenomena
of difficult access (low number of people, elusive population) and time constraints
(production of information within a defined time schedule). It is regarded as a dyna-
mic, permanent, ongoing process, which could have five different, but linked, steps:
data collection, identification, assessment, dissemination and feedback/follow-up.
These steps are presented in this chapter and described in more detail in the follo-
wing chapters. Additional concepts, such as Emerging Drug Phenomena and tar-
get audiences, are introduced. Finally, in its last section, chapter 1 presents the
three-tier information structure that has been adopted in order to define what types
of information should be produced by the EIF.
1.2. OBJECTIVE
The Early information function is one of the functions of the Drug Informa-
tion System (DIS) and needs to be sensitive to changes concerning drugs and drug
use. If this function is working satisfactorily, a variety of information on Emerging
Drug Phenomena may be produced and made available to the target audiences
(defined as people or groups of people to whom the information should be disse-
minated and which can be identified at several levels: European, national or
local/regional). It allows the development of actions against such potentially harm-
ful phenomena. In short, with this function the country, region, or province will be
better informed on early changes in the drug scene and thus able to avoid social harm
or harm to health.
The main objective of an Early Information Function is:
Quickly to identify, assess and categorize Emerging Drug Phenomena in order
to allow the production of relevant information and its timely dissemination to tar-
get audiences. 
The term Emerging Drug Phenomenon is understood to mean a drug-related
change which is observed for the first time. The fact that it is a first observation can
be linked to the fact that it is a new phenomenon or that it is a pre-existing pheno-
menon which has not been observed before but is perceived now for the first time.
An emerging drug phenomenon can, for example, deal with a new pattern of use,
a new drug, a new population, a new perception, etc.
22
1 - Objective and characteristics of the Early Information Function
1.3.2 Identification 
The identification step includes checking and identifying any relevant data from
among all the data collected in the collection step in order to produce relevant infor-
mation on EIF core indicators. The identification step consists, therefore, of deci-
ding whether it is worth continuing the process, i.e. undertaking an assessment of
the data collected. During the identification step, the information is compared (tri-
angulation) on the basis of reading grids in order to identify new phenomena. Iden-
tified EDP will be subjected to a standard assessment and sometimes to a specific
assessment. In the latter instance, the identification may generate the need to col-
lect more data. 
The identification strategy, i.e. the definition of selection criteria in relation to
the relevance of carrying out an assessment, is defined in more detail in Chapter 3
(see 3.3.2).
1.3.3 Assessment 
The assessment of the data derived from the identification step involves an ana-
lysis of the nature and extent of the phenomenon in order to describe the possible
consequences. The results of the assessment may provide further relevant data
likely to be used for the identification of other phenomena. 
The assessment process, which is described in detail in Chapter 3, starts with an
analysis, the standard assessment (see 3.3.3), of all the data available in the Early
information function data system. When it is possible to compare information from
different sources, the analysis is done in accordance with an analysis grid(s). The
result of the analysis is summarized in a standard assessment report. Finally, if neces-
sary, more data with a specific focus may be collected and a complementary assess-
ment report produced: this is the specific assessment (see 3.3.4). The decision on
whether to undertake a specific assessment will be made on the basis of the catego-
rization of the Emerging drug phenomenon and the resources available.
The assessment report should take into account the quality, i.e. reliability and
validity, of the information. The potential spreading of the phenomenon, i.e. its
potential to become an emerging trend, should also be taken into account in the
assessment. Finally, tje conclusion of the report should include the categorization,
according to the selection criteria (see 3.3.2.) assessed.
1.3.4 Dissemination 
After assessing and categorizing the phenomena, the strategies for using the
results of the assessment are defined. During this dissemination step recommen-
dations on effective actions should be made. Different dissemination strategies may
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1.3.1 Data collection
The data collection step includes collecting, describing and storing as much
relevant data as possible with as much detail as possible. Even a report on a single
case may be of interest. Even information considered as rumour should be repor-
ted.  In time this will provide the opportunity to confirm that it was only a rumour
or to describe its evolution into an Emerging drug phenomenon or a topic of inte-
rest. A high level of sensitivity in the collected data will allow earlier identification
of possible future problems and the development of more timely responses to future
problems.
Key elements relating to the data collection are described in more detail in
chapter 2. 
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Figure 1 - The Early Information Function for Emerging Drug Phenomena: An
outline of the operational steps
Data collection
Identification
Assessment
Dissemination
Follow-up and feedback
of interest are relevant and to find the EIF indicators that best characterize each
one. From all the EIF indicators, some are chosen as being of interest for the iden-
tification of EDP and, consequently, are called EIF core indicators. 
1.4.1 Main lines of inquiry
A main line of inquiry is a broad related to drug use. The main lines of inquiry
will serve as landmarks for collecting and analysing data that is relevant to identi-
fying, describing and analysing Emerging Drug Phenomena.  
In order to describe and analyse use-related drug phenomena, the EIF will have
to produce information on the narrow (directly related to the users) and broad
(socio-economic, political, etc.) setting. Therefore, the three main lines of inquiry
for data collection are:
- users, corresponding to any data or information on the person or closely
related to the person 
- substances, corresponding to any data or information on substances or clo-
sely related to these substances
- setting, corresponding to any data or information on the physical and social
environment. The narrow level relates to the user’s direct physical and social
environment. The broad level corresponds to the local, regional and natio-
nal environment. 
1.4.2 Areas of interest 
An area of interest is a particular topic of interest within a main line of inquiry.
For each main line of inquiry, various relevant areas of interest have been identi-
fied; together they form an interesting work set to guide the data collection and
analyses in the respective main line of inquiry. Table 1 presents the areas of inter-
est found to be relevant for each main line of inquiry.
Information on these main lines of inquiry and areas of interest will provide a
global picture of an Emerging drug phenomenon. This information allows it to be
described in its various dimensions, and provides the opportunity to look for links
between the different areas in order to understand the process of its development.
The Areas of interest are described in Table 1.
1.4.3 EIF Indicators
An EIF indicator is described as a variable, whatever its nature (qualitative or
quantitative), that reflects an interesting characteristic of drug use or related to drug
use. 
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be considered according to the nature of the information, the aims of the organi-
zation responsible for the dissemination and the various target audiences. Moreo-
ver, the type of information and the format to be used for disseminating the infor-
mation should be determined for each target audience. It is important that the
information released is easily understood and appropriate for the needs of the tar-
get audiences. It is also essential to avoid censorship of information and to ensure
credibility and the level of certainty in order to avoid false alarms from the relea-
sed information.
The strategy should also take into account what type of action can be expected
following the release of information and what type of information is to be disse-
minated to which target audiences. The dissemination step is described in more
detail in chapter 4.
1.3.5 Follow-up and feedback 
The last step deals with carrying out a follow-up process and promoting feed-
back. 
Regardless of whether or not the information is disseminated, it may be worth
carrying out a follow-up process for the Emerging drug phenomenon or a topic of
interest. Within the framework of an EIF, the follow-up is the act of continuing
with the observation of the phenomenon or topic of interest by collecting more
data and thus producing more information on it. 
Feedback is the act of sending the information produced by the Early infor-
mation function back to all the partners involved in operating the Early Informa-
tion Function. By improving the motivation of the individuals participating in the
production of information, feedback is a way of creating and/or maintaining a dyna-
mic of information production and circulation. The Feedback/follow-up step is
described in more detail in chapter 5.
1.4 INFORMATION STRUCTURE
This section presents the type of information needed to describe an EDP and
understand its development process or, in other words, it identifies the type of infor-
mation on which the EIF should focus. When trying to characterise “current” drug
phenomena and follow their development over time and space, several questions
have to be answered: “who”, “what”, “when”, “where”, and “how”, and – in order
to understand their causes, consequences and interrelations – the answers to “why”,
and “what for” also need to be known. 
This section focuses on three main lines of inquiry: users, substances and set-
tings. To describe these main lines of inquiry, it is necessary to specify which areas
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everal E
IF
indicators
are proposed for characterizing and describing the areas
of interest. T
hese allow
 detailed know
ledge to be obtained on key issues relating
to the areas of interest. T
he relevant inform
ation
to be produced by the E
IF
for its
purpose of identifying,describing and analysing E
D
P
w
ill therefore focus on these
E
IF
indicators. In term
s of identifying an E
D
P
,
inform
ation on som
e of the E
IF
core indicators is considered sufficient. T
he other E
IF
indicators
are regarded as use-
ful for an assessm
ent of identified E
D
P
. 
Table 1 show
s the three-tier inform
ation structure that has been adopted. It is
a useful tool for the various w
ork stages of an E
arly Inform
ation F
unction
(E
IF
),
especially the E
IF
’s data collection,identification and assessm
ent steps. It allow
s
a global view
 of all the m
ain lines of inquiry,areas of interest,E
IF
indicators
and
E
IF
core indicators. 
T
his table serves as a broad reference fram
ew
ork for carrying out standard and
specific assessm
ents. T
he table should be progressive and adapted to the national
w
ork context. A
vailable data/inform
ation and resources w
ill influence the feeding
of indicators. 
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Table 1 - Information structure of the Early Information Function (EIF) for Emerging Drug Phenomena (EDP) : 
Main lines of inquiry, areas of interest and indicators
MAIN LINES AREAS OF INTEREST EIF INDICATORS
OF INQUIRY Description EIF CORE INDICATORS are in bold
Demographic characteristics Age
Distribution and vital statistics of the drug user population Gender
Socio-economic characteristics Geographical locality : place of residence and/or drug use
Users' characteristics relating to both economic and Professional situation
social status: occupation, income, education, interactions Education level
and relationships with social institutions, etc. Housing
Social security cover 
Current family situation
Income/financial status
Source of money for the acquisition of drugs
Health status Physical health perception
Users' health conditions (physical and psychological) Psychological health perception
Ongoing treatment and contact with health services
Medical history
Comorbidity
Way of life/lifestyle Culture
Usual way of life, habits and leisure activities Entertainment
Dominant leisure activities
History of use Age at the first use
Chronological record of significant events regarding drug use Licit drug already used
Cannabis already used
Illicit substances already used
Perceptions and reasons for use Expected effects
Users' image of a given substance and user's grounds for use User's opinion of the substance
User's opinion of his/her own use
U
se
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MAIN LINES AREAS OF INTEREST EIF INDICATORS
OF INQUIRY Description EIF CORE INDICATORS are in bold
Patterns of use Method of administration
Ways of preparing and using a given substance Quantity
Frequency
Intensity
Polydrug use
Temporal aspects
Preparation
Health Consequences Psychological effects
Positive or negative effects in the short, medium or long term Physical effects
of drug use and/or pattern of use on the user's health
Social consequences Family relationships 
Positive or negative effects in the short, medium or long term Relationships with friends 
of drug use and/or pattern of use on the user's social situation Relationships with colleagues
Sexual relationships
Economic consequences Work situation
Positive or negative effects in the short, medium or long term Housing
of drug use and/or pattern of use on the user's economic situation Income situation
Share of the monthly budget allocated to drug use
Legal consequences Contacts with judicial system
Positive or negative effects in the short, medium or long term Contacts with police system
of drug use and/or pattern of use on the user's legal situation Contacts with prison
U
se
rs
MAIN LINES AREAS OF INTEREST EIF INDICATORS
OF INQUIRY Description EIF CORE INDICATORS are in bold
Identification Chemical name
Names of substance Street name
Common name (commonly used name)
International non-proprietary name 
(internationally accepted name)
Other names
Physical characteristics Physical appearance
Physical properties of substances Logo/brand name
Composition Purity
Way in which chemical substances are mixed and combined Active principles
in the substance: chemical formula Blended products
Pharmacological properties Pharmacological properties
Pharmacological profile of substances
Toxicity of the substance Chemical analysis
Toxic effects due to the chemical reactions produced in the Forensic analysis
body by the substance (usually causing health problems, 
even death)
Ascribed functions and properties Expected effects
Known/supposed effects (physical and/or psychological) Risk perceptions
of the substance and/or of the substance use
Legal status Licit or illicit status
Formal condition of substances derived from the law
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MAIN LINES AREAS OF INTEREST EIF INDICATORS
OF INQUIRY Description EIF CORE INDICATORS are in bold
Social setting Moment of the preparation/use
Social characteristics of the surrounding environment in which Presence of people at this moment
the substance preparation and/or use occur Methods, rules and rituals related 
to the preparation and use
Belonging to a specific cultural area
Physical setting Place for preparing/using the drug
Physical characteristics of the surrounding environment Reason(s) for choosing this place
in which the substance preparation and/or use occur Sanitary and hygiene conditions
Social consequences Representations
Positive or negative effects of the drug use on society Knowledge*/beliefs†
Violence
Extent of the phenomenon Prevalence‡ in the sub-culture
Number of observations of the potential EMERGING DRUG Prevalence in the general population
PHENOMENON
Distribution characteristics Retail price
Drug market characteristics Perceived availability
Accessibility
Method of acquisition
Dealer profile
Characteristics of small seizures
S
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n
g
MAIN LINES AREAS OF INTEREST EIF INDICATORS
OF INQUIRY Description EIF CORE INDICATORS are in bold
Broad context Legislative context
The combined social, cultural, economic and other conditions Substance regulation context
that influence the life of an individual, a community, or a country Policy context
Preventive context
Sanitary/health context
Drug market
Social context
Economic context
Cultural context
Geographical context
* knowledge: information that non-users have on users and drug use and that users have on drug use
† beliefs: non-users’ opinions and convictions about users and drug use and users’ opinions and convictions about drug use
‡ Prevalence : proportion of observations of the phenomenon in a given population and over a given period of time (Ahlbom et al.,1990)
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A
n E
IF
core indicators
is defined as an E
IF
indicator
that appears particularly
available,
accessible and useful for the identification of E
m
erging D
rug P
heno-
m
ena. In term
s of identifying an E
D
P
,inform
ation on the E
IF
 core indicators is
considered sufficient. C
hanges in one or m
ore E
IF
 core indicators w
ill serve as a
signal,a starting point for undertaking an assessm
ent of a possible E
D
P
. 
E
IF
core indicators
are detailed below
 through the m
ain lines of inquiry
and
areas of interest
(see Table 2). S
om
e definition elem
ents and exam
ples are given
in order to m
ake them
 m
ore com
prehensible. 
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Table 2 - Definition and examples of Early Information Function (EIF) core indicators of the areas of interest
for each main line of inquiry 
MAIN LINES AREAS EIF CORE Definition/Examples
OF INQUIRY OF INTEREST INDICATORS
Demographic Age Years of age 
characteristics E.g.: appearance of a given substance use among the under-25s
Gender The gender refers to the sex as perceived and referred to by the user
E.g.: decreasing use of a given substance among boys
Socio-economic Professional The professional situation is the principal calling, vocation, or employment for 
characteristics  situation gain or livelihood. This EIF indicator is also useful for reflecting unemployment
E.g.: increase in the use of stimulants among senior executives
Geographical The geographical locality refers to the particular place where the user lives and 
locality where the drug use takes place
E.g.: specific suburb, district, municipality, city/village, region 
Perceptions and Expected effects Expected effects refer to the user's expectations of the drug use in respect of the 
reasons for use psychic and physical consequences as well as the temporal aspects (drug's period of 
effectiveness)
E.g.: relaxation, empathy, stimulation (excitation, euphoria), loss of consciousness,
hallucination (visual and/or auditory), altered performance (physical, sexual), 
regulation effects (to overcome withdrawal), introspection (mystical or spiritual
experience), loss of memory, etc.
User's opinion The user's opinion of the substance is the evaluation/assessment
of the substance of the properties and effects of the substance. 
The opinion may come from : 
- drug users who use this given substance
- drug users who do not use this given substance
E.g.: the increase in cocaine injection could harm the users' perception of this 
substance
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MAIN LINES AREAS EIF CORE Definition/Examples
OF INQUIRY OF INTEREST INDICATORS
Perceptions and User's opinion This refers to the user's opinion of his/her own drug use
reasons for use  of his/her own E.g.: the users' perception may deteriorate when they realize the dangerousness of 
use their own use of a given substance
Patterns of use Method of Method of administration is the route or mode of administration,
administration i.e. the way in which a substance is introduced into the body (WHO, 1994).E.g.: oral
ingestion, intravenous, subcutaneous or intramuscular injection, inhalation, smoking,
or absorption through the skin or mucosal surfaces, such as the gums, rectum or 
genitalia
Quantity Quantity of drug used is the total amount of substance used for one dose
Intensity Intensity of use is the number of doses used per day
Frequency Frequency is the number of days of drug use per week, month or year
Polydrug use Polydrug use (or multiple drug use) is defined by:
- the combined use (combination) of more than one psychoactive and/or other sub-
stance by an individual, often at the same time or sequentially;
- and the conscious intention (regulation) of modifying the effects of one or more
substances already used or to be used
Health Psychological For the purpose of developing an EIF*, the psychological effects of interest are
consequences effects mainly the behavioural effects
E.g.: deterioration in emotional control, social behaviour or motivation, feelings of
losing control, despair, etc.
Physical effects Physical effects are the organic effects on the body. Within the framework of developing
an EIF* for EDP†, there is a particular interest in the toxic effects and effects related to the
method of administration
E.g.: sweating, palpitations, nausea, paraesthesias, etc.
U
se
r
MAIN LINES AREAS EIF CORE Definition/Examples
OF INQUIRY OF INTEREST INDICATORS
Identification Chemical name Name used in chemistry which deals with the composition, structure, and properties
of substances with the transformations that they undergo
E.g.: 3,4-methylen-dioxy-methamphetamine
Street name Name used in a drug-use environment
E.g.: XTC, E
Physical Physical The physical appearance of a substance is its form, colour, design, etc.
characteristics appearance E.g.: tablet, capsule, powder, liquid, etc.
Logo The logo is an identifying symbol (as in advertising) or something like a trademark
E.g.: "smiley", "butterfly",
Composition Purity Purity refers to the degree to which "the substance" is mixed with others. The 
quantitative dosage of the substances identified in one sample allows the purity to
be estimated
E.g.: a sample containing 20 % MDMA‡
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Sum
m
ary
This chapter gives an overview
 of the
elem
ents 
and 
organization 
of 
data 
collection.D
ata collection is a process
requiring inform
ation sources,data col-
lection professionals,
data collection
m
ethods,and instrum
ents:various infor-
m
ation 
sources 
and 
data 
collection
m
ethods are presented and described in
this chapter.As m
uch relevant data as
possible should be gathered from
 each
source by data collection professionals
using a specific m
ethod.
It is of the utm
ost im
portance that
tools of high quality – providing robust-
ness,flexibility and adjustability
as w
ell
as reliability and validity – are used for
this purpose.A high degree of m
otivation
on the part of the professionals collecting the inform
ation is also necessary.The quality
of the data collected also defines the obstacles for the later operational steps of the
Early Inform
ation Function
(E
IF) w
hich are based on the data collection.Broad data 
collection w
ith adequate quality is therefore crucial for an E
IF.Since these elem
ents
also have consequences at the institutional level,planning m
ust be long-term
.
D
ata collection
Identification
A
ssessm
ent
D
issem
ination
Follow
-up and feedback
MAIN LINES AREAS EIF CORE Definition/Examples
OF INQUIRY OF INTEREST INDICATORS
Social setting Moment of This refers to the moment of the day, week or month when the drug preparation/use
preparation/use occurs
E.g.: in the morning, before or during a party, before going to bed, etc. 
Presence of people This refers to the number and type of people who are with the user at the moment
at the moment of the drug preparation/use
of drug E.g.: the user is alone, with friends, etc. at the moment of the preparation/use
preparation/use
Methods/rules This refers to the accepted, common or preferred way of preparing/using the drug
relating to the including the rituals of use
preparation or use E.g.: sharing of equipment, etc.
Belonging The fact of the user belonging to a given cultural area refers to the customary
to a specific beliefs, social forms, shared values, norms and material traits in a specific racial,
cultural area religious, or social group to which the user belongs
E.g.: belonging to a musical scene, an ethnic group, etc.
Physical setting Place for preparing Characteristics of the place where drug preparation/use occurs 
or using the drug (the room, building, locality or particular event)E.g.: street, squat, apartment, night
club, rave party, etc. 
Distribution Retail price The retail price is the amount of money paid by the users to buy the drug, in small
characteristics quantities .
E.g.: the retail price of one gram of cocaine in Europe varies from 24  to 170 
(EMCDDA, 2001).  
Perceived The perceived availability is the subjective assessment based on the current individual
availability circumstances (users or observers) of the presence of the substance in a given 
geographical area
E.g.: a given substance that is perceived as available is easily acquired 
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* EIF: EARLY INFORMATION FUNCTION
† EDP: EMERGING DRUG PHENOMENON
‡ MDMA: 3,4-methylen-dioxy-methamphetamine
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a standard sense. Moreover, low-threshold facilities include activities related to
health promotion and harm reduction, such as needle/syringe exchanges.  
The data derived from low-threshold facilities may relate to the physical des-
cription of drugs and/or other relevant information on the accessibility of drugs, the
quality or price of drugs, the user profile and/or patterns of drug use, or drug traf-
ficking, i.e. characteristics of dealers, etc.
Health services, treatment and emergency facilities
Health services, which may or may not specialize in drug use, such as treat-
ment programmes, state hospitals and private mental clinics or mental organizations
providing treatment to drug users, as well as professionals, such as therapists, coun-
sellors or chemists and emergency facilities (e.g. professionals responsible for
emergency transportation or “Red Cross” services) may provide valuable infor-
mation regarding EDP. 
Law enforcement authorities
The law enforcement authorities collect a variety of data on illegal drug mar-
kets (e.g. data on drug prices or organized crime) derived from seizures, arrests or
charges, which may be useful for the purpose of the EIF.
Forensic and toxicological departments/laboratories
Forensic and toxicological departments, through the analyses of body fluids
(i.e. blood and urine tests) and drugs, can provide the EIF with relevant data.
Forensic laboratories, through the analyses of drug samples, can provide the
EIF with information on the physical and chemical description of drugs. In parti-
cular, data on the composition of drugs and the concentration of their active ingre-
dients can be collected through qualitative and quantitative drug analyses. 
Organizations producing sale statistics
Data on medical products, sterile injection equipment and opiate substitution
drug sales can be obtained from companies or institutions that deal, for example,
with the development and production of statistics.
Telephone helplines related to drug use
A telephone helpline is a first-aid service for drug users and/or their relatives
requesting help for a problem related to drug use. Moreover, it is an observation
tool which records in an exhaustive and continuous way the information relating
to the calls. The data that is usually collected concerns the type of request and the
type of response, the date of the request, as well as information on the caller’s
and/or the user’s demographic data and patterns of use.
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2 - Data collection
2.1. INTRODUCTION
The purpose of the Early information function (EIF) data collection is to col-
lect as much relevant data as possible with as much detail as possible. The type of
information needed for the identification and assessment of Emerging Drug Phe-
nomena (EDP) is defined and described in chapter 1 (see 1.4). In this chapter, the
main question is how to feed the EIF indicators identified in chapter 1. 
This chapter presents the key elements constituting the data collection system
and then provides explanations as to how the data collection could operate.
2.2. KEY ELEMENTS OF THE DATA COLLECTION
2.2.1. Sources of information
A “source of information” is a person, agent or organization which provides
the EIF with information on Emerging Drug Phenomena (EDP).
The information required can come from various information sources. Thus,
the list of information sources described below is neither prioritized nor exhaus-
tive. In fact, each country implementing the EIF will give priority to those infor-
mation sources that are considered important at national level. For example, in
some countries high priority may be given to drug users as a main source of
information while in others this source may be not available at all.
Drug users 
The term refers to all drug users, i.e. those who have contacted the health ser-
vices and/or those who have not. Drug users can provide the EIF with informa-
tion on personal data and/or on social and physical settings where drug use takes
place.
Self-help groups and ex-user groups
The operation of self-help groups is based on members of the public taking
action to cope with their problems within a framework of solidarity
(www.auth.gr/selfhelp). The same applies to ex-user groups.
These groups can provide the EIF with information derived from users’ expe-
riences, such as users’ perceptions on drug use, patterns of drug use, etc.
Low threshold facilities
Low-threshold facilities have direct contact with drug users. The term “low-
threshold” relates to the fact that the level of admission criteria is low. Thus, these
centres offer their services to drug users who do not wish to undergo treatment in
Key informants
Key informants are individuals who may be able to provide relevant informa-
tion on account of their social role or their community position. Moreover, key
informants can also participate in the data analysis process by participating in advi-
sory panels, for example. Finally, there are different categories of key informants
according to the type of information we are interested in collecting or analysing. 
The key informants could be as follows:
- Ex-users or current users
- Health professionals: general practitioners, nurses, drug-treatment personnel,
“emergency workers” (e.g. the fire brigade, the Red Cross, etc.)
- Law enforcement personnel
- Members of specific networks: i.e. systems of interlinked organizations. For exam-
ple, the Drug Dependence Evaluation and Information Centres, which is such a
network in France (see 2.3.2) 
- Youth workers, street workers, social workers and community workers, or other
“help” professionals who contact drug users
- Teachers
- Social workers participating in harm-reduction or prevention programmes imple-
mented in nightlife settings, or other professionals dealing with youth lifestyles or
working in nightlife recreational settings (e.g. DJs, door staff, event or party pro-
moters/producers, security staff, journalists, non-user peers etc.) 
2.2.2. Data collection methods
A data collection method is the way that data collection professionals gather
inputs from different information sources (e.g., drug users, health services, law
enforcement authorities, forensic and toxicological laboratories etc). For this pur-
pose, they use various instruments such as questionnaires, information notes, inter-
views, etc.
Each method can provide specific information on Emerging Drug Phenomena
(EDP). A general description of each method is given below together with exam-
ples from the member states where these methods have already been applied.
Population surveys
Description
Population surveys are epidemiological surveys that can provide a great deal of
information on the prevalence of existing drug use (prevalence rates) and in some
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Users’ family/social environment
Drug users’ family members, friends and acquaintances can provide the EIF
with information about the user and his/her environment (social and physical set-
tings).
Youth welfare facilities, drug prevention and counselling centres
Organizations providing support and/or other services, such as youth counsel-
ling services, can provide the EIF with useful information. In fact, prevention and
counselling centres operating at a local level contact users faced with an emerging
drug problem or drug users at risk. 
The personnel in these centres have the opportunity to collect data on the demo-
graphic and socio-economic characteristics of these groups of drug users, their per-
ception of drug use and their patterns of use or their reasons for use. 
Prisons and other criminal justice settings
Professionals working in special services implemented in prisons can offer
valuable information for the EIF, due to the fact that prisons are high-risk places
where drug users experiment with new methods of administration, new combina-
tions of drugs or new ways of drug preparation.
Mass media and the internet
The mass media can be a source of information for the detection of changes or
new phenomena appearing in drug-use patterns among different populations (Die-
mel et Blanken, 1999) (e.g. young population, “life-time users” etc). In fact, lifes-
tyle or music magazines for young people and relevant websites include a large
number of articles relating to nightlife activities and recreational substance use.
The same applies to certain newspapers.
The continuous monitoring of this type of press can provide data both on the
social and physical setting of certain populations and on drug users. The analysis
of data derived from the mass media can also contribute to our understanding of
the formation and distribution of users’ opinions and the social representations of
drug use in each country.  
Nightlife recreational settings
These settings refer to nightclubs and various music scenes, such as techno-
party, rock, house, etc.  
This source can provide valuable data on the perceptions of professionals
working in the “recreational industry” and frequenting nightclubs or data on pat-
terns of drug use.
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Ad-hoc surveys
Description
Epidemiological ad-hoc surveys are often cross-sectional studies. In fact, they
are surveys of the situation at a given time (or during a given period) carried out
in a group or population or in a set of groups or populations. Such a survey may
be descriptive, analytical or both. These studies may be contrasted with incidence
and other «time-span» studies that require information relating to two or more
points in time. In an epidemiological ad-hoc survey, the data collection can be pro-
spective or retrospective, exhaustive or otherwise, and based on a random sample
or on a defined sample. It allows the exploration of a specific sub-group during a
specific period. 
Example
Within the framework of the French TREND device, a specific assessment
was carried out in order to describe and better understand ketamine use and
the sociological and health characteristics of ketamine users. For this purpose,
an epidemiological ad-hoc survey, using an anonymous questionnaire which
was completed in the presence of the user, was carried out in order to collect
further quantitative data about the socio-demographic characteristics of the
users and their patterns of ketamine use (Akoka et Reynaud-Maurupt, 2003).
Routine information systems (Sentinel system/surveillance)
Description
Surveillance data results from the constant monitoring of the occurrence of a
disease or selected health conditions in the population. 
Surveillance is defined by Langmuir (1963) as “the continued watchfulness
over the distribution and the trends of incidence through the systematic collection,
consolidation, and evaluation of morbidity and mortality reports and of other rele-
vant data followed by early and regular dissemination to those who “need to know”
(Berkelman et al., 2002). 
Examples
Portuguese reports from Outreach Team Workers: every 6 months the Por-
tuguese dis (SNIDT) receives information from street workers on various indi-
cators including some of those included in this project.
In Sweden, data is collected twice a year by means of a questionnaire on
trends and new trends in the patterns of substance abuse. Data is collected from
225 reporters in 27 strategically sampled municipalities. The report includes
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cases incidence rates. In fact, when epidemiological surveys are carried out in a
standardized way over time, they can provide information on changes in patterns
of drug use and trends. In addition, correlations and consequences of drug use, as
well as data on user characteristics, are part of the output from such studies. Howe-
ver, although these surveys can be very valuable epidemiological methods, they
are highly likely to miss data on marginalized and “hidden” populations or on pro-
blematic drug users.  Moreover, due to the high cost of such a study, these are
usually repeated every 3-5 years, and in some countries the period between two
survey cycles is even longer. Population surveys are generally not carried out on
an annual basis because of the resources required. This implies that, frequently,
the results available will not  be as recent as desired. 
Examples
The “Representative Survey on the Use of Psychoactive Substances in the
German Adult Population (BUND)” is an ongoing, national survey, which has
been running since 1980. This Survey is on legal and illegal drug use, focusing
in particular on the consequences and assessment of substance use. A structu-
red questionnaire is used for the collection of the data. The survey is carried
out every year among a representative sample of the 18 to 59 year-old resident
population. 
INME – Inquérito Nacional em Meio Escolar is a School Population Sur-
vey carried out in Portugal in 2001, and designed to be repeated every 4
years. Sampling procedures include representative samples, at national, regio-
nal and local (main city) level, of students aged from 12 to 18. The ques-
tionnaire includes questions about lifestyles, music, licit and illicit substance
use (prevalence, patterns, places of use etc.), context variables (family, school,
and municipality), psychological and group variables. Open questions are
also included, such as the name of a new drug or the use of drugs in a new
place. 
The National Plan on Drug (Delegación Del Gobierno para el Plan Nacio-
nal sobre Drogas –DGPND-) carried out in Spain each two years national sur-
veys on school-aged population and adult population. (please visit the DGPND
web. In the following address you can find the reports from the school aged
population surveys of 1996, 1998, 2000 and 2002, as well as the reports for
the adult population surveys of 1995, 1997, 1999 and 2001,
http://www.mir.es/pnd/observa/html/estudios.htm).
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cipant observer considers everything as if it has happened for the first time, so eve-
rything is subject to inquiry. In fact, a participant observer makes an attempt to see
the world from the subjects’ point of view in order to understand their behaviour.
This is the main reason why participant observers have special training in obser-
vation techniques, which distinguishes them from regular participants. In particu-
lar, participant observation carried out by “trendsetters” in the drug field is consi-
dered important.
(www/csulb.edu/~msaintg/ppa696/696quali.htm).
Direct observation: this is either an open or an “undercover” operation. In fact,
it is a systematic and easy way of collecting data which allows a researcher to
understand drug-use behaviour and the context in which such behaviour takes place.
Direct observation tends to be a more focused observation than participant obser-
vation. In fact, the researcher observes certain “situations” or individuals rather
than getting involved in all activities of the group, and it is not as time-consuming
as participant observation.
Examples
Within the framework of the French observation scheme (TREND), an infor-
mation note on what is directly observed by “researchers” in urban areas or
in places where party events occur is written every month for each site invol-
ved in the TREND system (Bello et al., 2003).
In the Netherlands, a recent acceleration in the spread of GHB was obser-
ved at national level. In order to provide further information on the extent of
the use and the reasons for using this substance, as well as on the health conse-
quences and the GHB distribution characteristics, observations were carried
out in the places where GHB use was known to occur (Korf et al., 2002).
Interviewing
Description
One-to-one interviews are held with key informants owing to the fact that the
major research themes in question are explored in depth and participants are encou-
raged to express themselves. Moreover, these interviews are aimed at probing the
personal, environmental and social conditions relating to drug use. 
Open questions are usually used in one-to-one interviews. These interviews
can also be semi-structured or structured. In respect of structured interviewing,
there are several standardized questionnaires which can easily be adapted to the
local situation for use in such interviews.  
The key informants may provide the EIF with valuable information on the avai-
lability and accessibility of prevention and treatment programmes, or on their opi-
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information on the detection of new drugs as well as a description of new trends
in the use of alcohol and drugs.
The French National Identification System for Drugs and Toxic Substances
(SINTES) is a permanent observation device, which allows the collection of
data on the physical and chemical description of samples of synthetic 
substances (Giraudon et Bello, 2003).
In Greece, within the context of the early warning system on new synthetic
drugs, a network composed of three categories of agents, i.e. health services,
forensic and toxicological laboratories and law enforcement authorities, has
been in operation since 1998. Data on new substances and new ways of using
already known substances (new routes of administration or new combinations)
is collected by means of three questionnaires on the type of data each kind of
agent is able to provide. Finally, the data is assessed twice a year by an expert
committee which has the particular task of evaluating whether or not this data
is new for Greece (Greek Focal Point, 2000).
Spontaneous notification 
Description
Spontaneous notification is a method for the “free” reporting of drug use or
drug dependence cases by field workers, particularly by health professionals, to
an organization responsible for the collection and analysis of these notifications. 
Examples
The French NotS database collects on a permanent basis spontaneous noti-
fications of drug abuse or drug dependence. The CEIP network carries out the
permanent recording of spontaneous notifications relating to the same type of
data (www.centres-pharmacodependances.net/outils/index.html).
Observations 
Description
Ethnographic observations are aimed at an understanding of the subjective mea-
nings and social contexts of people’s behaviour (Anderson, 1923; Shaw, 1930;
Whyte, 1955). In respect of drug use, these observations allow the researcher to
gain “first-hand” experience of drug-user behaviours and of the contexts in which
these behaviours take place.
Participant observation is a period of intensive social interaction between the
researcher and the subjects which takes place in the latter’s environment. A parti-
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Risk Factors on Adolescents and Young People). This project employs quanti-
tative and qualitative methods (www.irefrea.org). In particular, in the second
research project on nightlife and recreational substance use (1998-1999), a
focus group was held to gather data on the following topics: leisure activities,
recreation and drugs, risk behaviour and popular music scenes. The data drawn
from the focus group interviews was used in a study entitled: Risk and control
in the recreational drug use culture. Sonar Project (Calafat et al., 2002).
Expert panel 
Description
The purpose of an expert panel is to allow the panel members to update each
other on a regular basis in order to gain an overview of a number of topics related
to drug use. The experts on this panel exchange information on new developments
in a timely manner so that they can adapt their activities to accommodate them. In
addition to this, the experts can have access, over a long period of time, to a sus-
tained, high-quality flow of information. This may involve rumours (unverified
data), signals (verified, episodic information and observations from individuals),
or verified data based on observations.
Furthermore, an expert panel can be convened again in the future to facilitate
a follow up. In fact, the experts on such a panel can be re-interviewed and studied
at a later date. 
Examples
The Greek Focal Point held an expert focus group in order to collect quali-
tative data concerning polydrug use which was one of the key issues developed
in the Annual Report on the Drug Situation submitted to the EMCDDA (2001).
Methodological tool: a number of open questions were developed on the main sub-
jects related to the issue (i.e., the definition of the term, reasons for polydrug use,
health and social consequences and specific approaches to the interventions).
Sample: nine professionals from therapeutic programmes and toxicological and
forensic laboratories were invited to express their opinions on polydrug use. The
sample selection was based on the fact that these professionals had proper kno-
wledge and experience of this issue (Greek Focal Point, 2002).  
Within the Frankfurt “Drug Trends Monitoring System” (MoSyD), the expert
panel is convened to allow the panel members to update each another in order
to provide an overview of the drug-use situation in this city. Sample: twelve
experts working in the drug-reduction field (drug care, social work with adults,
education system, police and judicial system). Methods: a focus group takes
place twice a year and a questionnaire is used once a year.
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nion of certain programmes. Furthermore, the data derived from key informant
interviewing allows us to gauge and understand the main perceptions on the pro-
blems of drug use and to gain information on a number of other important issues.
Finally, personal interviews may be used for investigating a particular topic on
drug use. 
Example
In Hamburg a Local Monitoring System for licit and illicit drug use is in the
process of being implemented. Semi-structured interviewing is one of the methods
being considered for use. The sample will be 20 key informants working with
young people (e.g., street workers or drug counsellors) or in the “recreational
industry” (e.g., DJs, bar/club owners or managers), as well as club/party-goers.
These key informants will be interviewed once a year.
Focus group 
Description
A focus group can be considered as a carefully planned discussion aimed at gene-
rating a group discussion on certain topics of interest and obtaining perceptions on
these defined areas of interest in a permissive, non-threatening environment. 
Focus groups can generate descriptive data on the nature of drug use, on indi-
vidual and group perceptions of the meanings associated with drug use, group
norms and practices, and on the contextual factors related to drug use. Focus groups
can be a useful method for exploring little-known topics and of validating findings
from other data sources (e.g. small-scale surveys) and conclusions drawn from
these sources. The categories of people participating in a focus group can be social
workers, teachers, secondary-school students, treatment specialists, drug users or
other groups of so called “key informants” (UNODCCP, 1999). 
Examples
Within the Hamburg Local Monitoring System, focus groups will be set up
to collect further information on how various drugs are used. Sample: four tar-
get groups each consisting of 6 to 8 people: 1) users of licit substances, 2) non-
users of licit substances, 3) users of illicit substances, 4) non-users of illicit
substances. In addition, a two-hour discussion on a specific topic related to
drug use led by an expert will take place once a year.
The Sonar Project is a European research project related to recreational
substance use, which is carried out in recreational nightlife settings (e.g. night-
clubs and parties). Ten countries participate in the project which has been deve-
loped and coordinated by the IREFREA (the European Research Institute of
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Within the framework of the Dutch “Antenna”, an expert panel critically dis-
cusses data on a regular basis with a team of researchers and prevention wor-
kers. In doing so, “we kill two birds with one stone”: the prevention workers
obtain information on new developments in time to gear their approach to them,
and researchers satisfy the requests of practitioners for new or more detailed
information, so that they can adapt their data collection activities to accom-
modate them. The results are published once a year study (Korf and Nabben,
2000).
2.3. TOWARDS AN OPERATIONAL DATA COLLECTION
2.3.1. Data collection tools 
For the purpose of this manual, a data collection tool is defined as a whole com-
posed of one or more data collection professionals who gather information from
an information source using a specific method and with a specific instrument (see
Figure 2).
Within the framework of developing an EIF for EDP, there are two kinds of
data collection tools: the general tools and the specific EIF tools.
A general tool is not specially constructed for the identification and description
of Emerging Drug Phenomena. However, it deals with subjects of interest for the
EIF and may provide data on Emerging Drug Phenomena as a by-product.
A specific EIF tool is constructed for identifying and assessing Emerging Drug
Phenomena. In fact, it is necessary for specific tools to be developed owing to the
fact that the data provided by general tools within the dis may not be sufficient for
the EIF for EDP. 
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PRACTICAL ISSUES
RECOMMENDATIONS ON DATA COLLECTION TOOLS
An EIF can be highly effective, but it does need funding. Given the long-term
aspect of planning for such an instrument, it is necessary to find cost-effective
and stable ways of implementing data collection methods in particular. The fol-
lowing considerations may help in this regard.
Examples
The function of the Coordination Assessment and Monitoring new drugs in
the Netherlands (CAM) is to perform a multiplidisciplinary risk-assessment on
new substances entering the drug market as soon as possible. Used methodo-
logy is the aural Delphy method. In the risk assessments a multiplidisciplinary
group of professionals participate. The CAM can be seen as a network. Infor-
mation about new drugs is centrally collected from different professionals, each
with their own grassroots.
A network of great importance to the subject in Sweden is the Network for
the Current situation of Drugs in Sweden (NADiS). Its aim is the early detec-
tion, collection and exchange of information, knowledge and experience rela-
ting to new substances (with the potential for or a record of drug abuse), old
drugs that suddenly reappear on the drugs market and changes in drug use.
The information exchange takes place in a discussion forum on a controlled
website as well as at regular meetings. Each member evaluates their own data
before putting it on the website and the data is discussed and assessed by the
group. NADIS consists of experts at national level who, on account of their pro-
fession, have an overview of their area of work.
In France, the network for the specific Drug Dependence Evaluation and
Information Centres (CEIP network) was created in 1990 in order to assist the
National Commission for Narcotics and Psychotropic Drugs in the evaluation
and collection of clinical data on drug use, dependence and misuse of psycho-
tropic substances (www.centres-pharmacodependances.net/outils/index.html) 
It is a network composed of three data collection tools:
- the system for monitoring drug-related deaths (DRAMES)
the NotS system, which collects spontaneous notifications of drug abuse
or drug dependence
- the system for monitoring illegal drugs and misuse of psychotropic medi-
cations (OPPIDUM)
2.3.3. Objectives and constraints
The objective of the EIF is quickly to identify, assess and categorize EDP in order
to allow the production of relevant information and its timely dissemination to tar-
get audiences. The early identification of an Emerging drug phenomenon means that
the EIF has to identify a phenomenon earlier than is possible using the standard dis
tools. 
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 Multiple tools
The EIF data collection is composed of multiple collection tools in order to
obtain information from various sources. Each collection tool needs a very clear
description of its purpose. Some of these could be organized within a network,
this network being a tool for the EIF.
 Permanent and temporary tools
The body of EIF collection tools should be composed of:
- permanent collection tools allowing ongoing collection 
- temporary tools which might be needed for carrying out a specific assessment of an EDP.  
collection tools should be cost-effective. The use of inexpensive sources of
information is to be preferred and the use of large-scale labour- and time-inten-
sive methods should be avoided wherever possible. Nevertheless, some topics
will require time- and labour- consuming methods because of their nature or
because qualitative data over a long period of time is needed. 
 Optimization of pre-existing tools
The objective is to optimize, i.e. to make as functional as possible, any pre-
existing sources, methods and people involved in the data collection tools. Never-
theless, a certain amount of money is needed to be able to afford the EIF, which
can function successfully only as a long-term process.
 Specific EIF tools
When the existing tools within the standard national observation device are not
sufficient, the institution responsible for developing the EIF will have to design a spe-
cific data collection tool, which should be complementary and have a clear added value
compared with the existing standard tools of the DIS. These specific EIF tools will
then be managed by the organization responsible for the EIF itself or contracted out
to another unit.  
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2.3.2. Networks 
Within the framework of the Euro-TREND Project, a network is defined as a
group or system of interconnected tools providing information on specific issues.
Networks exist at various levels, such as national, regional or local level. Moreo-
ver, a network can also link various of these levels. 
PRACTICAL ISSUES
RECOMMENDATIONS RELATING TO DATA COLLECTION PROFESSIONALS
 Co-ordination and interconnection 
In order to make the data collection operational, it seems essential for the co-
ordination and interlinking of the various tools and the various components of a
tool (sources of information, data collection methods and instruments, and peo-
ple involved in the collection step) to be provided by a specific national organi-
zation. The organization responsible for implementing the EIF will, as a rule, be
in the best position to provide this co-ordination. 
 Motivation of the professionals involved in the data collection
The quality and the sensitivity of the data collection are closely related to the
motivation and the awareness of all the professionals involved in the data col-
lection step. Lack of motivation could lead to a loss of existing data that might
be necessary for identifying, assessing and categorizing Emerging Drug Pheno-
mena.
In order to improve the motivation of the data collection professionals, cer-
tain benefits could be considered:
- Training for the professionals involved in the data collection step might be
a good strategy in order to improve their motivation and awareness. 
- Feedback might be a good way of encouraging data collection professionals
to deliver and report information into the system. 
Each organization responsible for a data collection tool should also be moti-
vated and convinced as to the value of its activity. Detailed below are some pos-
sible ways for increasing the organization’s motivation to participate in the EIF
data collection step:
- Promoting the issuing of publications in collaboration with the organization
responsible for the data collection tool
- Providing informative material
- Creating and articulating simple data collection methods in collaboration
with the organization that will implement them
- Negotiating the provision of other types of rewards, e.g. days off
- Offering a financial reward
- Networking with other institutions and data collectors.
The motivation method is closely linked to the resources available (e.g. finan-
cial resources) and the time frame. 
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The data collection carried out for the purpose of the EIF should therefore pro-
cess relevant and detailed data in a relatively short period of time. Data collection
plus the production of a specific assessment report should take less than a year.
For the purpose of organizing and carrying out the EIF data collection, some cons-
traints have to be considered which may restrict the implementation of the EIF to
a large extent:
- The availability of resources
The development of data collection tools requires financial means and depends
on the funding available – mostly at the national level
- The field of drug use is elusive
The hidden and stigmatized nature of drug use makes investigation difficult
(Rhodes, et. al., 2001). Therefore the data collection within this elusive field is no
easy task. 
The team responsible for the development of the EIF will have to weigh up
what is expected from the data collection (objective of the data collection) and the
existing constraints. Specific EIF tools to be developed should satisfy a number of
quality criteria, namely:
- robustness of the tool
- flexibility of the tool
- adjustability of the tool set
- validity of the data collected by the tool
- reliability of the data collected by the tool
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3 - IDENTIFICATION AND ASSESSMENT: 
THE DATA ANALYSIS PROCES
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Summary
In order to identify an Emer-
ging Drug Phenomenon (EDP)
and to assess its nature and
extent, this chapter describes the
data analysis process that follows
data collection within an Early
Information Function (EIF).
The different levels of the data
analysis process needed to iden-
tify, assess and categorize an edp
are presented. Each set of data
available from a data collection
tool follows a process of analysis
in order to produce relevant infor-
mation. All the available relevant
information is used for the identi-
fication, standard assessment and
categorization of EDP.To be able to identify EDP, a “reading grid” based on main lines
of inquiry, areas of interest and eif indicators is selected.All the information available for
each EIF core indicator is submitted to a process of triangulation and then to selection
criteria which allow the identification of EDP.Then, a standard assessment is carried out
for all identified EDP.This ends with the production of a standard assessment report.
Some edp which are considered high priority, as a result of the categorization process
and upon the advice of an external committee, will be subject to a specific assessment,
providing a more detailed description of the phenomenon.
Data collection
Identification
Assessment
Dissemination
Follow-up and feedback
Standard assessment and categorization of edp
Once EDP are identified, all the available relevant information on previously
identified EIF indicators is used to carry out a standard assessment of them and
categorize them according to pre-defined selection criteria.
Specific assessment 
For some important Emerging Drug Phenomena, a more detailed description 
of the nature and extent of the phenomenon and a more accurate estimate of its
growth potential might be needed. A specific assessment is then carried out,
possibly leading to additional data collection. 
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3.1. INTRODUCTION
This chapter describes the data analysis process of data collected on Emerging
Drug Phenomena (EDP) within an Early information function (EIF). 
As explained in the previous chapter, the main idea in the data collection step
is to collect as much relevant data as possible with as much detail as possible. Once
the data is collected it is necessary to use it in order to identify Emerging Drug
Phenomena (EDP) and, if necessary, to carry out assessments of identified pheno-
mena: this is the analysis process.
The present chapter therefore deals with the identification of EDP, the standard
assessment of their nature and extent, their categorization and the possible specific
assessment of certain EDP. Information and/or reports resulting from the data ana-
lysis will be used in the dissemination strategy detailed in the next chapter.
This chapter is structured in two main sections: a description of the key phases of
the analysis process and an explanation as to how each level of analysis operates.
3.2. KEY PHASES OF THE ANALYSIS PROCESS
3.2.1. Definition of the analysis process
Within the context of an EIF, the data analysis implies two operational steps:
firstly, the identification of EDP and, secondly, an assessment of these. The iden-
tification is aimed at checking and identifying the relevant data from among all the
data collected. The assessment is intended to describe and analyse EDP in order to
describe their possible consequences. Both activities (identification and assess-
ment) within the analysis process are interlinked. 
3.2.2. Definition and objective of each analysis level
Four key levels are identified in the analysis process (see Figure 3):
Data analysis for each collection tool
Data analysis for each collection tool is the analysis carried out separately on
data collected by each data collection tool in order to obtain relevant information
on previously defined EIF core indicators.
Identification 
The combined analysis of all relevant information produced by all available data
collection tools will, based on reading grids, allow the identification of EDP by comparing
information (triangulation) for each EIF core indicator and using pre-defined selection
criteria.
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Figure 3 - Data analysis process of the Early Information Function (EIF) for
Emerging Drug Phenomena (EDP)
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. Quick information (see Figure 4, scenario 1)
Raw data (collected by both general and specific EIF data collection tools) and
processed results (provided by general tools) may give quick information that could
be used directly by the EIF for possible dissemination as quick information notes
(see 4.2.1). Quick information will also be available for the identification of EDP.
Quick information is information on topics that require urgent decisions to be taken.
The production of quick information results from a fast-track analysis process
which allows a reduction in the time lag between collection of the data and avai-
lability of the information for target audiences. 
Example
The emerging use of a dangerous substance as a drug or the observation of
deaths related to the use of a defined drug is information that is worth inclu-
ding in a fast-track analysis process in order promptly to begin actions that
might contribute to stopping the phenomenon. 
. Selection of relevant information (Figure 4, scenario 2)
As explained in chapter 2 (see 2.3.1), some of the information sources in the
Early information function are information systems that pre-date and/or operate
separately from the EIF: general tools. These pursue their own goals but may contri-
bute to feeding the EIF. The data collected by these general tools is available in the
form of processed results. It has already undergone an analysis which converts it
into processed results. Some of these processed results may be relevant informa-
tion which can then be used directly by the EIF. Processed results provided by
general tools considered pertinent for the EIF are simply selected and then regar-
ded as relevant information for the purpose of the EIF. In this scenario, the data ana-
lysis carried out by the EIF team is merely a selection of relevant information within
the processed results provided by the general tools. 
Example
The results of a cross-sectional survey carried out among individuals aged
17 to 19 (general tool) could provide information on the increasing prevalence
of the first use of an emerging psychoactive substance. This relevant informa-
tion may be used directly for the purpose of the eif.
. Production of relevant information (Figure 4, scenario 3)
Within the EIF, raw data can be obtained either by a general tool or a speci-
fic EIF tool. In order to produce relevant information, these sets of data need to
be analysed by appropriate methods (e.g.: epidemiological analyses, qualitative
analyses). 
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3.3. TOWARDS AN OPERATIONAL DATA ANALYSIS
3.3.1. Data analysis for each collection tool 
The data analysis for each collection tool is the analysis carried out separately
on the data collected. This will produce information on previously selected EIF
indicators (see 1.4, Table 1). The expected output of the data analysis for each col-
lection tool should therefore be relevant information (information that is useful for
the purpose of the EIF) on previously identified EIF core indicators (see 1.4,
Table 2). The relevant information obtained will be used for the identification, stan-
dard assessment and categorization of EDP.
In practice, one may be faced with various types of situations - here referred to
as scenarios – when searching for relevant information from either raw data or pro-
cessed results obtained from general and/or specific EIF tools (see 2.3.1). Three pos-
sible scenarios have been considered (Figure 4): quick information, selection of
relevant information and production of relevant information. These three scena-
rios are described as follows.
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Figure 4 - The data analysis for each collection tool of the Early Information
Function (EIF) for Emerging Drug Phenomena (EDP)
Selected
relevant
information
Processed Results Raw data
Quick
information
Produced
relevant
information
Scenarios
General Tools Specific EIF Tools
1 32
PRACTICAL ISSUES
A TABLE FOR DISPLAYING ALL THE RELEVANT INFORMATION
 Building a global table showing all the available information on each indica-
tor. This table can be obtained from Table 1 in chapter 1, adding columns (one
for each data collection tool) to enter the results for each indicator (rows).
 This table will give a broad perspective of all the data collected by the diffe-
rent collection tools.
 The table will provide a starting point for the analysis process 
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Example
Within the framework of the French TREND device, raw data collected by
a qualitative questionnaire for low-threshold structures (specific eif tool) under-
goes an analysis with the aim of producing relevant information on methods
of preparation and use, perceived availability, retail prices and users’opinions
(Bello et al., 2003).
62
3 - Identification and assessment: the data analysis process
3.3.2. Identification 
Once the analysis of the data from each data collection tool has been underta-
ken, a large amount of relevant information is obtained. The next level of the ana-
lysis process is the identification, which is carried out using relevant information
in order to identify EDP.
The identification of an EDP implies the completion of various steps. Initially,
it is desirable to choose a defined approach for the entire set of available relevant
information. This approach is called the “reading grid” and will be explained in more
detail later on. Based on this reading grid, it is possible to organize the available
relevant information for each EIF core indicator. At a later stage, the available rele-
vant information for each EIF core indicator will be compared (triangulation) to
reveal any significant changes. In other words, any congruence or divergence of
information from different data collection tools, moments or places will be chec-
ked. Finally, predefined selection criteria of what is and what is not an EDP will
be used.
Reading grids
A reading grid is a technical way of looking at the information/results produ-
ced by the data analysis for each collection tool. Based on predefined EIF core
indicators (See 1.4.4, Table 2), the reading grid is the means of reading and ana-
lysing the information obtained by the different tools; is a thematic framework gui-
ding the data collection and analysis. As regards the likely amount of available
information, it seems necessary to rely on a search strategy for EDP. The esta-
blishment of one or more reading grids will be helpful for screening the informa-
tion. 
For example, and briefly, it is possible to start the reading with the different
substances and then examine, for each substance, the different characteristics of the
users and the settings (e.g.: heroin, description of heroin user and description of
heroin setting). It is also possible to start the reading with the user’s characteris-
tics (e.g.: users aged under 25/drugs used/setting) or with the setting (e.g.: low-
threshold users/description of user/type of drugs used). 
Triangulation of relevant information
This is a process for pooling items of information relating to a single EIF indi-
cator obtained from many and varied information sources and tools, often using dif-
ferent methods. Triangulation provides greater confidence in the validity and repre-
sentative nature of the information (Rhodes et al., 1998). Triangulation aims to
assess the support for a finding by showing the extent to which the various results
agree with each other. 
The dissimilarity between data derived from different collection methods does
not necessarily mean that one or more types of data are incorrect. Different types
of data reflect different aspects of the phenomenon and the researcher’s work is to
comprehend the cause of this dissimilarity (Riga, 2001). The combination of various
methods, and particularly the combination of quantitative and qualitative methods,
appears to be essential given the inadequacy of single-method techniques to encom-
pass all aspects of complex and elusive social problems. 
Selection criteria for the identification of an emerging drug phenomenon
After choosing a reading grid and comparing the relevant information (trian-
gulation) from the tool analyses, the information is read and analysed in order to
reveal the drug phenomena. The decision on whether or not to classify an identi-
fied drug phenomenon as an EDP is a difficult one: there is a continuum of varying
degrees. The final decision is based on the relevance of the phenomena evaluated
on the basis of predefined criteria.
The four criteria for identifying EDP are called “selection criteria”. These com-
prise, on the one hand, the diffusion potential and, on the other, the health, social
and economic consequences. 
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The diffusion potential can be low or high.  
Based on the EMCDDA definition (EMCDDA, 1999), the health, social and
economic consequences of a given EDP include:
- the probability that some consequences may occur: this concerns the capa-
city of the EDP to cause negative (harmful) or positive effects on health and the social
environment
- the degree of seriousness of such consequences: this concerns the impor-
tance of the health and social consequences related to an Emerging drug phe-
nomenon. 
Table 3 presents these criteria: diffusion potential and health, social and eco-
nomic consequences. EIF Indicators to be used for evaluating the selection crite-
ria are then presented in Table 4. 
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Table 3 - Selection criteria for the identification of an Emerging Drug 
Phenomenon (EDP)
Selection criteria Description
Diffusion potential is the capacity for, or the speed of, the numerical or
geographical extension of a phenomenon
Consequences Health are defined as the positive or negative effects in the
short medium or long term of a given EDP on health 
at the individual and community level
Social are defined as the positive or negative effects in the 
short medium or long term of a given EDP on the social 
environment at the individual and community level
Economic are defined as the positive or negative effects in the 
short mediumor long term of a given EDP on the 
economy at the individual and community level
Table 4 - Indicators for diffusion potential and health, social and economic
consequences
Selection criteria INDICATORS
Diffusion potential Number and/or proportion of people involved
Profiles of the population involved and relations among the various
groups (e.g.: old users, prisoners, trend-setters, young people). The
number of different profiles should also be mentioned, as well as
whether or not the various groups are interconnected
Number and/or proportion of geographical localities involved
Retail price
Perceived availability
Street name
Logo
Legal status of the substance
Method of administration
Expected effects
User's opinion of the substance and of his/her own use
Situation in other countries
Health Physical (organic), psychological and mental effects
Expected effects of the drug use
Patterns of use (method of administration, quantity, frequency, 
intensity)
Toxicity of the substance
Social Profile of the population involved.
Family relationships, relationships with friends, colleagues, sexual
relationships
Economic Work situation
Housing
Income situation
Share of the monthly budget allocated to drug use
3.3.3. Standard assessment and categorization
Within the context of developing an EIF for EDP, the EIF standard assessment
is the first-level assessment, which uses relevant information previously obtained
from data collection tools in order to give the most detailed description possible of
each identified EDP. An assessment report should be drawn up for each EDP: this
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is called a standard assessment report. This contains all or part of the relevant infor-
mation produced. Details on the standard assessment report will be provided later
(see 4.2.1).
The categorization process for identified EDP will help in deciding which EDP
are candidates for submission to a specific assessment process. Indeed, a specific
assessment could be conducted for some EDP identified as being important, depen-
ding on the available resources, regardless of whether or not they are urgent.
An identified Emerging drug phenomenon should be categorized according to
its status in relation to the predefined selection criteria: diffusion potential (high or
low), health, social and economic consequences (important or otherwise) at both
the individual and the collective level. Thus, the categorization of EDP will be
structured in 24 groups (see Table 5).
As previously indicated (see 1.4), the health, social and economic consequen-
ces may be explored through both the users and setting main lines of inquiry. For
example, the individual health consequences (for the user) of a single Emerging drug
phenomenon may be important, but they are not serious for the broader commu-
nity, i.e. the public health consequences of this phenomenon are not important. 
The combination of answers for all these criteria will help to categorize the
various EDP identified.
In addition to this categorization, an external committee of experts (see Figure
3), composed of individuals and professionals with some knowledge and expe-
rience of the drugs field, can assist the EIF team in the prioritization of a given
EDP.
Finally, the decision on whether or not to undertake a specific assessment will
depend on the political preoccupations and/or topical concerns.
This categorization and prioritization of identified EDP will help in deciding
whether or not to undertake a specific assessment as well as in developing the dis-
semination strategy. 
3.3.4. Specific assessment 
Specific assessment is a more detailed analysis of certain recently identified
important Emerging Drug Phenomena. The decision on whether undertake such
an assessment will be based on the categorization previously carried out, the exter-
nal committee’s advice and the resources available (funding and human resources)
for such work.
A specific assessment may or may not require additional data collection. If
required, this data collection can be direct (specific collection) or indirect (use of
previously available data). If not required, the main work will comprise a more
detailed analysis of information available within the EIF.
One important aspect is that the timeframe should be relatively short (a few
months) in order to produce the specific assessment report within a year of iden-
tification at the latest. The timeframe can vary depending on the type of EDP. Ove-
rall, specific assessment should be implemented as soon as possible. These time
constraints will have a direct impact on the methods chosen and on the logistics of
the specific assessment. The assessment process should activate flexible mecha-
nisms in a short time span.
Methodological aspects of the specific assessment
The method(s) to be used for a specific assessment will be chosen according to
the characteristics of the Emerging drug phenomenon and the time constraints.
There is some knowledge and profit to be gained from using the “Rapid Assessment
and Response” methodology. This methodology uses a combination of several
Table 5 - Categorization of identified Emerging Drug Phenomena (EDP)
Diffusion potential
Consequences Low High
Health Individual Not important
Important
Collective Not important
Important
Social Individual Not important
Important
Collective Not important
Important
Economic Individual Not important
Important
Collective Not important
Important
 : EDP candidates for a specific assessment 
All EDP with consequences categorized as “important” are candidates for spe-
cific assessment. Those with high diffusion potential will be considered a priority
concern. 
 Adaptation of the analysis process
Since the national contexts of the participating countries are different, the
adaptation of the proposed data analysis arrangement for each collection tool
should be appropriate: i) for the pre-existing tools in each country, ii) for the exis-
ting methods of working and collaboration between the various organizations
responsible for the collection tools.
 Building a table
Building a table displaying all the relevant information produced by data ana-
lysis for the collection tools is very useful.
 An ongoing quality improvement process
The relevance of the various methods to be used should be discussed and
assessed within the framework of a continuous quality improvement process. This
ongoing process of quality improvement is consistent with the need to develop
new tools while abandoning others which are no longer relevant for the purpose
of the EIF. This ongoing quality improvement process should be integrated within
a national and possibly a European logic.
 An external committee of experts
An external committee of experts may meet regularly (once/twice a year) and
assist the team responsible with identification and categorization decisions. The
group may consist of scientific experts from various disciplines (epidemiology,
ethnology, medicine, pharmacology, sociology, etc.), people involved in the field,
recorders of information (in specialized centres, general medicine, schools, the
field of risk reduction, etc.). The experts will have to use their knowledge and
experience in the drugs field to identify and categorize the EDP.
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quantitative and qualitative data collection techniques to depict the nature and
extent of certain health and social problems, such as drug abuse, and to suggest
ways in which these may be improved (UNODCCP, 1999; Stimson et al., 1998a;
Stimson et al., 1998b; Rhodes et al., 1998; Vincent et al., 2000). In order to obtain
a reliable and more complete picture of a drug phenomenon in a short period of time,
including context information to facilitate a better understanding of a complex phe-
nomenon, the rapid assessment approach uses various sources of information and
multiple collection and analysis methods to feed multiple EIF indicators.
Examples
A recent acceleration in the spread of Gammahydroxybutyrate (GHB) (Korf
et al., 2002) throughout the Netherlands was observed. A specific assessment
was carried out to provide further information on the use, the reasons for use,
the health consequences, and the distribution characteristics of the GHB. A
survey of a sample of 72 GHB users was supplemented with:
- in-depth interviews with drug prevention workers, police officers, drug
producers and drug users
- observations in places where GHB was known to be used
- laboratory analyses of samples of GHB actually taken by the users
- users’ discussions about GHB on the internet
After studying data from 2001 (Akoka et Reynaud-Maurupt, 2003), the
French eif identified a growth in the recreational use of ketamine. A specific
assessment was decided upon, aimed at describing the use and users of keta-
mine. The chosen methods combined a quantitative survey, 40 interviews and
two focus groups. The final report is due 11 months after the beginning of the
specific assessment.
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PRACTICAL ISSUES
 The role of the EIF team 
The organization implementing the EIF will be responsible for each level of
the analysis process: data analysis for each collection tool, identification, standard
assessment and specific assessment. This means that the EIF team will carry out
each level of the analysis process or contract it out to another unit/organization.
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4 - DISSEMINATION 
Summary
After the analysis process described
in chapter 3 of this manual, information
on an important change in drug use is
reported and available for further use.
These written documents are called
inputs (quick information notes, standard
assessment report, specific assessment
report).
Four key elements relating to disse-
mination strategies have been conside-
red: inputs, purposes of the dissemina-
tion, target audiences and methods of
dissemination. The purposes of the 
dissemination strategy depend on the
sorts of action that are expected. target
audiences refer to people or groups of
people to whom the information should
be disseminated.Dissemination methods imply definition of the format of dissemination,
the mode of distribution and the timing.
The process for developing the dissemination strategy must first include the recom-
mendations on the dissemination strategy proposed by the EIF team.These recom-
mendations have to be validated before embarking on any action.Dissemination actions
will be carried out by the EIF team and/or by partner teams, depending on the disse-
mination formats.
Data collection
Identification
Assessment
Dissemination
Follow-up and feedback
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4 - Dissemination
4.1. INTRODUCTION
This chapter describes the dissemination process within the EIF. This disse-
mination is developed based on the results of the previous steps. Once the relevant
data has been collected and converted into information by the EIF (collection, iden-
tification and assessment), information on EDP is reported in order to be used
appropriately. The dissemination step consists of developing the strategy for dis-
seminating the information in the appropriate manner to the target audiences. 
This chapter therefore explains how the dissemination strategy for Emerging
Drug Phenomena (EDP) should be drawn up. The first section presents the key 
elements to be considered for drawing up the dissemination strategy (inputs, pur-
poses of the dissemination, target audiences, and dissemination methods). The
second section addresses the organizational means of drawing up the dissemination
strategy. 
4.2. KEY ELEMENTS OF A DISSEMINATION STRATEGY
The following key elements should be considered when developing the disse-
mination strategy:
- The inputs of the dissemination strategy contain the information produced by
the EIF, and the dissemination strategy is formed on the basis of these
- The purposes of the information dissemination: these correspond to the actions
that may be undertaken using the available information and/or the responses that
may be made in order to deal with the EDP
- The target audience(s): these are the people or groups of people to whom the
information should be disseminated
- The dissemination methods: these correspond to the format to be used,
the way of distributing it and the appropriate moment for disseminating the infor-
mation
Each of these four key elements is described in detail later on. Figure 5 shows
how these key elements are interlinked. 
4.2.1. Inputs
The development of a dissemination strategy is rooted in the available infor-
mation on the topic. The information produced by the EIF analysis process will
result in the creation of relevant reports. These written documents correspond to the
inputs of the dissemination strategy. 
Three types of inputs can be distinguished (see also chapter 3):
. Quick information note 
Using the raw data and the processed results, the EIF should be able to provide
quick information and quickly draft a note and submit it to a fast-track process.
Caution should be used because of the possibly unclear level of certainty. The fast-
track process will be detailed later in this chapter (4.3, Practical issues).
. Standard assessment report
The combined analysis of all the available relevant information allows to carry
out a standard assessment of identified EDP and to categorize them. As stated in
chapter 3 (3.3.3.), a standard assessment report based on the results of the identi-
fication and standard assessment will be drawn up for each identified Emerging
drug phenomenon. 
Figure 5 - Key elements of the dissemination strategy for an Emerging Drug
Phenomenon (EDP) within an Early Information Function (EIF) for EDP
* Several inputs may be produced for any one EDP 
†Various purposes for disseminating the information may be considered for any one EDP reported in an input 
Target Audience(s) Target Audience(s) Target Audience(s)
Purpose† Purpose Purpose
Dissemination
methods
Dissemination
methods
Dissemination
methods
Inputs*:
- Quick information note
- Standard assessment report
- Specific assessment report
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. Specific assessment report
Depending on the categorization of EDP, and the available means (financial
resources), political preoccupations and/or topical concerns, the EIF should be able
to carry out a specific assessment to produce further information on certain recently
identified Emerging Drug Phenomena. A specific assessment report will therefore
be drawn up for each EIF specific assessment.
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PRACTICAL ISSUES
CONTENTS OF THE INPUTS
Whatever type of information is produced by the EIF, the document should
be written by the team responsible for the EIF and should include the follo-
wing points:
 The reason for examining the phenomenon
 Methodological aspects: explanation of the EIF system
How the data is collected: information sources and data collection tools used
How the information is produced: data analysis process used
 The information produced for each indicator and the quality of this informa-
tion
 Recommendations on the dissemination strategy to be adopted and the fol-
low-up and feedback planned. Recommendations for appropriate responses to
changes in drug use should include the following topics:
- The content or message to be communicated
- The geographical level at which the action should be undertaken
- The group of target audience(s) for whom the intervention is intended
- Methods for reaching certain target audiences
- Suggested methods for checking whether the target audiences have been
reached
- Suggested methods for checking whether the purpose of the dissemination
strategy has been achieved
- Expected effect on target audiences and possible side effects
- Experiences from the past should be taken into account
4.2.2. Purposes of the information dissemination
After the assessment of a phenomenon is complete, the dissemination strategy
is developed. The strategy describes the exploitation possibilities of the reports
produced in order to deal with the phenomenon in the best way possible. The first
phase in defining the strategy is to express the purposes of the information disse-
mination, i.e. the types of actions that are expected. The information produced will
be disseminated in order to be used in carrying out actions in specific fields, such
as health care, prevention/education, legislation, law enforcement, etc. 
Certain specific fields in which the information could be disseminated and
actions carried out are given below. This list is neither closed nor exhaustive.
. Legislation 
The information produced by the EIF could result in changes in legislation.
Example
The observation of an increasing number of HIV infections among heroin
users in Germany was one of the reasons for the liberalization of methadone
treatment. In France, the same observation was one reason for promoting the
free sale of syringes in pharmacies.
. Care/emergency services
The information produced by the EIF analysis process may be useful for imple-
menting or adapting existing care strategies.
Examples
Information produced by a Dutch specific assessment on GHB use could
be very useful for developing prevention and care strategies. Armed with this
information, prevention and care workers could take a closer look at the audience
they wish to target (Korf et al., 2002).
The growing use of cocaine in France led to a change in the emergency ser-
vice strategy. Before this, the emergency departments were more used to pro-
viding care for heroin users.  
. Prevention/education 
The information could be distributed to organizations working in the preven-
tion field and/or in health education programmes. 
information produced by the EIF (input) and according to the actions to be pro-
moted and/or the responses made to the identified EDP (purposes). Possible tar-
get audiences are presented in the following table (Table 6). 
Depending on the type of information, the target audiences to be reached will
vary from a restricted number of individuals involved in the operation of the EIF
to a broad dissemination to all target audiences. The audiences could also be tar-
geted at different levels – European, national, local-regional – depending on the
information. The decision as to which target audiences need to be reached will be
made based on the estimated advantages and possible disadvantages of the disse-
mination. For example, in order not to draw attention to a specific substance or to
promote unhealthy behaviour, it may be preferable not to disseminate the infor-
mation widely. All information produced by the EIF will have to be reported to a
restricted number of individuals directly involved in the operation of the EIF. The
best level to target within a target audience should be included in the recommen-
dations for the dissemination strategy.
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Examples
The observation, in France, of a significant proportion of injecting drug
users having incorrect information on their Hepatitis C status was a moti-
vation for providing the low-threshold structures with information on this
topic so that they could adapt their prevention and health education activi-
ties. 
By participating in interviews and discussions in the newspapers and on
television and radio, the public relations department of the Trimbos Institute
(Institute Netherlands Institute of Mental Health and Addiction) aims to influence
image-building in relation to substances and their users, in particular the public
image of GHB. The result should be a less sensational and more realistic or
more objective public image. This should eventually result in less (problema-
tic) drug use and thus better public health.
. Research and enhancement of knowledge of target audiences
The information produced by the EIF could be released in order to improve
knowledge on drugs and drug addiction (e.g. general public knowledge, drug-user
knowledge, professional knowledge). 
Example
The observation of PMA (Paramethoxyamphétamine or Méthoxy-4-amphe-
tamine) in a geographical area leads to information being given to drug users
in order to promote more cautious behaviour. 
. Law enforcement strategies
Law enforcement strategies are often developed as a consequence of a change
in legislation. The information produced by the EIF may be used to amend the law,
which is then applied by the law enforcement authorities. 
Example
The observation of increasing use of a licit drug could lead to this 
substance being classified as an illicit drug. This decision implies a change
in law enforcement activities. 
4.2.3. Target audiences
The third element to be addressed when developing the dissemination stra-
tegy is the people or groups of people to whom the information should be dis-
seminated: the target audiences. Target audiences will be chosen for each type of
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Table 6 - Possible target audiences for the information dissemination 
of an Early Information Function on Emerging Drug Phenomena
TARGET AUDIENCES Groups
Professionals Prevention/education sector
Health care sector
Research sector
Law enforcement sector
Recreation sector
Monitoring systems
Policy makers Political decision-makers
Institutional decision-makers
Information Journalists
specialists Specialized web managers and others specialists
Population Specific groups Drug users
Self-help groups
At-risk groups
People involved: user's social network 
General population
- Executive summary
The executive summary is a technical note which contains the main informa-
tion essential to the decision-making process. This should be short (1 or 2 pages)
and should emphasize the results and recommendations. The reader should be able
to find and understand the results quickly. The executive summary may be parti-
cularly relevant to decision-makers, who are often very busy and require an appro-
priate form of language. 
- Summary
The summary should be informative and should present, in a condensed version,
the content of the full report. This should contain the purpose of the research/pro-
ject, the methodological aspects (the information producers, data collection tools
used, etc.), the results and the conclusions. The summary will be particularly use-
ful for those people who are interested in the topic but who are very busy or not
motivated enough to read the complete report. 
- Press release and press file
The press release and press file are intended for journalists and, as a last resort,
for the general public. These should not be exhaustive and they are not summa-
ries. They should make the main results easily accessible and understandable. The
press release should be very short (1 to 3 pages) while the press file, which is ful-
ler (about 10 pages), may contain certain methodological aspects as appendices. 
- Scientific paper
A scientific paper is a published document which provides the results of the
study in a review or in professional or scientific journals. A scientific paper should
set out the working methods, the results of the research/project and a discussion on
these results. Nevertheless, scientific journals are not relevant to rapid information
delivery because there is a delay of several months due to the reviewing, printing,
and distribution of written publications. 
. Secondary media for disseminating the information
Depending on the purpose of the dissemination strategy, the appropriate format
for disseminating the information could, for example, be flyers, public notices, refe-
rences, films and television programmes, oral communications, press articles, medi-
cal protocol, official documents (regulations, agreement, etc.), and so on.
Secondary media are dissemination tools that may take various forms: preven-
tion tools, care tools, knowledge-enhancement tools, law-enforcement tools, etc.
Appropriate ways of “packing the message” may differ between target audiences.
The accessibility of the target audiences will need close attention; some groups are
hard to reach. The format of secondary media will therefore have to match certain
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4.2.4. Dissemination methods
The final element to be considered when drawing up the dissemination stra-
tegy is the methods of dissemination. These refer to the way the information is dis-
seminated and include the format to be used, the manner of distributing the cho-
sen format and the timing of the dissemination. 
The dissemination methods will depend on the type of information and the pur-
pose of the dissemination strategy. They will also have to be appropriate for the
needs of the target audiences. For a single EDP, appropriate responses or actions
to be implemented over time may vary for different target audiences. 
The format
The production of one or more formats from a given input is intended to faci-
litate its use by a given target audience. Nevertheless, inputs – standard assessment
report, specific assessment report or quick information note – may be used as they
are by some target audiences. Two types of format for releasing the information can
be produced: primary media and secondary media. 
. Primary media for disseminating the information
Primary media are written documents produced directly from the inputs without
using any other material. Inputs, as such, are also primary media. 
The EIF coordination team will be responsible for producing primary media
and for choosing between them: they do not all have to be produced for a given EDP.
Further organizational information on the involvement of different actors in the
development of the dissemination strategy is given in the following section. 
Presented briefly below are some examples of primary media (the list is not
exhaustive)
- Full report
The full report should set out the justifications of the reasons for the research/pro-
ject, a complete description of the methods used, all the results, and a detailed dis-
cussion on the implications of the results of the research/project. The dissemina-
tion of the full report is often limited to professionals, the partner in the study and
the financing organization.
- Quick information note
The quick information note should briefly include the methodological aspects
of how information is produced (information sources, data collection method) and
the quick information produced by the EIF. Recommendations on the dissemina-
tion of the quick information will be included in the note. 
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 Information specialists may primarily use press releases/files and summaries. 
 For disseminating information among the population (the general population
as well as specific groups), primary media do not seem the most appropriate tools.
Secondary media (such as press articles, prevention tools, etc.) may therefore be
used to reach the population. 
Each target audience may wish to have access to the inputs as they are, and
should be able to obtain these on request. 
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characteristics of the target audiences. Thus the development of secondary media
requires, in addition to the inputs or primary media, more information and/or spe-
cific competences: specialists will be needed to produce secondary media.
The release of secondary media is not necessarily the task of the EIF team.
Nevertheless, the EIF coordination team could collaborate with other organiza-
tions to produce secondary media. Further organizational explanations on the invol-
vement of different actors in the process of developing the dissemination strategy
are given in the following section. 
Example
Information on an emerging drug phenomenon identified by the eif (the gro-
wing use of cocaine, for example) may be useful for health professionals. The
purpose is to develop a care strategy to improve the care given to drug users
within the emergency department. From the information contained in the sum-
mary of the full report (primary medium for disseminating the information)
which is disseminated among health professionals, a medical protocol (secon-
dary medium) produced by emergency professionals could be disseminated
among the professionals working in the emergency departments. The produc-
tion of this secondary medium requires further information and specific com-
petences relating to the emergency. 
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PRACTICAL ISSUES
CHOICE OF FORMAT
The format chosen for disseminating the information should be accessible,
i.e. it should be appropriate to meet the needs of a target audience which is some-
times hard to reach. The optimal dissemination is when as many members of the
target group as possible are exposed to the product. Moreover, the wording of the
information should be comprehensible, i.e. the language and the structure should
be appropriate for the target audience. Finally, it must be stressed that the format
to be used will depend on the national and local context in which the Emerging
drug phenomenon is identified. 
 Professionals need firstly to receive condensed information with the executive
summary. They can also be reached with scientific papers. 
 For policy makers, the most important primary medium is the executive 
summary.
Distribution of the media
There are various channels for distributing a given primary medium. The infor-
mation can be distributed to the chosen target audience by e-mail services, via post
as a printed version, on websites (web papers, etc.), and so on. The various distri-
bution methods may have not only different costs but also different effects for the
target audience. The financial aspects relating to the production and distribution
of the media will have to be considered. 
Timing the dissemination of information
The moment at which the dissemination takes place can strongly influence the
effect: e.g. during the summer holidays no access to pupils is possible through the
schools. Sometimes a great deal of attention can be generated in a topic through
media attention whereas at other times this target group displays no interest at all.
Thus, timing the dissemination means choosing the best moment for dissemina-
ting the information depending on the expected effects of the dissemination. 
Once the dissemination strategy has been drawn up, it should be implemented
as soon as possible, particularly in respect of the quick information notes. Howe-
ver, it is necessary to take into account the availability of the target audiences to be
reached when implementing the dissemination strategy. 
4.3. DEVELOPMENT OF A DISSEMINATION STRATEGY
The process for developing the dissemination strategy is structured in three
steps: the recommendation step, the validation step and the action step
These three steps are presented in Figure 6 and detailed below. The role of the
participating actors and organizations during each step is also presented. 
tification and assessments) and included within the inputs (standard and specific
assessment reports and quick information notes). Additionally, the EIF team may
seek advice from the external committee of experts which is already set up for the
analysis process. 
For each input, i.e. for each identified EDP or topic of interest, recommenda-
tions are made on:
- The purposes, i.e. the actions that could be carried out using the information
disseminated 
- The target audiences, i.e. the people or groups of people to whom the infor-
mation should be disseminated
- The dissemination methods to be used for achieving the purpose and the
target audience, i.e. the appropriate format for each target audience and the sui-
table time for disseminating the information to each target audience. Particular
attention should be given to the methods for disseminating information to spe-
cific groups because certain information could be harmful if it reaches other tar-
get audiences.
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Figure 6 - Development of the dissemination strategy within the Early 
Information Function (EIF) for Emerging Drug Phenomena (EPD)
Recommendations
- purposes
- target audiences
- dissemination methods
Steps leading to the dissemination Possible actors taking part in each
step who may differ among countries
- Team responsible for the EIF
- Committee of external experts 
Validation
- purposes
- target audiences
- dissemination methods
- Team responsible for the EIF 
- Decision makers
- Organization involved in the action
Action: dissemination
Primary media 
- Own action
- Intermediary action
Secondary media
- Partner action
- Team responsible for the EIF 
- Intermediary organization
- Partner organization
4.3.1. Recommendation step
The dissemination strategy should be initiated and proposed by the EIF team.
Thus, the recommendation step allows the team to offer suggestions and advice on
how to use the information. For a single phenomenon, appropriate responses can
vary for different target audiences and different expected effects of the informa-
tion dissemination. These recommendations are neither rigid nor a top-down way
of developing the dissemination strategy. They are put forward on the basis of the
recommendations already made during the analysis process (at the time of the iden-
PRACTICAL ISSUES
THE EXTERNAL COMMITTEE OF EXPERTS
 The composition of the external committee should be adapted to the national
context. In some countries for example, policy makers should have the opportu-
nity of participating in the recommendation step because of their influence in
financing the activities of the EIF. 
 The experts should apply their knowledge and experience within the drugs
field in order to put forward proposals on how to manage the information produced
by the EIF. 
 The committee of external experts could periodically be asked to make com-
ments on the standard assessment reports, while an extra meeting could be orga-
nized for each specific assessment report produced. Regarding the quick infor-
mation notes and for the purpose of speeding up the development of the
dissemination strategy, the EIF team could quickly consult the members of the
external committee by telephone, fax or e-mail.
. Partner action: production and dissemination of secondary media 
Based on information from the EIF, suitable products can be developed for spe-
cific groups. Using a primary medium, a partner organization can produce a secon-
dary medium which needs additional work and specific competences. For exam-
ple, an organization specializing in the prevention field could use the report summary
in order to develop a prevention tool such as a flyer or a film. The partner action
therefore includes the production of a secondary medium and its release to a given
target audience. The partner action could be carried out in collaboration with the
EIF team. 
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4.3.2. Validation step
The recommendations previously made on the purposes of the dissemination
strategy, the target audience(s) to be reached and the method(s) to be used for dis-
seminating the information will have to be discussed, possibly modified, and vali-
dated during the validation step. 
The individuals who will, in the last resort, decide the dissemination strategy
to be adopted will depend on the national context. Nevertheless, the validation step
should promote interaction between the following groups of people:
- the individuals involved in the EIF and responsible for producing recom-
mendations on the dissemination strategy,
- the decision-makers in the drugs field,
- the individuals directly responsible for executing the action to be carried out
using the information produced by the EIF. 
Concerning quick information notes, the various elements to be addressed in
developing the dissemination strategy should be quickly validated by telephone, fax,
or e-mail communication. 
4.3.3. Action step
The final step is the action step, which corresponds to the dissemination of the
information produced by the EIF and reported in the inputs.
. Own action: production and dissemination of primary media
Depending on the availability, within the EIF team, of the specific competen-
ces required for producing and disseminating primary media, the EIF team could
itself undertake the production and dissemination of such documents or it could
resort to external competences and expertise. In the latter instance, the EIF team
remains responsible for producing and disseminating the primary media, which
will be disseminated according to selected procedures (choice of format, distribu-
tion methods, appropriate moment for the dissemination, etc.).
. Intermediary action: dissemination of primary media already produced 
This corresponds to a second level of primary media dissemination. The EIF team
disseminates a primary medium to a partner organization which, in turn, takes over
the task of distributing this to other target audiences. In this case, the partner orga-
nization acts as a mediator for communicating primary media that have already
been produced by the EIF team
84
4 - Dissemination
PRACTICAL ISSUES
PREDEFINED MODELS
 Aimed at facilitating the development of the dissemination strategy, certain
models for disseminating the information may be developed and agreed in advance
by the EIF team and those involved in the process: these are predefined models.
They are set up for a given type of Emerging drug phenomenon identified by the
EIF. As soon as such an Emerging Drug Phenomenon is identified, the predefi-
ned model may be used for quickly disseminating the information.
 For a given type of EDP, this model should provide:
- the purpose of the dissemination,
- the target audiences,
- advice on the appropriate format and time for disseminating the information.
 Predefined models will be useful for saving time. It must be stressed that pre-
defined models should be used in a rational and non-automatic way, and on cer-
tain occasions they should not be used: see the Dutch example below. 
 Ad-hoc models could be defined for disseminating information from specific
assessment reports.
Examples
The Dutch Drug Information and Monitoring System (DIMS) had developed
a rather explicit protocol for disseminating information in the event that a
tablet, sold as Ecstasy, turned out to have a potentially strong negative influence
on health. One of the rules was that in the event that a single tablet was found
on the market, no action should be undertaken. To spread information natio-
nally or only in the region where the tablet was found would cause harm rather
than improve health. Nevertheless, when a single tablet containing strychnine
and MDMA entered the DIMS system, this protocol was overruled. 
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SINTES is a French substance identification system which allows information
to be produced on pharmacological analyses (composition of the product and pro-
portion of different compounds) and the context in which the sample was collec-
ted (the type of event, user profiles, etc.). Within the framework of the SINTES
system, a fast-track process has been developed for producing quick information
notes on dangerous substances. This process allows the rapid dissemination of
the information.
The fast-track process for the quick information note is divided into three
steps:
- The production of a note reporting the information on an unusual or possi-
bly dangerous substance identified by the EIF
- Quick consultation, during the day and by means of fax and e-mail, with the
TREND partners and the decision-makers in order to make a rapid decision on
the dissemination strategy. The information note is submitted to the interdepart-
mental mission for the fight against drugs and drug addiction (MILDT), the French
agency on the health safety of health products (AFSSAPS) and the Health Gene-
ral Directorate (DGS). In some cases, the AFSSAPS and the DGS take the deci-
sion to issue a health warning. 
- The health warning is quickly disseminated to the Regional directorates for
health and social action (DDASS) and to the care facilities specializing in the
drug addiction field. As for the quick information note, its rapid dissemination
allows the results to be communicated to the technical and institutional partners
within 24 hours of their being received. Moreover, the quick information note is
available on a public website.
BASIC CONDITIONS FOR DISSEMINATING THE INFORMATION
The following four conditions, at least, must be met before any actual actions
take place (Griffiths et al., 1999)
 Clarity is required with regard to the target audience or ‘data consumers’ of the
information.
 The information needs to be configured in a way that makes it appropriate to
the needs of the target audience.
 Different types of dissemination are likely to be appropriate for different tar-
get audiences.
 To ensure credibility, the target audience has to be aware of the status of the
information (i.e. level of certainty) and information should not be disseminated
in a manner that raises false alarms or proves with hindsight to be erroneous. 
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5 - FOLLOW-UP AND FEEDBACK
Summary
Follow-up and feedback can
serve several purposes in detail. In
general, follow-up and feedback
are instruments for maintaining or
improving the quality of the Early
Information Function (EIF).
Within the framework of an
eif, the follow-up process is the act
of continuing with the observation
of an edp or topic of interest. It
leads to a new data collection per-
iod and underscores the dynamic
aspect of the eif.
Feedback, communicating
informations on an identified
Emerging Drug Phenomenon (EDP) to individuals involved in data collection, promotes
good working practices and stimulates staff satisfaction and motivation.
Data collection
Identification
Assessment
Dissemination
Follow-up and feedback
For example, the identification of an increasing use of a licit drug could lead
to this information being disseminated in order to change the law on this drug pres-
cription. The follow-up process may contribute to evaluating this change in the
law.
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5.1. INTRODUCTION
Once the strategy for disseminating the information has been drawn up, a fol-
low-up process is carried out and the information is sent back to all the partners invol-
ved in its production. This chapter explains therefore what is meant by follow-up
and feedback within the Early information function (EIF) for Emerging Drug Phe-
nomena (EDP).
The first section of Chapter 5 addresses the follow-up process and explains how
it allows the cycle of information production, i.e. the continuous EIF process, to
be completed. The second section deals with feedback and shows its usefulness
for improving the quality of the continuous EIF process.
5.2. FOLLOW-UP
5.2.1. Definition
During the EIF analysis process, information is read and analysed in order to
reveal drug phenomena and identify some of these as being EDP. In some cases,
information produced by the EIF is not sufficiently robust to identify an EDP, but
this information reveals a possible concern and merits being monitored. This infor-
mation is a topic of interest that will be subject to continuous observation, which
should allow it to be identified if it evolves into a formal EDP or if it remains as a
cluster of events or a “rumour”. 
Within the framework of an EIF, the follow-up of an Emerging Drug Pheno-
menon or a topic of interest is the act of continuing with the observation of this
EDP or topic of interest by collecting more data and thus producing further infor-
mation on it. 
5.2.2. Usefulness
The follow-up process links the last and the first operational steps (dissemina-
tion and data collection) of the EIF. Once all elements of the EIF work process are
complete, the process continues and starts all over again. This ensures the conti-
nuation of the whole process. The follow-up process can therefore improve the
EIF’s ability to identify EDP. 
More information on an identified EDP produced by the follow-up process may
be useful for contributing to evaluating the action carried out after the dissemina-
tion step. 
88
5 - Follow-up and feedback
PRACTICAL ISSUES RELATED TO THE FOLLOW-UP PROCESS
 Choosing the Emerging Drug Phenomena and topics of interest to be moni-
tored
During the EIF analysis process, certain EDP are identified and topics of inte-
rest revealed. A follow-up process should be carried out automatically by the EIF
for all identified EDP. Regarding the topics of interest revealed by the EIF ana-
lysis process, the team responsible for implementing and coordinating the EIF
should be responsible for choosing the topics of interest to be monitored, i.e. to
be included in the EIF’s observation task. 
 Integrating the topics of interest 
The topics of interest chosen by the EIF team should be integrated into the EIF’s
routine and continuous data collection. The existing EIF data collection system
should be flexible and able to collect data in order to supplement the knowledge
on previously identified topics of interest and EDP. 
For example, without creating a new collection tool and spending more money,
certain items could be added into an existing questionnaire in order to monitor a
topic of interest or an EDP identified by the EIF. 
5.3. FEEDBACK
5.3.1.Definition
Feedback is the act of sending the information produced by the EIF back to all
the partners involved in operating the EIF: data collection professionals, local coor-
dinators, etc. – all the people who provided some information. 
PRACTICAL ISSUES RELATED TO FEEDBACK
 A continuous process
As soon as the information is produced by the EIF, it should be sent to the pro-
fessionals involved in the data collection step. They are able to check the quality
of the information produced and possibly send more information.
 A cost-effective process
The feedback should be cost-effective and the local technical possibilities
should be taken into account. 
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5.3.2. Usefulness
Firstly, feedback allows validated information to be provided to the data col-
lection professionals: this information is very useful to them.
Feedback, communicating information on an identified drug phenomenon to
the individuals involved in data collection, promotes good working practices and
stimulates staff satisfaction and motivation. It therefore allows a relationship of
exchange to be created between the EIF coordination team and the data collection
professionals. This improves the motivation of the professionals and partners invol-
ved in the proper development and functioning of the EIF. 
Finally, feedback allows more data to be obtained. Feedback encourages the
data collection professionals to deliver and report information into the system. It
is a way of improving the quality of the continuous EIF process and of maintaining
the network of data collection professionals and other partners. 
Examples
One part of the Frankfurt Drug Trends Monitoring System (MoSyD) is the
school survey which is conducted once a year by drug-counselling teachers.
When these teachers receive the report, the school authorities initiate a dis-
cussion with them on the results of the school survey.
Another part of MoSyD is the expert panel: when the data from the ques-
tionnaire is analysed, a discussion takes place with all the members of the expert
panel. A type of Delphi methodology is also followed which involves sending
out intermediate results, including feedback, in two phases.
Within the framework of the Treatment Demand Indicator (TDI), the Greek
collaborating agents that provide the information are invited to an annual mee-
ting where the analysed data relating to the previous year is presented prior to
the official publication of the “Annual Report on the Greek Drug Situation”.
In addition, the Focal Point offers its network detailed statistical tables in which
data is presented i) per centre and ii) for the entire network (Greek Focal Point,
1997).
On the basis of the Early Warning System (EWS) operation, constant feed-
back is provided to the collaborators through the dissemination either of infor-
mation on new synthetic drugs derived from Europe or of data already asses-
sed as concerning new drugs or new ways of using known substances in Greece
(Greek Focal Point, 2003).
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6 - PROSPECTS 
This manual is aimed at people who are interested in more quickly identifying
and understanding changes in drug use or new drugs, elusive phenomena that are
not usually very visible with standard monitoring systems. It gives a general and
theoretical overview of the dynamic process of an Early Information Function (EIF)
for Emerging Drug Phénomena (EDP). 
The development of an EIF within a Drug Information System (DIS) comple-
ments the traditional monitoring of indicators and trends. A properly functioning
EIF will be able to inform the target audiences in a shorter period of time, in order
to promote health and prevention actions for users and the general population. If
it is not linked to actions, this production of information will be of less interest. 
The dynamic and ongoing process of the EIF presented in this manual, struc-
tured in five operational steps, is a theoretical model. The implementation of this
common EIF model in different countries should be adjusted to the national situa-
tion. Available sources of information will vary from country to country. Availa-
ble resources for an EIF will also vary and thus the volume of work will also change.
The political structure of a country (federal or centralized) will certainly have an
influence on the final design of a national EIF as well. In any event, the imple-
mentation of such a function is not a short-term action and it is necessary to have
time to be able to build a properly working function.
The expected results should merit the investment. New developing drugs, emer-
ging patterns of use or emerging harm will be identified much earlier than with a
standard monitoring system. It will allow earlier intervention and the avoidance of
significant burdens of suffering and expenditure in care and law enforcement.
With the development of the European community and the acceleration of
exchanges of people and knowledge, a link between the European countries is very
necessary. The heterogeneity of the DISs in the countries that participated in this pro-
ject implies that the proposals included in the manual are sufficiently adaptable to
cope with national realities and will also provide a general EIF model that will
facilitate exchanges countries and among people within countries. These exchan-
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GLOSSARY
This glossary includes operational definitions of key concepts (indicated with
a red fount), as well as definitions from reference books/authors for other concepts
generally related to public health. 
The development of a common theoretical model of an Early Information Func-
tion (EIF) for Emerging Drug Phenomena (EDP) required the sharing and valida-
tion of a common operational definition for key concepts. 
For other concepts, definitions commonly adopted in the drug field are pre-
sented. Sometimes several definitions are proposed for the same concept in order
to provide the opportunity for choosing the definition most appropriate for the
national context. 
Absolute risk reduction (see “Risk”) 
Abuse (WHO, 1994)
(drug, alcohol, chemical, substance, or psychoactive substance) 
A group of terms in wide use but of varying meaning. In DSM-IIIR, “psychoac-
tive substance abuse” is defined as “a maladaptive pattern of use indicated by …
continued use despite knowledge of having a persistent or recurrent social, occu-
pational, psychological or physical problem that is caused or exacerbated by the use
[or by] recurrent use in situations in which it is physically hazardous”. It is a resi-
dual category, with dependence taking precedence when applicable. 
The term “abuse” is sometimes used disapprovingly to refer to any use at all, par-
ticularly of illicit drugs. Because of its ambiguity, the term is not used in ICD-10
(except in the case of non-dependence-producing substances-see below); harmful
use and hazardous use are the equivalent terms in WHO usage, although they usually
relate only to effects on health and not to social consequences.
“Abuse” is also discouraged by the Office of Substance Abuse Prevention in the
USA, although terms such as “substance abuse” remain in wide use in North Ame-
rica to refer generally to problems of psychoactive substance use.
In other contexts, abuse has referred to non-medical or unsanctioned patterns of
use, irrespective of consequences. Thus the definition published in 1969 by the
WHO Expert Committee on Drug Dependence was “persistent or sporadic exces-
sive drug use inconsistent with or unrelated to acceptable medical practice”.
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ges could take place on at least two levels: exchanges of information on identified
and assessed Emerging Drug Phenomena and exchanges on collection,
analysis and dissemination techniques.
We hope that this is a starting point, and that step by step it will be possible to
implement and improve Early information function for Emerging Drug Phéno-
mena at both national and European level.
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Typically, tolerance is prominent and a withdrawal syndrome frequently occurs
when a substance use is interrupted. The life of the addict may be dominated by
substance use to the virtual exclusion of all other activities and responsibilities.
The term addiction also conveys the sense that such substance use has a detrimental
effect on society, as well as on the individual; when applied to the use of alcohol,
it is equivalent to alcoholism.
Addiction is a term of long-standing and variable usage. It is regarded by many
as a discrete disease entity, a debilitating disorder rooted in the pharmacological
effects of the drug, which is remorselessly progressive. From the 1920s to the 1960s
attempts were made to differentiate between “addiction” and “habituation”, a less
severe form of psychological adaptation. In the 1960s, the WHO recommended
that both terms be abandoned in favour of dependence, which can exist in various
degrees of severity.
Addiction is not a diagnostic term in ICD-10, but continues to be very widely
employed by professionals and the general public alike.
Addiction (EMCDDA, 1997)
Repeated use of a psychoactive substance or substances, with the consequen-
ces of:
- psychological dependence on a substance that produces drug-seeking behaviour
- an inability to stop use of the drug because of the physical dependence on the
drug and the tolerance to its effects
- deterioration of physical and mental health as a result of continued substance
abuse.
Adjustability (Euro-TREND, 2003)
Adjustability of the tool set should be ensured by the organisation responsible
for the EIF data collection step. The co-ordination team responsible for the EIF
should be able to develop strategies for implementing new collection tools, i.e. for
identifying new information sources, for developing new collection methods, trai-
ning new people and including them within the EIF (Euro-Trend, 2003).
Area(s) of interest (Euro-Trend 2003)
An area of interest is a particular topic of interest within a main line of inquiry. 
For each main line of inquiry, various relevant areas of interest have been iden-
tified; together they form an interesting work set to guide data collection and ana-
lyses in the respective main line of inquiry. 
Categorization (Euro-TREND 2003)
Categorization process for identified EDP will help in deciding which EDP are
candidates for submission to a specific assessment process. Indeed, a specific assess-
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Abuse (EMCDDA, 1997)
A maladaptive pattern of use of illicit psychoactive substance leading to clini-
cally significant impairment or distress, as manifested by one (or more) of the fol-
lowing criteria occurring within a 12-month period :
- recurrent substance use resulting in a failure to fulfil major role obligations at
work, school or home ;
- recurrent substance use in situations in which it is physically hazardous ;
- recurrent substance-related legal problems ;
- continued substance use despite having persistent or recurrent social or interper-
sonal problems caused by the effects of the substance.
Abuse: substance abuse (American Psychiatric Association, 2000)
A maladaptive pattern of substance use leading to clinically significant impair-
ment or distress, as manifested by one (or more) of the following, occurring within
a 12-month period:
- recurrent substance use resulting in a failure to fulfil major role obligations at
work, school, or home (e.g. repeated absences or poor work performance related
to substance use; substance related absences, suspensions, or expulsions from
school; neglect of children or household)
- recurrent substance use in situations in which it is physically hazardous (e.g., dri-
ving an automobile or operating a machine when impaired by substance use)
- recurrent substance-related legal problems (e.g. arrests for substance-related dis-
orderly conduct)
- continued substance use despite having persistent or recurrent social or interper-
sonal problems caused or exacerbated by the effects of the substance (e.g., argu-
ments with spouse about consequences of intoxication, physical fights)
Abuse liability (WHO, 1994)
The propensity of a particular psychoactive substance to be susceptible to abuse,
defined in terms of the relative probability that use of the substance will result in
social, psychological, or physical problems for an individual or for society. Under
international drug control treaties, WHO is responsible fro determining the abuse
liability and dependence potential, as distinct from therapeutic usefulness, of control-
led substances.
Addiction (WHO, 1994)
Repeated use of a psychoactive substance or substances, to the extent that the
user (referred to as an addict) is periodically or chronically intoxicated, shows a com-
pulsion to take the preferred substance (or substances), has great difficulty in volun-
tarily ceasing or modifying substance use, and exhibits determination to obtain
psychoactive substances by almost any means.
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Cluster analysis (Last, 2001)
A set of statistical methods used to group variables or observations into stron-
gly interrelated subgroups, i.e., to detect clusters in routine surveillance of disease.
Clustering (Last, 2001)
(Synonymous: disease cluster, time cluster, time-place cluster)
A closely grouped series of events or cases of a disease or other health-related
phenomena with well-defined distribution patterns in relation to time or place or
both. The term is normally used to describe aggregation of relatively uncommon
events or diseases, e.g., leukemia, multiple sclerosis.
Clustering (Elliot et al., 2000)
It is carried out to provide early detection of raised incidence of disease when
there is no specific aetiological hypothesis. More general studies of clustering, that
is the tendency for disease cases to occur in a non-random spatial pattern relative
to the pattern of the non-cases, have a more robust statistical formulation and again
may give clues as to aetiology.
Collection tool(s) (see “Tool(s)”)
Data (Last, 2001)
A collection of items of information
Data consumer (Griffiths et al., 1999)
Person responsible for translating the information into action of some form
Data producer (Griffiths et al., 1999)
Person responsible for compiling the data sets
Dependence (F1x.2) (WHO, 1994)
As a general term, the state of needing or depending on something or someone for
support or to function or survive. As applied to alcohol and other drugs, the term implies
a need for repeated doses of the drug to feel good or to avoid feeling bad. (…) In the ICD-
10 context, the term dependence could refer generally to any of the elements in the syn-
drome. The term is often used interchangeably with addiction and alcoholism.
(…) In unqualified form, dependence refers to both physical and psychological
elements? Psychological or psychic dependence refers to the experience of impaired
control over drinking or drug use (craving, compulsion), while physiological or phy-
sical dependence refers to tolerance and withdrawal symptoms. In biologically-orien-
ted discussion, dependence is often used to refer only to physical dependence. 
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ment could be conducted for some EDP identified as being important, depending
on the available resources, regardless of whether or not they are urgent.
An identified Emerging Drug Phenomenon should be categorized according to
its status in relation to the predefined selection criteria: diffusion potential (high or
low), health, social and economic consequences (important or otherwise) at both
the individual and the collective level. Thus, the categorization of EDP will be
structured in 24 groups (see the following Table).
All EDP with consequences categorized as “important” are candidates for spe-
cific assessment. Those with high diffusion potential will be considered a priority
concern. 
Categorization of identified edp
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Cluster (Last, 2001)
An aggregation of relatively uncommon events or diseases in space and/or in
time in amounts that are believed or perceived to be greater than could be expec-
ted by chance.
Putative disease clusters are often perceived to exist on the basis of anecdotal
evidence, and much effort may be expended by epidemiologists and biostatisti-
cians in demonstrating whether a true cluster exists.
Categorization of identified Emerging Drug Phenomena (EDP)
Diffusion potential
Consequences Low High
Health Individual Not important
Important
Collective Not important
Important
Social Individual Not important
Important
Collective Not important
Important
Economic Individual Not important
Important
Collective Not important
Important
 : EDP candidates for a specific assessment 
Dependence syndrome ( F1x.2) (WHO, 1994)
A cluster of behavioural, cognitive, and physiological phenomena that may develop
after repeated substance use. Typically, these phenomena include (1) a strong desire to
take the drug, (2) impaired control over its use, (3) persistent use despite harmful conse-
quences, (4) a higher priority given to drug use than to other activities and obligations,
(5) increased tolerance, and (6) a physical withdrawal reaction when drug use is dis-
continued. In ICD-10, the diagnosis of dependence syndrome is made if three or more
of six specified criteria were experienced within a year.
The dependence syndrome may relate to a specific substance (e.g. tobacco,
alcohol, or diazepam), a class of substances (e.g. opioids), or a wider range of phar-
macologically different substances.
Diffusion (OFDT, 2000)
The concept of diffusion is defined as a dynamic process which begins when
one or several persons (the initiated persons) use a substance until then unknown
or adopt a new way of consumption of a well-known substance, in given histori-
cal period and geographical area. These initiated persons promote the new sub-
stance or pattern of use, deliberately or not, creating therefore the geographical
and numeral spread of this use. 
This process can be divided in 4 phases: the “initiates circle” phase, the diffu-
sion phase, the plateau phase and the decreasing phase.
The length of this process and of each phase can be short (months), medium
(years) or long (decades). A substance or a pattern of use can have in the same geo-
graphical area one or several diffusion cycle.    
Diffusion of Innovation Theory (Griffiths et al., 1999)
Theoretical descriptive model of how new ‘innovations’ (products, ideas, etc.)
spread through populations over time.
If this theoretical model is to be helpful in predicting future trends a prelimi-
nary task will be to improve the collection of leading-edge indicators to which dif-
fusion of innovation theory can be applied.  As well as guiding the assessment of
data, diffusion theory may also provide a framework for identifying Leading Edge
Indicators because of the way it specifies the relevant roles and conditions for adop-
tion of an innovation. The eventual task would involve systematically mapping the
theory onto drug use in order to answer questions such as:
- In which social spheres do we find innovators and early adopters of psychoactive
substances? 
- What communication systems and cultural reference points are relevant? 
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Glossary
Dependence or physical dependence is also used in the psychopharmacologi-
cal context in a still narrower sense, referring solely to the development of with-
drawal symptoms on cessation of drug use. In this restricted sense, cross-depen-
dence is seen as complementary to cross-tolerance, with both referring only to
physical symptomatology.
Dependence (EMCDDA, 1997)
A medical diagnostic term according to which three or more of the following
criteria coincide within a 12-month period:
- strong desire or sense of compulsion to take substance
- difficulties in controlling substance-taking behaviour
- a physiological withdrawal state or syndrome
- evidence of increasing tolerance
- progressive neglect of alternative pleasures because of the psychoactive substance use
- persisting with substance use despite harmful consequences of the use.
Dependence Substance (American Psychiatric Association, 2000)
A maladaptive pattern of substance use, leading to clinically significant impair-
ment or distress, as manifested by three (or more) of the following, occurring at any
time in the same 12-month period:
- tolerance, as defined by either of the following:
(a) a need for markedly increased amounts of the substance to achieve intoxication
or desired effect
(b) markedly diminished effect with continued use of the same amount of the substance
- withdrawal, as manifested by either of the following:
(a) the characteristic withdrawal syndrome for the substance (refer to Criteria A and
B of the criteria sets for Withdrawal from the specific substances)
(b) the same (or a closely related) substance is taken to relieve or avoid withdrawal
symptoms
- the substance is often taken in larger amounts or over a longer period than was intended
- there is a persistent desire or unsuccessful efforts to cut down or control substance use
- a great deal of time is spent in activities necessary to obtain the substance (e.g., visiting
multiple doctors or driving long distances), use the substance (e.g., chain-smoking), or reco-
ver from its effects
- important social, occupational, or recreational activities are given up or reduced
because of substance use
- the substance use is continued despite knowledge of having a persistent or recur-
rent physical or psychological problem that is likely to have been caused or exa-
cerbated by the substance (e.g., current cocaine use despite recognition of cocaine-
induced depression, or continued drinking despite recognition that an ulcer was
made worse by alcohol consumption)
to emphasise the point that the data is not a direct measure of drug use in the gene-
ral population. Thus, treatment demands may be indirectly related to wider pat-
terns of drug use, but cannot be assumed to directly represent the wider and unk-
nown patterns of drug use found in society. Even probability surveys of the general
population are considered indirect indicators of actual prevalence rates and cor-
responding patterns of use, as methodological problems inherent in their design
do not allow data to be taken on face value.     
Drug Information System (DIS) (Griffiths et al., 1999)
It is a “system that seeks to understand patterns of drug use by analysing data
from one or more data sources”. DIS should be able to meet the needs of different
information consumers. A DIS consists of data sources; procedures for analysis, eva-
luation and dissemination; and data providers and consumers.
Drug policy (see “Policy”) 
Drug related morbidity (see “Morbidity”)
Drug related mortality (see “Mortality”)
Drug related Problem (see “Problem”)
Early Information Function (eif) (Euro-TREND, 2003)
The EIF is one of the functions of a DIS. It is intended quickly to identify,
assess and categorize Emerging Drug Phenomena in order to allow the production
of relevant information and its timely dissemination to target audiences. To reach
its objective, the EIF should be a dynamic model structured in five operational
steps, which are connected in an ongoing process:
- data collection step 
- identification step: identification of EDP
- assessment step: standard and/or specific assessment of identified EDP
- dissemination step: selection and realization of a strategy for disseminating the
information produced
- follow-up/feedback step
EIF Indicator / eif Core Indicator (see “Indicator”)
Early Warning Function (EWF) (Griffiths et al., 1999)
Whilst some Drug Information Systems are dedicated to responding rapidly to
changes in patterns of drug use (i.e. an EWS), this does not necessarily imply that
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Disorder (WHO, 1994)
A group of conditions related to alcohol or other drug use. In ICD-10, section
F10-F19, “Mental and behavioural disorders due to psychoactive substance use”,
contains a wide variety of disorders of different severity and clinical form, all
having in common the use of one or more psychoactive substances, which may or
not have been medically prescribed. The substances specified are alcohol, opioids,
cannabinoids, sedatives or hypnotics, cocaine, other stimulants including caffeine,
hallucinogens, tobacco, and volatile solvents.
The clinical states that may occur, though not necessarily with all psychoactive
substances, include acute intoxication, harmful use, dependence syndrome, with-
drawal syndrome (state), withdrawal state with delirium, psychotic disorder, late-
onset psychotic disorder, and amnesic syndrome.
Drug (Zinberg, 1984) (see also «Set» and «Setting»)
The phamacologic action of the substance itself.
Drug characteristics (WHO, 2001)
- Substance identification: International Nonproprietary Name (INN) ; Chemical
Abstract Service (CAS) Registry Number; Other Names; Trade Names; Identifi-
cation Characteristics; WHO Review History
- Chemistry: Chemical Name, IUPAC Name, CA Name; Chemical Structure; Stereo-
isomers
- General pharmacology (psychoactive properties, other properties)
- Toxicology – Including adverse Reactions in Man
- Pharmacokinetics
- National control
- Therapeutic and industrial Use
- Illicit Manufacture, Illicit Traffic, and Related Information (Criminal use)
Drug control (WHO, 1994)
The regulation, by a system of laws and agencies, of the production, distribu-
tion, sale, and use of specific psychoactive drugs (controlled substances) locally,
nationally, or internationally. Alternatively, equivalent to drug policy.
Drug indicator (Griffiths et al., 1999)
Can be used to describe any data source on drug use used, together with a set
of agreed rules for recording and reporting, to measure drug use prevalence or inci-
dence.  Typical indicators include: first treatment demand; all treatment demands;
drug seizures; drug arrest; drug related deaths; survey data; price and purity infor-
mation; drug related medical emergencies etc.  The term ‘indicator’ is employed
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Fieldwork is traditionally defined as a particular kind of labour or work one
engages in to produce results. This labour requires means-end knowledge – a set
of procedural or tool skills (a kind of technical knowledge) used to solve the puzzle
of understanding human action.
Flexibility (Euro-TREND, 2003)
The flexibility of a collection tool refers to its capability to adapt to new, dif-
ferent, or changing requirements. A tool should be able to adjust to new situations
and changes over time and not become rigid.
Fluctuations (Griffiths et al, 1997)
In time series data, any short term back and forth movements that are unrela-
ted to long term trends. Sometimes fluctuations are so large that they make trends
difficult to see. The example often given is that of global warming, where it is dif-
ficult to assess whether the long term trend is for the planet to be getting warmer,
as it still gets cold in the winter (regular fluctuation). Also, sometimes temperatu-
res can be quite low in the summer (random non predictable fluctuation).
Follow-up (Euro-TREND, 2003)
Within the framework of an EIF, the follow-up of an Emerging Drug Phenomenon
or of a topic of interest is the act of continuing with the observation of this EDP or topic
of interest by collecting more data and thus producing further information on it. 
General (collection) tool(s) (see “Tools”)
Hard / soft drug (EMCDDA, 1997)
Hard drug: drugs defined in national legislation or in national court practices,
the use of which is associated with unacceptable risks.
Soft drug: drugs defined in national legislation or in national court practices, the
use of which is associated with less harmful risks.
Harmful use (WHO, 1994; EMCDDA, 1997)
A nondependent pattern of use of psychoactive substances that causes damage
to health, either mental or physical. Often also has adverse effects on the drug use-
r’s family, the community and society in general.
Social consequences in themselves, however, are not sufficient to justify a dia-
gnosis of harmful use.
Harm reduction (WHO, 1994)
Policies or programmes that focus directly on reducing the harm resulting from
the use of alcohol or drugs. The term is used particularly of policies or program-
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a broader DIS can not also incorporate this function as one part of its overall ope-
rational goals. In this model, a DIS would have an ‘early warning function’ without
being a dedicated ‘early warning system’. 
Early Warning System (EWS) (Griffiths et al., 1999)
Term commonly used without precision. It is taken as a Drug Information Sys-
tem (DIS) designed specifically for the purposes of identifying changes at an early
stage only. General assumption that attention is focussed on changes that have
implications for policy or interventions or other public health concerns. May be
focussed on one particular drug related concern such as HIV infection. 
The assumption that EWS are primarily interested in changes that have some
importance in terms of generating a response implies the analytical function of the
DIS is a necessary contingent. 
Emerging drug phenomenon (Phenomena) (edp) (Euro-TREND, 2003)
This is a drug-related change, which is observed for the first time. The fact that
it’s a first observation can be linked to the fact that it is a new phenomenon or that
it is a pre-existing phenomenon that has not been observed before but is perceived
now for the first time.  
An Emerging Drug Phenomenon can deal with a new pattern of use, a new
drug, a new population, a new perception, etc.
Feedback (Euro-TREND, 2003)
Feedback is the act of sending the information produced by the EIF back to all
the partners involved in operating the EIF: data collection professionals, local coor-
dinators, etc. – all the people who provided some information. 
Field work (Collins English dictionary and thesaurus, 1998)
An investigation or search for material, data, etc., made in the field as opposed
to the classroom or laboratory.
Field work (Schwandt, 2001)
This term refers to all those activities that one engages in while in the field,
including watching, listening, recording, interpreting, dealing with logistics, and
facing ethical and political dilemmas. It is an intensely personal and social pro-
cess requiring both physical and intellectual stamina, political acumen, and moral
sensitivity. Participant observation has traditionally been thought of as the metho-
dology employed in fieldwork, but interview studies (including life-history work
and oral history), case studies of various kinds, and co participative inquiries such
as action research all entail some aspects of fieldwork as well. 
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Illicit / Licit drug (EMCDDA, 1997)
Illicit drug: a psychoactive substance, the production, sale, possession or use of
which is prohibited in particular circumstances in national legislation.
Licit drug: a psychoactive substance that is legally available usually by medi-
cal prescription according to national legislation.
Indicator: eif Indicator / eif Core Indicator (Euro-TREND Project, 2003)
An EIF indicator is described as a variable, whatever its nature (qualitative or quan-
titative), that reflects an interesting characteristic of drug use or related to drug use. 
An EIF core indicator is an EIF indicator that appears particularly available,
accessible and useful for the identification of Emerging Drug Phenomena. In terms
of identifying an EDP, information on EIF core indicators is considered sufficient.
Changes in one or more EIF core indicators will serve as a signal, a starting point
for undertaking an assessment of a possible EDP. 
Informant (Schwandt, 2001)
This is one of several terms – including participant, subject, actor, respondent,
collaborator, interviewee, and the observed – used to identify the individuals that
a researcher studies. Informants are knowledgeable insiders and assist the field-
worker in gaining and maintaining access, developing an insider’s understanding
(or learning the actor’s point of view), and checking emerging understandings.
They act as a fieldwork assistant, debriefer, and guide and often provide the field-
worker with information on what or she cannot experience.
A researcher-informant relationship reflects the assumption that the field-worker
is in position of learning about a culture or group, and t he informant serves as a spe-
cial kind of teacher, guide, and facilitator. This relation and role is often cultivated by
the field-worker; an informant is identified, selected, and trained to the role. Infor-
mants often become the confidant and trusted adviser of the field-worker, developing
a special bond of trust. Whereas rapport characterizes the field-worker’s relationship
with most participants in a given study, friendship is more likely with informants. 
Information / Quick information / Relevant information 
Information is facts (i.e., data) that have been arranged and/or processed to pro-
vide the basis for interpretation and conversion into knowledge. (Last, 2001)
Quick information (Euro-TREND, 2003) is information on topics that require urgent
decisions to be taken. It is, for example, information on urgent problems, such as the
emerging use of a dangerous substance, or the observation of deaths related to drug use. 
relevant information (Euro-TREND, 2003) is information that is useful for the
purpose of the EIF, i.e. information which concerns the identified areas of inte-
rest and EIF indicators .
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mes that aim to reduce the harm without necessarily affecting the underlying drug
use; examples includes needle / syringe exchanges to counteract needle-sharing
among heroin users. Harm reduction strategies thus cover a wider range than the
dichotomy of supply reduction and demand reduction. 
Harm reduction (Griffiths et al, 1997)
A harm reduction philosophy takes the view that it is of greater benefit to the
common good to actively attempt to reduce the harm that drugs can cause rather
than simply try to prevent drug taking. It is a pragmatic approach that, recognises
the difficulties inherent in attempting to prevent all forms of illicit drug taking, and
emphasises maximising benefits and minimising harm.
Hazardous use (WHO, 1994)
A pattern of substance use that increases the risk of harmful mental health (as
in harmful use); some would also include social consequences. In contrast to harm-
ful use, hazardous use refers to patterns of use that are of public health significance
despite the absence of any current disorder in the individual user.
Hidden population (Griffiths et al., 1999)
In its simplest form, a population group for which no easily identifiable sam-
pling frame exists.  Often used to refer to groups such as the users of illicit drugs
in which the behaviour is sanctioned and therefore often ‘hidden from view’.  For
research purposes, poses problems of access and generalisation.
Human network (Griffiths et al., 1999)
Configured from a range of individuals or organisations represented by indivi-
duals. Members are chosen to bring either general or scientific knowledge or exper-
tise to the DIS. In general, networks adopt an unstructured approach with flexible
information flow. Different members bring information or analytical comment in
accordance with their specific background or expertise.
Illicit / Licit drug (WHO, 1994)
Illicit drug: a psychoactive substance, the production, sale, possession or use of
which is prohibited. Strictly speaking, it is not the drug that is illicit, but its pro-
duction, sale, or use in particular circumstances in a given jurisdiction. “Illicit drug
market”, a more exact term, refers to the production, distribution, and sale of any
drug outside legally sanctioned channels.
Licit drug: a drug that is legally available by medical prescription in the juris-
diction in question, or, sometimes, a drug legally available without medical pres-
cription. 
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The symptoms are not due to a general medical condition and are not better
accounted for by another mental disorder. 
Joint Action on Synthetic Drugs (Griffiths et al., 1999)
Full title ‘Joint Action on the information exchange, risk assessment and the
control of new synthetic drugs’.  European Union agreement that establishes a
bipartisan structure with national intelligence agencies reporting to EUROPOL
and National Focal Points of the REITOX Network reporting to EMCDDA. The
system is designed to provide an early warning system on the use of new synthe-
tic compounds.
Lagged indicator (Griffiths et al., 1999)
Term used to describe an indicator that has a structural and pronounced time lag
in terms of reporting drug incidence. Treatment demands are a classic lagged indi-
cator as individuals typically consume an illicit substance for several years before
approaching treatment services. Should be viewed as indicating a position on a
continuum rather than an explicit category, may vary by drug type and geographi-
cal and temporal location.
Leading Edge indicator (LEI) (Griffiths et al., 1999)
Any indicator that can be considered particularly sensitive to change i.e. those
indicators that respond first to changes in drug consumption patterns (drug incidence).
This sensitivity, by definition, is associated with volatility. As such, LEIs may be
unreliable in the medium term if viewed in isolation from other data sources.
Most developed indicators of drug consumption can be considered lagged to
some extent. Other indicators, and to some extent those less commonly used in
information systems, may be more sensitive to change. For the purposes of this
report, we have coined the term ‘leading edge indicator’ to refer to those data sour-
ces that may be most efficient in identifying changes at an early stage in their deve-
lopment.  It is important to remember that this distinction is conceptual rather than
strictly categorical. 
Weaknesses exist in all information sources in this area and all indicators can
be seen to perform poorly in some respect.  The task for an integrated Drug Infor-
mation System is to balance the strengths of one information source against the
weaknesses in others. The fact that the use of LEI may often raise more questions
than provide answers should be seen as a strength, rather than a weakness of these
kind of information sources. The task is to raise the issue earlier than is currently
the case and allow other more time consuming but more stable indicators to be
focussed on the potential problem. Scientifically rigorous evidence of an indispu-
table change in drug consumption patterns is unlikely to ever be rapidly available
and may often be produced so long after the event that the information is only of
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Information system (Last, 2001)
As applied in epidemiology, a combination of vital and health statistical data
from multiple sources, used to derive information about the health needs, health
resources, costs, use of health services, and outcomes of use by the population of
a specified jurisdiction. The term may also describe the automatic release from
computers of stored information in response to programmed stimuli. For example,
parents can be notified when their children are due to receive booster doses of an
immunizing agent against infectious disease.
Information system (Rothman et al, 1998) 
It is a large data bases collected for general, rather than disease-specific pur-
poses, which can applied to the surveillance of specific conditions. In some instan-
ces, their use for monitoring health may be secondary to other objectives. Because
these Information Systems serve multiple objectives, their use for surveillance (or
research) requires care. 
Intoxication (WHO, 1994)
A condition that follows the administration of a psychoactive substance and
results in disturbances in the level of consciousness, cognition, perception, jud-
gement, affect, or behaviour, or other psychophysiological functions and respon-
ses. The disturbances are related to the acute pharmacological effects of, and
learned responses to, the substance and resolve with time, with complete reco-
very, except where tissue damage or other complications have arisen. The term
is most commonly used with regard to alcohol use; it’s equivalent in every day
speech is “drunkenness”. (…)
Intoxication is highly dependent on the type and dose of drug and is influen-
ced by an individual’s level of tolerance and other factors. Frequently, a drug is
taken in order to achieve a desired degree of intoxication. The behavioural expres-
sion of a given level of intoxication is strongly influenced by cultural and per-
sonal expectations about the effects of the drug. 
Intoxication: Substance Intoxication (American Psychiatric Association,
2000)
The development of a reversible substance-specific syndrome due to recent
ingestion of (or exposure to) a substance. Note: Different substances may produce
similar or identical syndromes.
Clinically significant maladaptive behavioural or psychological changes that are
due to the effect of the substance on the central nervous system (e.g., belligerence,
mood liability, cognitive impairment, impaired judgement, impaired social or occu-
pational functioning) and develop during a shortly after use of the substance.
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Misuse (EMCDDA, 1997)
Excessive use of (usually licit) psychoactive substances inconsistent with or
detrimental to social, legal or medical guidelines and consequences.
Monitoring (Last, 2001)
The intermittent performance and analysis of routine measurements, aimed at
detecting changes in the environment or health status of populations. Not to be
confused with surveillance which is a continuous process. To some, monitoring
also implies intervention in the light of observed measurements.
Episodic measurement of the effect of an intervention on the health status of a
population or environment. Not to be confused with surveillance, although the
techniques of surveillance may be used in monitoring. The process of collecting and
analysing information about the implementation of a program for the purpose of
identifying problems such as non compliance and taking corrective action.
(WHO,1989).
In management, the episodic oversight of  the implementation of an activity, see-
king to ensure that input deliveries, work schedules, targeted outputs, and other
required actions are proceeding according to plan.
Morbidity: Drug related morbidity (EMCDDA, 1997)
The existence of any health problem either physical or mental that is related to
drug use, independently of whether this is defined with a primary or a secondary
diagnosis of the disease.
Mortality: Drug related mortality (EMCDDA, 1997)
Deaths related to drug use whether directly, when drug use is included in the
main causes of death, or indirectly.
Multi-Indicator Model (Griffiths et al., 1999)
Term used to describe a common method for modelling patterns of drug use that uti-
lises and contrasts two or more different indicators of drug consumption. It is assumed
that the use of multiple indicators mitigates for the inadequacies of any individual indi-
cator and that multiple indicators plotted over time therefore give a better picture of
underlying trends.    
Multiple drug use (see “Polydrug use”)
Policy: Drug policy (WHO, 1994)
In the context of psychoactive drugs, the aggregate of policies designed to affect
the supply and/or the demand for illicit drugs, locally or nationally, including edu-
cation, treatment, control, and other programmes and policies. In this context, “drug
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historical interest. Leading edge indicators might include media and cultural moni-
toring, incorporating information from panels of known drug users, or key infor-
mant data.
Main line(s) of inquiry (Euro-TREND, 2003)
A main line of inquiry is a broad field of interest related to drug use. The main lines
of inquiry will serve as landmarks for collecting and analysing data that are relevant to
identify, describe and analyse Emerging Drug Phenomena.
To describe and analyse drug phenomena, related to use, the EIF will have to pro-
duce information on the narrow (directly related to the users) and broad (socio-econo-
mic, political, etc.) setting. Therefore, the three main lines of inquiry for data collection
are:
- “users” corresponding to any data or information on the person or closely rela-
ted to the person 
- “substances” corresponding to any data or information on substances or closely
related to these substances
- “setting” corresponding to any data or information on the physical and social
environment. The narrow level is related to the direct physical and social users’
environment. The broad level corresponds to the local, regional and national envi-
ronment. 
Media (Medium in the singular): Primary media / secondary media
(Euro-TREND, 2003)
Primary media for disseminating the information are written documents pro-
duced directly from the inputs without using any other material. Inputs, as such,
are also primary media. These are called “primary” media because they are the
inputs as they stand (quick information note, standard report, specific report)
or documents produced directly from the inputs without using any other mate-
rial. 
Secondary media are dissemination tools that may take various forms: preven-
tion tools, care tools, knowledge-enhancement tools, law-enforcement tools, etc.
The format of secondary media will therefore have to match certain characteristics
of the target audiences. Thus the development of secondary media requires, in addi-
tion to the inputs or primary media, more information and/or specific competen-
ces: specialists will be needed to produce secondary media. 
Misuse (WHO, 1994)
Use of a substance for a purpose not consistent with legal or medical guideli-
nes, as in the non-medical use of prescription, medications. The term is preferred
by some to abuse in the belief that it is less judgemental.
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Primary Media (medium) (see “Media”)
Problem: Drug related problem (WHO, 1994)
Any of the range of adverse accompaniments of drug use, particularly illicit
drug use. “Related” does not necessarily imply causality. The term can be used to
refer to problems at an individual or societal level. In international drug control, drug-
related problems are taken into account in setting a level of control for a control-
led substance through a WHO assessment of the drug’s dependence potential and
abuse liability. “Drug problems” is a possible cognate term, but can be confused
with “the drug problem”, meaning illicit drugs as a policy issue.
Psychoactive substance (EMCDDA, 1997)
A substance that, when consumed, affects mental processes, e.g. cognition or
affect.
Psychoactive substance (WHO, 1994)
This term is the most neutral and descriptive terms for the whole class of sub-
stances, licit and illicit, of interest to drug policy. “Psychoactive” does not neces-
sarily imply dependence-producing.
Psychotropic (WHO, 1994)
In the most general sense, the term means affecting the mind or mental pro-
cess. Strictly speaking, a psychotropic drug is any chemical agent whose primary
or significant effects are on the central nervous system. In the context of interna-
tional drug control, “psychotropic substances” refers to substances controlled by
the 1971 Convention on Psychotropic Substances. 
Psychotropic substance (EMCDDA, 1997)
Any chemical agent whose primary or significant effects are on the central ner-
vous system.
Polydrug use or multiple drug use (WHO, 1994)
The use of more than one drug or type of drug by an individual, at the same time
or sequentially, and usually with the intention of enhancing, modifying, potentia-
ting or counteracting the effect of another drug.
The term is also used more loosely, to include the unconnected use of two or
more by the same person. It carries the connotation of illicit use, though alcohol,
nicotine, and caffeine are the substance the most frequently used in combination
with others in industrialized societies.
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policy” often does not include pharmaceutical policy (except with regard to diver-
sion to non-medical use), or tobacco or alcohol policy.
In the context of WHO’s Action Programme on Essential Drugs, “national drug
policy” refers to a national pharmaceutical policy concerning the marketing, avai-
lability, and therapeutic use of medicines. WHO recommends that every country
should have such a policy, formulated in the context of a national health policy.
The WHO List of Essential Drugs is an effort to assist developing countries to
develop a pharmaceutical policy attuned to allocating scarce funds for pharma-
ceuticals on the basis of health needs rather than market considerations.
Policy: Pharmaceutical policy (WHO, 1994)
The system of regulations intended to affect the availability of and demand for
pharmaceutical drugs.
Prevention (Last, 2001)
Actions aimed at eradicating, eliminating, or minimizing the impact of disease
and disability, or if none of these feasible, retarding the progress of disease and dis-
ability. The concept of prevention is best defined in the context of levels, traditionally
called primary, secondary, and tertiary prevention. A fourth level, called primordial pre-
vention, was later added. In epidemiologic terms, primordial prevention aspires to
establish and maintain conditions that minimize hazards to health, primary preven-
tion aims to reduce the incidence of disease, secondary prevention aims to reduce the
prevalence of disease by shortening its duration, and tertiary prevention aims to reduce
the number and/or impact of complications.
Primordial prevention consists of actions and measures that inhibit the emer-
gence and establishment of environmental, economic, social and behavioural condi-
tions, cultural patterns of living, etc., known to increase the risk of disease. This is
the task of public  health policy and of health promotion.
Primary prevention is protection of health by personal and communal efforts,
such as enhancing nutritional status, immunizing against communicable diseases,
and eliminating environmental risks, such as contaminated drinking water sup-
plies. This is the task of public health.
Secondary prevention is a set of measures available to individuals and com-
munities for the early detection and prompt intervention to control disease and
minimize disability, e.g., by the use of screening programs. This is the task of pre-
ventive medicine.
Tertiary prevention consists of measures aimed at softening the impact of long-
term disease and disability by eliminating or reducing impairment, disability, and
handicap; minimizing suffering; and maximizing potential years or useful life. This
is the task of rehabilitation.
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Quantitative data (Last, 2001)
Data in numerical quantities, such as continuous measurements or counts.
Qualitative research (EMCDDA, 2000)
The role of qualitative research into illicit drug use can be envisaged as a means
of understanding the lived experiences and meanings of drug use from the per-
spectives of drug users themselves. Additionally, as a means of understanding action
as socially organised, qualitative research aims to understand how the lived expe-
riences and meanings associated with drug use are influenced by different social,
cultural and economic contexts. At the outset, qualitative research aims to describe
the context-based nature of drug use and the social meanings that such behaviours
are perceived to have.
The multiple roles played by the qualitative research include:
- reaching and researching hidden populations;
- understanding the experience and meaning of drug use; 
- understanding the social context of drug use;
- informing the design of quantitative research; 
- complementing and questioning the results of quantitative research; and
- developing effective interventions and policy responses.
In short, qualitative research is seen as a prerequisite for understanding and
responding to drug use.
Quick information (see “Information”)
Rapid Assessment Methodology (RAM) (Griffiths et al., 1999) 
Term coined for set of methods developed initially to rapidly assess the drug
&/or health situation in countries where the epidemiological systems are poorly
developed. Increasingly used to describe specific methodologies, strategies deve-
loped by the World Health Organisation (WHO) and United Nations Drug Control
Program (UNDCP). RAMs provide a toolbox of assessment tools that allows the
rapid collection of key informant accounts and other qualitative data as well as
auditing existing quantitative information to quickly produce an information set
to guide policy formation or interventions. Intended as a pragmatic and practical
approach to informing health care delivery rather than seeking to produce scienti-
fically rigorous research.   
Rapid Assessment and Response Methodology (Stimson et al., 1998)
Rapid Assessment and Response methodology is a means for depicting the
extent and nature of social and health problems and for suggesting ways in which
they may be improved. Rapid Assessment and Response provides an appropriate
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Multiple drug use disorder is one of the “Mental and behavioural disorders
due to psychoactive substance use” in ICD-10, diagnosed only when two or more
substances are known to be involved and it is impossible to assess which sub-
stance is contributing most to the disorder. The category is also used when the
exact identity of some or even all of the substances being used is uncertain or
unknown, since many multiple drug users often do not know themselves what
they are taking. 
The French term “polytoxicomanie” conveys a meaning similar to that of multi-
ple drug use, except that dependence on one or more of the drugs taken is assumed.
Qualitative (Schwandt, 2001)
This is a not-so-descriptive adjective attached to the varieties of social inquiry
that have their intellectual roots in hermeneutics, phenomenological sociology, and
the Verstehen tradition. Many scholars use the phrase qualitative inquiry as a blan-
ket designation for all forms of social inquiry that rely primarily on qualitative data
(i.e., data in the form of words), including ethnography, case study research, natu-
ralistic inquiry, ethnomethodology, life-history methodology, and narrative inquiry. 
To call a research activity qualitative inquiry may broadly mean that it aims at
understanding the meaning of human action. 
Perhaps the clearest use of the adjective is to distinguish between qualitative data
– nonnumeric data in the form of words – and quantitative data – numeric data.
The term is also used, however, as a modifier for method, methodology, research,
and paradigm and as a synonym for nonexperimental and ethnographic. Because
the adjective is used in so many different ways, it does not clearly signal a parti-
cular meaning or denote a specific set of characteristics for qualitative research.
Often, the use of the term qualitative involves both implicit and explicit com-
parisons to some equally ambiguously used adjective, “quantitative”- as, for exam-
ple, in the phrase “qualitative methods versus quantitative methods”. Broadly spea-
king, qualitative methods are procedures including unstructures, open-ended
interviews and participant observation that generate qualitative data, whereas so-
called quantitative methods (e.g., structured questionnaires, psychometric measu-
res, and tests) are means of generating quantitative data. 
Qualitative data (Last, 2001)
Observation or information characterized by measurement on a categorical
scale, i.e., a dichotomous or nominal scale, or, if the categories are ordered, an
ordinal scale.
Systematic nonnumerical observations by sociologists, anthropologists, etc.,
using approved methods such as participant observation or key informants. Qua-
litative data can enrich understanding of complex problems and help to explain
why things happen.
114
Glossary
(similar observations within the same period across different methods, e.g., obs-
ervation and interview). Others argue that reliability can and must be addressed in
fieldwork by using conventionalised methods for recording fieldnotes and analy-
sing transcripts as well as making interrater checks on coding and categorization
procedures and results. Still others have called for establishing dependability –an
analog to reliability- through careful documentation of procedures for generating
and interpreting data. Here, reliability is a matter of assembling dependable evidence,
and the methods used to assemble this evidence matter. (Making a claim about the
meaning of this evidence is a validity issue.) Finally, some argue that reliability in
qualitative study is a fiction because no investigator can ever literally replicate ano-
ther’s fieldwork. 
Risk (Last, 2001)
The probability that an event will occur, e.g., that an individual will become ill
or die within a stated period of time or by a certain age. Also, a non technical term
encompassing a variety of measures of the probability of a (generally) unfavoura-
ble outcome.
Risk (EMCDDA, 1999)
The concept of “risk” should be understood in its dual sense, which includes
both the element of probability that some harm may occur (usually defined as
“risk”) and the degree of seriousness of such a harm (usually defined as “hazard”).
If possible, both elements should be evaluated in the final phase of the risk-assess-
ment process. In addition, and where feasible, a risk-benefit ratio should be asses-
sed for each candidate drug.
Risk related to any psychoactive drug, whether legal or illegal, medical or recrea-
tional, can originate from several sources and assume many shapes and forms. For both
analytical and pragmatic (social control options) purposes, it is essential to clarify both
the type and origin of drug-related risks as they manifest themselves in society.
The sources from which drug hazards emanate: (i) properties of the substance
(pharmacology and toxicology); (ii) measures of social control (regulatory poli-
cies and informal norms); (iii) modalities of drug use (patterns, context of use);
(iv) individual characteristics of users (age, gender, genetic, personality).
The type of hazardous effects that may be caused by drug use:
On the user: (i) biological (toxicity, dependence); (ii) psychological (functio-
nal impairment, effects on personality); (iii) behavioural (neglect of social roles,
violence, etc.). Distinguishing domains from which the harmful effects of drugs
originate has obvious consequences for the drug policy options to be taken after the
risk-assessment procedure.
On the social environment: (i) family –micro level (disruption, neglect, vio-
lence); (ii) neighbourhood and community – meso level (public disorder and inse-
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methodology not only for planning interventions, but also for assessing the deve-
lopment and implementation of interventions.
Rapid assessment is the application of Rapid Assessment and Response to spe-
cific problems in specific locations.
Rapid assessments can identify:
- the appropriateness of proposed interventions
- obstacles to proposed interventions
- the feasibility of proposed interventions
Recreational use (WHO, 1994)
Use of a drug, usually an illicit drug, in sociable or relaxing circumstances, by
implication without dependence or other problems. The term is disfavoured by
those seeking to define all illicit drug use as a problem. 
Relevant information (see “Information”)
Reliability (Euro-TREND, 2003)
The Reliability of the collected data indicates whether the measurements are
consistent and replicable over time by another researcher. Reliability is necessary
but not sufficient for establishing the truth of an account or interpretation of the
drug phenomenon.
Reliability (Last, 2001)
The degree of stability exhibited when a measurement is repeated under iden-
tical conditions. Reliability refers to the degree to which the results obtained by a
measurement, procedure can be replicated. Lack of reliability may arise from diver-
gences between observers or instruments of measurement or instability of the attri-
bute being measured.
Reliability (Schwandt, 2001)
This is an epistemic criterion thought to be necessary but not sufficient for esta-
blishing the truth of an account or interpretation of a social phenomenon. An account
is judged to be reliable if it is capable of being replicated by another inquirer. Tra-
ditionally, social scientists assume that although not all repeatable or replicable
observations or accounts are necessarily valid, all valid accounts are (at least in
principle) replicable. Opinion is divided among qualitative researchers regarding
whether this criterion has any meaning whatsoever in judging the accuracy of field-
work accounts. Some scholars emphasize the importance of repeatability of obs-
ervations within a given study both diachronically (the stability of a field-worke-
r’s observations across data drawn from different time periods) and synchronically
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Risk management (Last, 2001)
The steps taken to alter, i.e., reduce, the levels of risk to which an individual or
a population is subject. The managerial, decision-making, and active hazard control
process to deal with environmental agents of disease, such as toxic substances, for
which risk evaluation has indicated an unacceptably high level of risk. The pro-
cess consists of three steps, as follows:
- Risk evaluation: Comparison of calculated risks or public health impact of
exposure to an environmental agent with the risks caused by other agents or socie-
tal factors, and with the benefits associated with the agent, as a basis for, deciding
what is acceptable risk
- Exposure control: Actions taken to keep exposure below an acceptable maxi-
mum limit
- Risk monitoring: The process of measuring reduction in risk after exposure
control actions have been taken in order to reassess risks and initiate further control
measures if necessary
Robustness (Euro-TREND, 2003)
The Robustness of a collection tool is the ability to provide data that is suffi-
ciently accurate and comprehensive for identifying and assessing an Emerging
Drug Phenomenon even under difficult data collection. A tool that uses a rough
and ready method will be preferred to a sophisticated and expensive one. 
Secondary media (medium) (see “Media”)
Sensitivity analysis (Last, 2001)
A method to determine the robustness of an assessment by examining the extent
to which results are affected by changes in methods, values of variables, or assump-
tions. The aim is to identify variables whose values are most likely to change the
results or to find a solution that is relatively stable for the most commonly occur-
ring values of these variables.
Sensitivity / Specificity (Last, 2001)
The proportion of truly diseased persons in the screened population who are
identified as diseased by the screening test
Sensitivity is a measure of the probability of correctly diagnosing a case, or
the probability that any given case will be identified by the test (syn: true posi-
tive rate).
Specificity is the proportion of truly nondiseased persons who are so identified
by the screening test. It is a measure of the probability of correctly identifying a
nondiseased person with a screening test (syn: true negative test).
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curity); (iii) society at large – macro level (effects on the economy, public health
and judicial systems)
The risk assessment of new synthetic drugs should include a strategy for deci-
ding the different weights and priorities of both the sources and the effects of drug
hazards for the final evaluation. In assessing the risks of a particular drug, five key
variables likely to affect the hazards and risks related to that drug should be taken
into consideration:
- Dose and frequency of use
- Short-term and especially long-term effects
- Interactions with other substances (including alcohol and medicaments)
- Individual characteristics
- Characteristics of the social environment
Risk: Absolute risk reduction (Last, 2001)
The amount, preferably expressed as a percentage, by which the risk of a dis-
ease is reduced by elimination or control of a particular exposure. It is possible
from this to estimate the number of people spared the consequences of an exposure.
In clinical epidemiology, the proportion of untreated persons who experience
an adverse event, minus the proportion of treated persons who experience this
event; used in calculating number needed to treat.
Risk assessment (Last, 2001)
The qualitative or quantitative estimation of the likelihood of adverse effects that
may result from exposure to specified health hazards or from the absence of bene-
ficial influences
Risk assessment uses clinical, epidemiologic, toxicologic, environmental,
and any other pertinent data. The process of determining risks to health attri-
butable to environmental or other hazards. The process consists of four steps, as
follows:
- Hazard identification: Identify the agent responsible for the health problem,
its adverse effects, the target population and the conditions of exposure.
- Risk characterisation: Describing the potential health effects of the hazard,
quantifying dose-effect and dose-response relationships.
- Exposure Assessment: quantifying exposure (dose) in a specified population
based on measurement of emissions, environmental levels of toxic substances, bio-
logic monitoring, etc.
- Risk estimation: combining risk characterisation, dose-response relationship,
and exposure estimates to quantify the risk level in a specific population. The end
result is a qualitative and quantitative statement about thee health effects expected and
the proportion and number of affected people in a target population, including estimates
of the uncertainties involved. The size of the exposed population must be known.
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Substance withdrawal (see “Withdrawal”) 
Surveillance (Last, 2001)
Systematic ongoing collection, collation, and analysis of data and the timely disse-
mination of information to those who need to know that action can be taken. Surveillance
is the essential feature of epidemiological practice. It is distinguished from monitoring
by the fact that it is continuous and ongoing, whereas monitoring is intermittent or epi-
sodic. Surveillance has been defined and described at greater length, e.g., by the Cen-
ters for Disease Control and Prevention: The ongoing systematic collection, analysis,
and interpretation of health data, essential to the planning, implementation, and evalua-
tion of public health practice, closely integrated with the timely dissemination of these
data to those who need to know. The final link in the surveillance chain is the applica-
tion of these data to prevention and control. A surveillance system includes a functional
capacity for data collection, analysis, and dissemination linked to public health programs
(Centers for Disease Control, 1996).
Another definition gives some details about sources of surveillance data: conti-
nuous analysis, interpretation, and feedback of systematically collected data, gene-
rally using methods distinguished by t heir practicality, uniformity, and rapidity
rather than by accuracy or completeness (Eylenbosch et al., 1988). 
By observing trends in time, place, and persons, changes can be observed or anti-
cipated and appropriate action, including investigative or control measures, can be
taken. Sources of data may relate directly to disease or to factors influencing dis-
ease. Thus they may include: (i) mortality and morbidity reports based on death cer-
tificates, hospital records, general practice sentinels, or notifications; (ii) laboratory
diagnoses; (iii) outbreak reports; (iv) vaccine utilization-uptake and side effects; (v)
sickness absence records; (vi) disease determinants such as biological changes in
agent, vectors, or reservoirs; (vii) susceptibility to disease, as by skin testing or
serological surveillance e.g., serum banks. 
Surveillance (Rothman et al, 1998)
It is a continuous and systematic process of collection, analysis, interpretation,
and dissemination of descriptive information for monitoring health problems. Sur-
veillance systems are networks of people and activities that maintain this process
and may function at a range of levels, from local to international. […] When new
public health problems emerge, the rapid implementation of surveillance is criti-
cal to an effective early response. […] In the long term, surveillance is used to
identify changes in the nature or extent of health problems. […] Surveillance sys-
tems are generally called upon to provide descriptive information regarding when
and where health problems are occurring and who is affected – the basic epide-
miologic parameters of time, place and person. The primary objective of surveillance
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Sensitivity / specificity (Rothman et al, 1998)
In the case of discrete variables, the sensitivity of an exposure measurement
method is the probability that someone who is truly exposed will be classified as
exposed by the methods. The false-negative rate of the methods is the probability
that someone who is truly exposed will be classified as unexposed: it equals one
minus the sensitivity.
The specificity of the method is the probability that someone who is truly unex-
posed will be classified as unexposed. The false-positive rate is the probability that
someone who is truly unexposed will be classified as exposed; it equals one minus
the specificity.
These terms (sensitivity, specificity, false-negative rate, false-positive rate) can
also be applied to descriptions of the methods of disease measurement.
Set (Zinberg, 1984)
The attitude of a person at the time of use, including his personnality structure.
Setting (Zinberg, 1984)
The influence of the physical and social setting within which the use occurs.
Specific assessment (Euro-TREND, 2003)
The EIF specific assessment is a more in-depth analysis of certain recently
identified important Emerging Drug Phenomena which may or may not require an
additional data collection. 
Specific eif tool(s) (see “Tool(s)”)
Specificity (see “Sensitivity”)
Standard assessment (Euro-TREND, 2003)
The EIF standard assessment is the first-level assessment that uses relevant
information previously obtained from data collection tools in order to give the most
detailed description possible of each identified EDP.
Substance abuse (see “Abuse”)
Substance intoxication (see “Intoxication”) 
Substance use disorder (see “Disorder”) 
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Tools: Collection tool(s) / General Tool(s) / Specific EIF Tool(s) (Euro-
TREND, 2003)
A collection tool is defined as a whole composed of one or more data collec-
tion professional(s) who gather information from an information source by using
a specific method, with specific instrument.
A general tool is not specially constructed for the identification and description
of Emerging Drug Phenomena. However, it deals with topics of interest for the
EIF and they could provide data on Emerging Drug Phenomena as a by-product.
A specific EIF tool is constructed for identifying and assessing Emerging Drug
Phenomena. In fact, it is necessary for specific EIF tools to be developed owing to
the fact that the data provided by general tools within the DIS may not be sufficient
for the EIF for EDP. 
Topic of interest (Euro-TREND, 2003)
A topic of interest is information produced by the EIF which is not sufficiently
robust to identify an EDP, but which reveals a potential concern and merits being
monitored. A topic of interest will be subject to continuous observation which
should allow it to be identified if it evolves to a formal EDP or if it remains as a
cluster of events or a “rumour”. 
Triangulation (Euro-TREND, 2003)
Triangulation is a process for pooling items of information relating to the same
EIF indicator obtained from many and varied information sources and tools, often
using different methods. This allows a greater confidence in the validity and repre-
sentative nature of the information (Rhodes et al., 1998). Triangulation aims to
assess the support for a finding by showing to what extent to which the various
results agree with each other. 
Triangulation (Stimson et al, 1998a and 1998b )
Adequacy rather than scientific perfection, one of the special features of rapid
assessments, distinguishes them from the other social science investigations. Relia-
bility and validity are established through cross-checking multiple sources of data,
sometimes referred as “data triangulation”. Triangulation means getting informa-
tion from different and multiple sources, often using different methods, until the
researcher is confident of the validity and representativeness of the information,
and of the diversity, conflicts and contradictions within a society. 
Triangulation (Schwandt, 2001)
This is a procedure used to establish the fact that criterion of validity has been
met. The field-worker makes inferences from data, claiming that a particular set of
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is most commonly to monitor the incidence or prevalence of specific health pro-
blems over time to document their impact in defined populations. […] Monitoring
trends is the cornerstone objective of most surveillance systems. The detection of
an increase in adverse health events can alert health agencies to the need for fur-
ther investigation. When outbreaks or disease clusters are suspected, surveillance
can provide an historical perspective in assessing the importance of perceived or
documented change in incidence. Alternatively, trends identified through sur-
veillance can provide an indication of the success of interventions, even though
more detailed studies may be required to evaluate programs formally. […] Trends
detected through surveillance can be used to anticipate future trends, assisting
health planners. […] Surveillance systems can also characterize persons who are
affected by health problems and to identify groups at highest risk for these pro-
blems. […] Surveillance systems can be used to describe health problems them-
selves.
Synthetic drug (Griffiths et al., 1997)
A useful catch-all term referring to psychoactive substances artificially produ-
ced in laboratories from chemical raw materials (precursors) rather than from natu-
ral products. In this instance, it refers to ecstasy and analogues, amphetamine and
LSD. The term should be used with care as there are synthetic sedative-depres-
sants and analgesics, as well as hallucinogens and stimulants.
Target audience (Euro-TREND, 2003)
Target audiences are people or groups of people to whom the information should
be disseminated. They should be identified at several levels: European, national or
local/regional.
Target population (Last, 2001)
The collection of individuals, items, measurements, etc., about which inferen-
ces are desired. The term is sometimes used to indicate the population from which
a sample is drawn and sometimes to denote any “reference” population about which
inferences are required.
The group of persons for whom an intervention is planned.
Time series (Griffiths et al., 1999)
A set of measures of a single variable recorded periodically over time.
A single-group research design in which measurements are made at several dif-
ferent times, thereby allowing trends to be detected. An interrupted time series fea-
tures several measurements both before and after an intervention and is usually
more valid than a simple pretest-postest design. A multiple time series involves
several groups, including a control-group
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Validity (Schwandt, 2001)
In ordinary usage, validity is a property of a statement, argument, or procedure.
To call one of those things valid is to indicate that it is sound, cogent, well groun-
ded, justifiable, or logically correct. 
Psychologically, validity means having confidence in one’s statements or kno-
wledge claims. In social science, validity is one of the criteria that traditionally
serve as a benchmark for inquiry. Validity is an epistemic criterion: to say that the
findings of social scientific investigations are (or must be) valid is to argue that the
findings are in fact (or must be) true and certain. Here “true” means that the fin-
dings are backed by evidence –or warranted- and there are no good grounds for
doubting the findings, or the evidence for the findings in question is stronger than
the evidence for alternative findings.
Validity / Validity, measurement (Last, 2001)
This term, derived from the Latin validus, “strong”, has several meanings usually
accompanied by a qualifying word or phrase.
Validity, measurement: An expression of the degree to which a measurement
measures what it supports to measure.
Several varieties are distinguished, including construct validity, content vali-
dity, and criterion validity (concurrent and predictive validity).
Withdrawal syndrom (WHO, 1994)
A group of symptoms of variable clustering and degree of severity which occur
on cessation or reduction of use of a psychoactive substance that has been taken
repeatedly, usually for a prolonged period and/or in high doses. The syndrome may
be accompanied by signs of physiological disturbance.
A withdrawal syndrome is one of the indicators of a dependence syndrome. It
is also the defining characteristic of the narrower psychopharmacological meaning
of dependence.
The onset and course of the withdrawal syndrome are time-limited and are rela-
ted to the type of substance and dose being taken immediately before cessation or
reduction of use. Typically, the features of a withdrawal syndrome are the oppo-
site of those of acute intoxication.
Withdrawal: Substance withdrawal (American Psychiatric Association, 2000)
- The development of a substance-specific syndrome due to the cessation of (or
reduction in) substance use that has been heavy and prolonged.
- The substance-specific syndrome causes clinically significant distress or
impairment in social, occupational, or other important areas of functioning.
- The symptoms are not due to a general medical condition and are not better
accounted for by another mental disorder.
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data supports a particular definition, theme, assertion, hypothesis, or claim. Tri-
angulation is a means of checking the integrity of the inferences one draws. It can
involve the use of multiple data sources, multiple investigators, multiple theore-
tical perspectives, multiple methods, or all these. The central point of the proce-
dure is to examine a conclusion (assertion, claim, etc.) from more than one van-
tage point.
Trend (Last, 2001)
A long term movement in an ordered series, e.g., a time series. An essential
feature is that the movement, while possibly irregular in the short term, shows
movement consistently in the same direction over a long term. The term is also
used loosely to refer to an association which is consistent in several samples or
strata but is not statistically significant.   
Trend (Griffiths et al., 1999)
Movement in one direction of the values of a variable over a period of time
(time series data). A trend is dependent on the time range considered. Changes
attributed to an underlying trend should be distinguished with random or regular
‘fluctuations’ which are movements in time series data that are unrelated to a long
term trend.  In regard to trends in drug consumption, this distinction may be 
subjective and context governed. An other difficult task is to detect when a trend
become significant.
Trend Analysis (Griffiths et al., 1999)
Descriptive rather than explanatory analysis that seeks to explain the observed
movement in one or more sets of time series indicator data.
Use (EMCDDA, 1997)
Voluntary or self-administration of a psychoactive substance.
Use (alcohol or drug) (WHO, 1994) 
Self-administration of a psychoactive substance
Validity (Euro-TREND, 2003)
The Validity of the data refers to the fact that the data is (or must be) true and
certain. Here, “true” means that the data accurately represents the phenomena to
which it refers and “certain” means that the data is backed by evidence – or gua-
ranted - and that there are no grounds for doubting the data, or the evidence for
the data in question is stronger than the evidence for alternative data. 
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DUTCH CONTRIBUTION
INTRODUCTION
In the Netherlands, the Trimbos Institute is responsible for carrying out the
Euro-Trend project. 
The Trimbos Institute, Netherlands Institute of Mental Health and Addiction,
is an independent national centre of expertise that provides services in the field of
prevention and care of mental health problems and substance (ab) use. These ser-
vices include development of innovative approaches, training of health professio-
nals and research. 
More information at: www.trimbos.nl.
Document Structure
In this report, important aspects of the Dutch National Drug Monitor (NDM)
are explained. Major source used in this contribution is the NDM Annual Report
2002. This concerns the text about the NDM, Substance use and Drug Criminality. 
Used data-sources can be found at  
http://www.trimbos.nl/Downloads/English_General/NDM_2002_attachments.pdf
The NDM, on a yearly basis, publishes a statistical overview of drug and alco-
hol dependence and substance use and its consequences: the Annual Report.
(http://www.trimbos.nl/default.asp?id=298)
The NDM receives statistics on drug dependence and substance use from various
agencies, differentiating between data from surveys (periodic monitoring) and
information systems (continued tracking of data). 
After the general explanation about the NDM, from a public health perspective
important developments concerning substances are explained.
The situation in the field of drug criminality is described. This is followed by
an example of the dissemination strategy in the Netherlands. 
‘Prospects’ is the title of the last part, important features for a future EIF in the
Netherlands are described as well as some major benefits of implementing EIF in
the Netherlands.
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THE NATIONAL DRUG MONITOR
The National Drug Monitor (NDM) was established in 1999 on the initiative
of the Minister of Public Health, Welfare and Sports. Data collection and reporting
tasks are delegated to the Trimbos Institute, where the Dutch Focal Point (DFP) for
the EMCDDA is also operative. Formerly the Dutch Focal Point is the responsi-
bility of the Ministry of Health, Welfare and Sport (VWS) (www.minvws.nl), in close
co-operation with the Ministry of Justice (www.minjust.nl). Again, data collection
and reporting tasks for the DFP are delegated to the Trimbos Institute. The NDM
is an inter-institutional grouping with two main functions:
1. Acting as a co-ordinating body for surveys in progress in the Netherlands
and for recorded data on substance use (drugs, alcohol, and tobacco) and depen-
dence. Surveys are periodic measurements, whilst the recording of data is conti-
nuous. This involves tracking information from care and treatment facilities, which
have to keep records with regard to their work and clientele. 
2. Submitting statistical reports to national authorities/governments and inter-
national and domestic organisations. The reports are based on the outcomes of sur-
veys and recorded data, as well as on results from (other) studies. The internatio-
nal organisations that are furnished with reports by the NDM include the WHO
(World Health Organisation), the United Nations and the EMCDDA (European
Monitoring Centre for Drugs and Drug Addiction).
At the centre of the NDM is the collection and integration of figures, accor-
ding to a limited number of key indicators, or policy barometers, which were agreed
by the Member States of the European Union in the framework of the EMCDDA.
At issue is information on:
 substance use in the general population
 problem use and dependence
 and the consequences of the above for:
- The burden placed on drug treatment and social services
- Illness
- Mortality.
Substance use
A few facts and developments in the Annual Report 2002 catch the eye.
 The percentage of Dutch cannabis users in the general population aged 12 and
above showed a slight increase between 1997 and 2001. This means, in absolute
figures, that the number of current cannabis users rose from 326,000 to 408,000 in
these four years. However, among young people aged 12 to 15 and secondary edu-
cation pupils, the percentage of cannabis users remained stable over the past years.
 The popularity of cocaine has grown, which is indicated by the following:
- The number of current cocaine users in the general population doubled bet-
ween 1997 and
2001. The increase was most prevalent among women.
- The Netherlands has the second largest percentage of ever users of cocaine in
the European
Union, and the fourth largest number of current users.
- Cocaine, especially in ‘ready-made’ smoke-able form (crack cocaine), pre-
sently is the main drug for many problematic hard drug users.
- Cocaine sniffing has become popular in the (Amsterdam) club and party scene.
- An increasing number of cocaine users seek professional help. Two in three
of them experience problems with crack cocaine.
- The recorded acute mortality from cocaine is low, but rising.
 The number of ecstasy users in the general population increased between 1997
and 2001, in particular among women.
 Of all Member States in the European Union, the Netherlands has the lowest
number of problem users of hard drugs (often opiates) per thousand inhabitants.
 In spite of a legal ban, the availability of alcoholic beverages among young peo-
ple under the age of 16 is high, particularly in the hotel and catering industry.
 Quite a large proportion of young men between the age of 18 and 24 are heavy
drinkers. This age group also has a relatively high percentage of victims of alco-
hol-related traffic accidents.
 There are indications that the popularity of GHB has risen. Use of this drug has
been associated with sex offences, traffic accidents and deaths. However, the num-
ber of serious incidents linked to the use of GHB appears limited; exact figures are
not available.
Drug criminality
The Annual Report for 2002 regarding the situation in the Netherlands also
contains a chapter with figures and information on subjects related to the work of
the Ministry of Justice. Until now, crime-related statistics had been included in the
NDM to a rather limited extent, but since policy-makers and international organi-
sations are expressing a growing demand for such information, this new chapter (…)
includes data on:
 drug-related crime and nuisance, such as violations of the Opium Act, property
crime, violent offences, and drug use among arrestees;
 the number of addicts in the criminal justice system and information on the func-
tioning of the modalities for the care and treatment of addicts;
 production, trafficking and distribution, including information on drugs sales,
confiscations, supply lines and illegal laboratories.
The three main objectives are:
1. The demand for drugs is discouraged by providing high-quality prevention and
assistance.
2. The supply of drugs is checked by combating organized crime.
3. No tolerance for drug use causing disturbance of the peace or any other type
of nuisance. 
The benefit of implementation EIF in the Netherlands would be more efficient
use of existing data systems. Existing data systems all have their own restrictions,
objectives, and etceteras. There is no system that can be compared with EIF but all
systems together cover almost every aspect of EIF. All relevant data about chan-
ges in drug use should be collected from the data systems. 
Value would also be added to the existing system, by the exploitation of data
(sources) which are not used yet. 
The EIF in the Netherlands should centrally collect bits and pieces from exis-
ting systems, build a database containing information about changes in drug use. 
In time a scientific model should be developed, that completely explains deve-
lopment of changes in drug use.      
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The Ministry of Justice in 1999/2001 has ordered an inventory of sources and
an evaluation of the quality of available key figures. The results show that, at pre-
sent, not all the data needed are of adequate quality for inclusion in the NDM. A
project has been started in order to improve the information structure, and this will
require considerable investments in the coming years by the police and the justice
authorities. However, it is possible, on the basis of the available figures, to present
an approximate picture of the recorded crime and the relevant penal response. (…)
 The drug problem indisputably places a heavy burden on the resources of the
police and the criminal justice system.
 A distinction between three main offender types can be made with regard to
drug crime:
- offenders of (more serious) forms of organised crime;
- drug offenders (Opium Act) with a relatively low level of involvement in orga-
nised drug crime;
- persistent, chronically drug-dependent recidivists, who mainly commit crime
against property.
 Forms of organised crime receive the harshest sentences. Other drug offenders
are punished less severely, but still receive stiffer penalties than all other crime.
Particularly the offenders of drug crimes involving hard drugs receive the harshest
sentences.
 Crime committed by drug users often results in custodial sentences.
Dissemination Strategy
Reports about changes in drug use such as the GHB research ‘GHB: tussen
extase en narcose’, are not disseminated actively towards a specific target group. 
The GHB research can be seen as a specific assessment report. 
The GHB assessment was initiated by the Antenne research. Indications for
GHB to become a trend were found. A possible trend in drug use was identified and
within the Antenne report, recommendations were formulated for further research. 
According the Dutch experts, the organisation that has commissioned the
research should take responsibility to implement research findings. 
Local authorities should take responsibility to react on research figs and initiate
interventions. 
Prospects
In the Netherlands for more than twenty years, initiatives to gather data about
changes in drug use are taken. 
Dutch drug policy aims at the prevention and limitation of the risks of drug use
for users, their immediate environment and for society. 
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FRENCH CONTRIBUTION
INTRODUCTION
The observation and monitoring of drug phenomena in France are carried out
primarily by the French Monitoring Centre for Drugs and Drug Addiction (Obs-
ervatoire Français des Drogues et des Toxicomanies, OFDT, www.ofdt.fr). The
OFDT is a public body aimed at collecting and analysing data on drugs and drug
addiction and disseminating information. It is the French focal point of the REI-
TOX network.
In 1999, in order to satisfy the policy makers’ wish to have earlier information
on Emerging Drug Phenomena, the OFDT set up the TREND device. This is aimed
at quickly providing policy makers, professionals, and users with information on
Emerging Drug Phenomena. This early information should allow the aforemen-
tioned actors involved in the drugs field to develop adequate responses at various
levels – political, professional, and individual. This present report gives an over-
view of the existing TREND device, which has been operating in France for 4
years, and which is contributing to the development of an Early Information Func-
tion for Emerging Drug Phenomena.
THE FRENCH TREND DEVICE
Data collection 
The data collection system of the TREND device involves existing partner infor-
mation systems and specific data collection tools. 
The specific information collection system
This is composed of three data collection tools: a network of 12 sites in metro-
politan France and overseas departments, the National Identification System for
Drugs and Toxic Substances (SINTES) aimed at analysing synthetic substances, and
the Media watch (analysis of the representations of illicit drugs offered by selec-
ted monthly magazines dedicated to young people).
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codépendances, CEIP network, www.centres-
pharmacodependance.net/outils/index.html). This gives a description of drug users
attending treatment and reception centres. The main source of information is the
user. 
 The SIAMOIS (Information on the Accessibility of Medicinal Equipment for
Injection and Substitution) system is managed by the Health Monitoring Institute
(Institut de Veille Sanitaire, InVS, www.invs.sante.fr/index.htm) and describes the
trends in sales of substitution drugs and sterile injection material.
 The ESCAPAD (Health and drug use survey) survey of the OFDT is carried out
during the conscription and preparation for defence day. This annual quantitative
survey describes the psychotropic substance uses of individuals aged from 17 to 19. 
 The Central office for illegal drug trafficking (Office Central de Répression du
Traffic Illicite des Stupéfiants, OCRTIS) analyses its data and thus provides the
TREND device with a description of deals, seizures and questionings, and deaths
by overdose.
 Toxicological analyses of heroin, cocaine and cannabis seizures are carried out
by a network of laboratories run by the scientific police and customs services. This
provides information on purity levels and adulterants. 
Data analysis 
All the data collected through the TREND device is stored in various data bases
at the OFDT. For each set of data, a specific analysis is carried out and a document
is written. Once a year, a comparative analysis (triangulation) of all the informa-
tion is carried out by the co-ordination team at the OFDT. This gives a global view
of any Emerging Drug Phenomena identified by the data collection tools. 
Some “specific investigations” are also carried out. These can pursue three
objectives: to explore in greater detail an Emerging Drug Phenomenon (e.g., uses
and users of ketamine in France), to explore a social area not covered by data col-
lection tools (e.g., drug uses in the rock party scene), to test a new method for
gathering data (e.g., a quantitative approach for party scenes). 
Dissemination strategy
Information on all the Emerging Drug Phenomena identified by the TREND device
in the course of a year is reported in an annual national report. This full report also inclu-
des the results of specific assessments carried out during the year (specific investiga-
tions). These assessments are also included in a specific assessment report. All reports
published by the TREND device are available free of charge on demand and can be
downloaded. Using the annual full report, the OFDT draws up a press release and a
press file in order to target policy makers, journalists and professionals. 
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 The Network of national sites
The national network of TREND sites collects data, on a continuous or perio-
dic basis, from users, low-threshold facilities, self-help groups, law enforcement
units, and health professionals using the following methods: observations, quali-
tative questionnaires, focus groups and quantitative ad hoc surveys. It focuses
mainly on two social areas: techno area (people participating in techno music
events) and the urban area (people using drugs in the street or using low-threshold
structures).
Data collected provides information on:
- Users: age, gender, professional situation, geographical locality of the user,
expected effects, user’s opinion of the substance, user’s opinion of his/her own
use, method of administration, quantity, frequency, intensity, poly-drug use,
- Substances: street name, physical appearance, logo
- Setting: social setting, retail price and perceived availability.
 The national identification system for toxins and substances SINTES 
Within the framework of SINTES, synthetic drugs samples from some of the
seizures made by the law enforcement services and from collections made from
users by the socio-health players are analysed by toxicological analysis laborato-
ries. 
These provide information on the substances: purity, chemical name, physical
appearance and logo of synthetic drugs
In addition, a questionnaire is filled in for each of the products collected allowing
the collection of data about the context of use. Thus, for each of the products collec-
ted by the socio-health players, information is produced via a questionnaire on:
- Users: expected effects, user’s opinion of the substance, user’s opinion of
his/her own use, method of administration, quantity, frequency, intensity, poly-
drug use,
- Substances: street name 
 The Media watch
Six monthly magazines with a wide distribution are analysed in order to moni-
tor the trends in the representations conveyed by the young adult media. Each expli-
cit or implicit reference to drugs and drug uses is noted down and are used for fee-
ding core indicators on the identification and description of Emerging Drug
Phenomena. 
The existing partner information systems 
 The OPPIDUM (Observation of Illegal Drugs and Misuse of Psychotropic Medi-
cations) survey is an annual survey carried out by the Drug Dependence Evalua-
tion and Information Centres (Centre d’Evaluation et d’Information des Pharma-
146
Appendix: national contributions
Bello PY, A Toufik, M Gandilhon et I Giraudon. Phénomènes émergents liés aux
drogues en 2001. Rapport TREND. Juin 2002. Paris: OFDT, 2002.
http://www.ofdt.fr/BDD/publications/fr/bleu02.htm,
Short English version available at http://www.ofdt.fr/BDD/publications/an/tends.htm
Bello P-Y, A Toufik, M Gandilhon, I Giraudon et N Bonnet. Phénomènes émergents
liés aux drogues en 2002. Quatrième rapport national du dispositif TREND. Juin
2003. Paris : OFDT, 2003. 
http://www.ofdt.fr/BDD/publications/fr/bleu03.htm
Giraudon I et PY Bello. Regards sur l’ecstasy et d’autres produits de synthèse en
France. Paris, OFDT, 2003.
http://www.ofdt.fr/BDD/publications/fr/bleu03.htm
OFDT. Tendances récentes. Rapport TREND. Paris, OFDT, 2000.
http://www.ofdt.fr/BDD/publications/fr/bleu00.htm
149
A European Manual of the Early Information Function 
for Emergeng Drug Phenomena
Within the framework of SINTES, a fast-track process has been developed for
producing quick information notes on new and/or potentially dangerous substan-
ces. This process allows the fast dissemination of the information. It implies the pro-
duction of a note and a quick consultation of the TREND partners (Afssaps, MILDT,
DGS) on whether a health warning should be issued. Depending on the final deci-
sion a health warning or a quick information note will be disseminated.
PROSPECTS
The TREND device in France is a recent project and has been set up in a short
period of time. It now needs to mature in order to improve its operation. The results
of the work achieved in the Euro-TREND project will be helpful in this respect.
During next year, the TREND device will have to be examined and considered
in light of the Euro-TREND manual, in order to adapt the Euro-TREND propo-
sals to the French context as far as possible. At the data collection level, a diagno-
sis of all the core indicators, those covered and those not covered, will have to be
made. At the dissemination level, it may be worth developing different strategies
for the various target audiences. 
The continuity of a common European way of thinking on this subject would
be very welcome in order to assist in the continuous improvement of the national
EIF.
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GERMAN CONTRIBUTION
INTRODUCTION
In Germany the Institute for Therapy Research (IFT) is responsible for carrying
out the Euro-TREND Project. The IFT is a non governmental and non-profit orga-
nization in the field of addiction research (epidemiology, prevention, treatment and
care systems). Concerning the observation and monitoring of drugs the IFT colla-
borates with several partners. The key partners are The Federal Criminal Investi-
gation Office (BKA), the Federal Statistical Office (StBA), Federal Centre for
Health Education (FCHE) and the Robert Koch – Institute (RKI).
The key partners of the existing system concerning early identification function
are described. Moreover, the key sources of information as well as the key data
collection tools which are presented. An overview which core indicators are met
by them is given. The future perspectives of an integration of local monitoring sys-
tems as well as of alternative concepts are described.
RESOURCES
Key partners
In Germany there are at two institutions running local monitoring systems and
working on the early identification and detection of emerging trends in drug use.
The ‘Monitoring System Drug Trends’ (MoSyD) is located in Frankfurt. It started
to function in spring 2002 and was designed, implemented and carried out by the
Centre for Drug Research/ Goethe – University on behalf of the City of Frankfurt.
In Hamburg the Büro für Suchtprävention/ Office for Drug prevention is currently
working on the implementation of a Local Monitoring System (LMS). Their main
tasks are doing drug prevention and providing information for target groups as well
as the general public. 
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The survey “Schoolchildren and Teachers Survey about the Perception and Beha-
viour related to Drugs” (SCHULBUS) is an instrument for forecasting drug consump-
tion trends and evaluating prevention measures in the region. This survey will use a
paper-pencil questionnaire (where possible computer-assisted). It will be carried out
yearly among pupils from the 7th class on and their teachers. It is planned to include
about 1.500 to 2.000 schoolchildren and 60 – 80 teachers and cover licit as well as illi-
cit substances. Not only the drug-user will be asked for their motivation of using a
specific drug but also non-users will be asked for their reasons of abstinence. 
The data described above are collected and analysed by the team which runs the
local monitoring systems, the Centre for Drug Research/ Goethe – University in Frank-
furt and the. Büro für Suchtprävention/ Office for Drug prevention in Hamburg 
As both projects have been involved in the Euro-TREND project a close rela-
tionship is already given between these regional networks and the EIF standards.
Depending on the specific topics under discussion especially in the focus groups
a broad variety of the core indicators mentioned in the EIF concept will be cove-
red through these projects.
At the moment the reporting of these projects takes place only regionally and
local policy and public authorities are the principle target groups which also are in
a position to react in an adequate way.
Other sources
Beside these systematic data collection networks available in the regional sys-
tems a number of information sources produce data throughout the year, which
can be used at the national level and in parts also at regional or local level. The
extensive information network, which is used by the National Focal Point, also is
available for EIF purposed. Due to the character of the different sources, the infor-
mation is updated and reported on different schedules:
 Treatment demand indicator: collection: ongoing, report: annually
 Population surveys: collection: every 2-3 years, report: delayed 6-9 months after
data collection
 Drug related deaths (police register): collection: ongoing, report: annually
 Law enforcement data on seizures and offences: collection: ongoing: report:
update every three months, full report annually
PROSPECTS
The future development of an EIF in Germany has to touch different aspects.
Starting from the status quo, which is described above, additional activities and
investments are needed in several fields:
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Key sources of information and key data collection methods 
As key sources of information in particular the drug users, the low threshold faci-
lities, the nightlife recreational centres and the key informants provide informa-
tion in terms of an early identification function. MoSyD in Frankfurt above all uses
an expert panel, the key informant interviewing and two surveys: The expert panel
consists of 12 representatives which are associated and confronted with the drug
using phenomenon (drug care, social work with adults, education system, police
and public prosecutor’s office).As methods a focus group takes place twice a year
and a questionnaire was created and is used once a year.
Concerning the key informant interviewing so-called “trend-scouts” are inter-
viewed. The sample consists of 20 persons who have direct and wide contacts to
drug using social milieus and scenes because of their social position and closeness
to such social groups due to their leisure time activities and/ or occupation. The
sample covers the relevant spectrum of leisure-time scenes, sub-cultures, youth
scenes and social milieus in which drug consumption plays – or potentially could
play – a significant role. The interviewees can directly and authentically report on
new emerging drug using phenomena from the inside of relevant social networks
and scenes. The key informants are interviewed every six months, using a structu-
red interview.
Furthermore, two surveys are used, the “School-Survey” and the “Drug-Scene-
Survey”. The school-survey has a sample-size of 1,500 pupils aged 15 to 18 cove-
ring the whole spectrum of schools and training programmes. A structures ques-
tionnaire is used within a survey interval of one year. In contrast to the school-survey
the drug-scene-survey covers a sample of 150 persons using illicit drugs. The inter-
viewees are recruited from the open drug scene in Frankfurt and are asked a struc-
tured questionnaire in a face-to-face interview situation. It is done every second
year.
The three pillars of the LMS in Hamburg are nearly the same as the ones of
MoSyD: There is also a key informant interviewing, a focus group and a school –
survey in order to collect new data. Within the key informant interviewing about
20 persons are interviewed. The persons are either related in a professional or in a
private way with the scene: They are e.g. users, DJ’s, barkeepers, street workers or
drug counselors. The key informants are interviewed once a year, using a semi-
structured interview. The focus groups are used in order to gain further informa-
tion about the way of using different kinds of drugs. The target groups are users and
non-users of licit and illicit drugs. 
Each group consists of 6 to 8 persons. The persons are asked to participate in
the discussion which is led by an expert and which lasts about 2 hours. Those dis-
cussions have a very clear topic in order to get specific information about the cho-
sen aspects of using drugs. The discussion takes place once a year.
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 More regional networks have to be integrated and/or setup. Especially the situa-
tion in the new Laender and the more rural areas is quite different from the metro-
politan areas, where the EIFs are already functioning. In order to catch relevant
phenomena in all parts of the country, a regional extension would be needed
 Information dissemination at the moment takes place mainly locally in these
projects. Local policy has organised and funded these projects and is the primary
target group. However, information channels also to other national partners would
be needed
 Politically this would need an common decision taken by the Federal and at
least some of the Land authorities which also includes a division of responsibili-
ties
 Technically a national EIF in a country like Germany – rather big scope for
European standards, federal structure – would need an active national coordina-
ting unit. The primary purpose of this unit would be to collect, synthesize and report
information collected at different places in Germany. 
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GREEK CONTRIBUTION
INTRODUCTION
Within the current Greek context, the observation and monitoring of drug phe-
nomena at a national level is carried out through the various information systems
run by the Greek Focal Point (Greek FP). The Greek FP operates in the context of
the European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) and
its main objective is to provide and disseminate reliable and comparable informa-
tion on all of the parameters of the drug problem. 
Along these lines, the Greek FP is responsible for several national activities, such
as a) to collect, analyse and process information on drugs, on the demand, as well
as on the demand reduction needs and priorities (i.e. supply reduction, prevention,
treatment, rehabilitation), b) to provide guidelines and support for improving the
validity and comparability of the existing indicators, c) to provide guidelines for
the establishment of new indicators for the study of the drug phenomenon, d) to pro-
vide information to organisations and professionals in the drug field, e) to train
health professionals, etc. (http://www.ektepn.gr).
The present document gives an overview of the drug information systems ope-
rating in Greece with regard to the main objective of the Early Information Func-
tion (EIF). Moreover, the main impediments for the implementation of the EIF
within the national context are described and, thus, relevant suggestions are intro-
duced. Finally, the perspectives for implementing the theoretical model of the EIF
in Greece are presented.
THE GREEK DRUG MONITORING SYSTEMS AND SOURCES OF INFORMATION
The following list includes the existing Greek recording systems that could
provide information on new drugs and on new ways of using known substances,
which is data on potential new trends on drug use.
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Drug-related Infectious Diseases Indicator among Intravenous Drug
Users 
The Greek FP has established a national network, in order to assess the preva-
lence and incidence of infectious diseases among drug users. 
The aforementioned network consists of all types of drug treatment program-
mes, low-threshold and outreach services, reference centres, public laboratories, and
a state hospital. 
The relevant data are collected by an individual and anonymous questionnaire
on a monthly basis. Each participating agent provides data on the medical tests for
Hepatitis B and C and HIV/ADIS of their clients, as well as some other characte-
ristics (i.e. age, gender and risk factors). As with TDI, the FP performs the quality
control, the data-entry and the double entries check. The analysis takes place yearly.
Drug-related deaths indicator
This indicator refers to data on deaths caused by acute intoxication (i.e. over-
dose or synergic activity of different drugs).
Within this framework, the Greek FP provides special registry data, routinely
collected by the Hellenic Police annually based on acute intoxications (i.e. deaths
caused by overdose or the synergic activity of different drugs).
Other drug-related data
In addition to the above drug monitoring systems, the Greek FP collects yearly
aggregated data on convictions, imprisonments, seizures, arrests, charges and
price/purity of the substances. The information derives from the Ministry of Public
Order and the Ministry of Justice. 
Moreover, the Greek FP in collaboration with the University Mental Health
Research Institute carries out epidemiological surveys (that is, general population and
school surveys) and small-scale qualitative studies. The information deriving from
these data collection methods could offer a general and broader background and could
be used as an additional and supplementary instrument to the EIF. These data collec-
tion methods aim mainly at monitoring trends in use and public attitudes.
Feeding the core indicators of the EIF
The incoming information varies with the information source. Overall, all the
information sources which already collaborate with the Greek FP could offer valua-
ble information and respond to the core indicators of the EIF according to the cir-
cumstances. The type of the information provided is defined by the nature of the
collaborating agent.
More specifically, new information regarding the “substance” (i.e. chemical
name, street name, physical appearance, logo and purity), the “user” (i.e. method
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Description of the existing drug monitoring systems
Early Warning System (EWS) of the Joint Action 
The aim of the Early Warning System (EWS) is to collect information on new
synthetic drugs which pose a serious threat to public health and which are of limi-
ted therapeutic value (EMCDDA, 2002). Within this framework, the operation of
the Greek EWS is based on a national information network bringing together various
agents within the drug field. 
More specifically, the following sources provide the Greek FP with informa-
tion:
 Health care services specialised in the care of dependent individuals, that is,
drug treatment programmes, low-threshold and outreach services, programmes for
drug-dependent prisoners, prevention centres and telephone help-lines specialised
in drug-related issues.
 Law Enforcement Authorities, that is, the Central Anti-drug Co-ordination Unit
as well as the Ministries of Public Order, Merchant Marine and Finance.
 Forensic services, that is, drug services of the General State Chemical Labora-
tory and of Forensic Medicine Laboratories.
As regards the collection of information, three short questionnaires have been
constructed addressing the various sources. The network partners record the rele-
vant information and send them to the Greek FP on a regular basis, that is, as soon
as this type of information is observed or reported.
Moreover, a scientific evaluation committee consisting of experts in the drug
field assesses twice a year the incoming information and produces a list of new
substances and new ways of using already known substances. 
Treatment Demand Indicator (TDI)
Treatment Demand Indicator (TDI) constitutes a recording system for the col-
lection of data on the socio-demographic characteristics of dependent persons
requesting treatment and their patterns of use. 
The implementation of this indicator is based on a national partner network
that consists of all types of drug treatment programmes (residential and non-resi-
dential), low-threshold and outreach services.
The collaborating agents provide individual data by completing questionnai-
res on a monthly basis. For each completed questionnaire an anonymous identifi-
cation code is used, so that confidentiality is assured and double entries are exclu-
ded. The Greek FP performs the data-entry and quality checks and, in collaboration
with the contact persons in each agency, makes corrections on the collected data.
The results are produced yearly.
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As far as the recording of the information is concerned, modifications should
be made on the way and the type of the already available or collected information.
In this sense, new questions should be added to the existing questionnaires concer-
ning the collection of information on new trends. Overall, the modified or new
methodological instrument should be concise and short in order to become useful,
to be easily adopted by the agents and to be completed with valid information. 
Finally, the current condition in Greece should be taken into consideration. In
particular, Greece is not a priority drug market, so all the new synthetic drugs are
imported long after they are tried in other drug markets. Consequently, the infor-
mation on new drugs is rather limited. 
Perspectives for implementing the EIF
The data deriving from the existing drug information systems should be fur-
ther analyzed for the detection of information on new trends. Along these lines,
the implementation of the EIF in Greece should be undertaken by the Greek FP in
the framework of the EWS, as it is run in the country. In particular, the Greek EWS
operates beyond the strict requirements of the Joint Action and collects informa-
tion on new substances in general (including natural and synthetic drugs) as well
as on new ways of using known substances (i.e. new combinations, new routes of
administration, new groups of users).
As far as the implementation of the dissemination strategy is concerned, two sce-
narios were envisaged:
a. The EIF would forward its reports to the policy makers, i.e. the relevant
Ministries and the drug policy co-ordination body, who would undertake further dis-
semination of the information, or 
b. The EIF would be involved in all the steps of the dissemination strategy. Bea-
ring in mind the possible political implications, the dissemination should be made
with great caution.
REFERENCE
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of administration, quantity, intensity, frequency, poly-drug use, psychological and
physical effects) and the “setting” (i.e. moment of the preparation/use, methods/rules
related to the preparation/use, place of use) is already collected by the EWS Network. 
In addition, in the context of the TDI, the Greek Focal Point receives data on
the “substance” (i.e. chemical name) and the “user” (i.e. age, gender, nationality,
professional situation, geographical locality, method of administration, frequency
and poly-drug use).
Moreover, the indicators regarding drug-related deaths, mortality and the pre-
valence of infectious diseases provide data on the “user” (i.e. physical effects).
The existing dissemination strategy
All information collected and analysed by the Greek FP is annually published
in the Greek Annual Report available to professionals, policy makers and the gene-
ral public.  
In particular, on the grounds of the EWS operation a constant feedback is pro-
vided to the network partners through the dissemination of information on new
synthetic drugs and new ways of using known substances. Moreover, a relevant
database has been developed with regard to strengthen the flow of information bet-
ween the agent implementing the EWS and the national partner network. Howe-
ver, the access to the database is restricted to the professionals participating in the
EWS network, since the information produced is confidential.
In addition, the networks of the TDI and the Infectious Diseases Indicator are
provided annually with detailed, analysed data in the format of tables and graphs.
THE IMPLEMENTATION OF THE THEORETICAL MODEL OF THE EIF
Envisaged improvements in the context of the EIF 
In the context of the development of the EIF, the Greek Focal Point envisages
the reformulation and development of the existing recording systems.
Within this framework, it would be of major importance to broaden the exis-
ting network of partners. In Greece, there are specific data sources that have not been
fully and systematically used so far, such as, private treatment centres or clinics,
prisons, and telephone help-lines. Moreover, other sources, such as the emergency
wards of public hospitals and the informal data sources (i.e. recreational nightlife
settings) are still largely unexploited. Due to certain impediments, such as the lack
of a recording system regarding the public hospitals or the limited number of inter-
ventions in nightlife settings, the involvement of the professionals in these settings
in the information collection on a regular basis would be an ambitious venture. 
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PORTUGUESE CONTRIBUTION
INTRODUCTION
Since the end of last decade, the drug phenomena in Portugal has been approa-
ched under a global and integrated perspective in order to enable a better unders-
tanding of its development, a better control of the different aspects it concerns, and
a maximization of the synergies resulting from networking. A body of legislative
measures was produced in order to provide society with the means to achieve this
general objective. 
Surveillance and monitoring drug phenomena, in all the legislation produced,
was a main concern. In fact, either in the Portuguese Drug Strategy (Resolution of
the Council of Ministers Nr. 46/99, from May, the 26th.), or in The National Action
Plan Against Drugs and Drug Addiction – Horizon 2004 (Resolution of the Coun-
cil of Ministers N. 39/2001 from April the 9th), the implementation of a National
Information System on Drugs and Drug Addiction is addressed.
The IDT – Instituto da Droga e Toxicodependência (Institute for Drug and Drug
Addiction) - resulting from a merging between the formers IPDT - Portuguese
Institute for Drug and Drug Addiction, and SPTT - Drug Addiction Prevention and
Treatment Service - took the major responsibility, at national, regional and district
levels, in the coordination and implementation of the National Strategy and the
National Action Plan – Horizon 2004. IDT is placed under the Ministry of Health. 
Included in the IDT organisational structure is the ODT – Observatório da
Droga e da Toxicodependência (National Monitoring Centre on Drug and Drug
Addiction) (Portaria Nr. 484/2003 from April, the 15th) having a mandate for deve-
loping actions in the areas of National Drug Information System (DIS), Research,
Documentation/Information and to act as the EMCDDA Focal Point. 
The implementation of the actions targeted to achieve the goals related to sur-
veillance and monitoring drug phenomena, is then an attribution of the ODT within
the IDT. The Portuguese EURO-TREND partner is the IDT, and the Portuguese
National Coordinator belongs to the ODT.
The objective of developing an Early Information Function for early detection
of Emerging Drug Phenomena fits perfectly within the IDT mission and is an ODT
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Another drug information system operating, in Portugal, in a completely dif-
ferent way, is the Early Warning System on New Synthetic Drugs (EWS) develo-
ped according to the EMCDDA guidelines to implement at European level a Joint
Action target to ensure a fast gathering and analysis of information related to new
synthetic drugs. This information system works in an opportunistic and informal
way, being activated whenever some “new relevant information” about a “new syn-
thetic drug” is notified in some EU country.
These are the two Information Systems with more relevance in the drug field.
They summarise information obtained from multiple partners, sources and methods.
Among the key partners already providing raw data or information to the two
referred DIS, with relevance to an Early Information Function are:
 IDT (Ministry of Health):
- IDT Research Unit
Quantitative and qualitative information about multiple indicators; 
- IDT Treatment Department
Data about heath consequences of drug use (treatment and harm 
reduction indicators);
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responsibility. The Portuguese participation in this European project represents
then, an important added value to the existing Information Systems and is a chal-
lenge to go further in timely tracking, and to understand the evolution of drug phe-
nomena. 
This short report describes in a first part the state of art of the available Portu-
guese Drug Information Systems, and, in a second part, improvements need and gaps
to be filled in order to implement an EIF for Emerging Drug Phenomena. 
THE EXISTING DRUG INFORMATION SYSTEM
The IDT is the body in charge of providing information to decision makers,
experts working in the different drug fields, drug users and public in general. An
annual report is produced to attain this objective.
The National Information System on Drug and Drug Addiction – NISDDA
(Sistema Nacional de Informação sobre Droga e Toxicodependência – SNIDT) has
the competence to annually gather information collected by different agencies wor-
king primarily or secondarily with drug use related issues, and to globally analyse
and report about the situation. The NISDDA runs, primarily, in the Statistical Unit
of ODT. 
The NISDDA already provide some information about all main lines, areas of
interest and many of the indicators presented in this manual. The main concern of
this national DIS is on the following areas:
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Areas of interest Indicators about: Periodicity 
Extent of drug use Prevalence of drug use
in
General populations each  4 years
Specific populations:
Schools each 2 years 
(INME-each 4 years
ESPAD-each 4 years) 
prisons each  3 years
minors under tutelage each  3 years
problematic drug use each  2 years
Health consequences First treatment demands annually
Follow up treatment demands annually
Substituion treatment annually
Drug related mortality annually
and non-fatal emergencies
Syringe distribution annually
and exchange
Infectious diseases      
(HIV/AIDS, hepatitis B and C, 
and tuberculosis) annually
Legal consequences Dissuasion trials annually
Police interpellations/ annually
presumed offenders
Judicial decisions annually
Prisoners because annually
drug related crimes
Market Seizures and significant 
quantities seized annually
Drug prices annually
Purity annually
supported by the National Outreach Network, or to drug users being followed by
the National Dissuasion Network, as well as from multiple groups of general popu-
lation (like clubbers, students, etc.) being target by the National Prevention Network.
Also key informants, experts working in the field and media (press, TV and Inter-
net) are sometimes used as data sources. 
Concerning data collection methods, information obtained at national level rela-
ted to the extent of drug use either in the Portuguese population or in sub-popula-
tions is obtained through epidemiological surveys carried out in representative sam-
ples at national, regional or local level. The estimation of problematic drug use
prevalence is addressed by multiple quantitative and qualitative methods.
Information about health and legal consequences of drug use is mainly provi-
ded by routine information systems collecting and analysing data from the Health
and Justice above reported bodies. In general, data from these different partners
reach the National Drug Information System either as raw data or after a prelimi-
nary analyse made by the entity in charge of data collection (in the format of a
report or as single aggregate data in tables).
Among more qualitative methods, interviews are frequently used either in struc-
tured, semi-structured or non-structured format, particularly in research designed
to reach the processes underlying the development of some phenomenon. 
Less used methods include spontaneous notifications, focus group, expert panel
or panel studies.
The ODT Statistical Unit after collecting all data and information produced by
IDT partners  conducts a global analysis comparing information on the different
indicators obtained from different sources in the same period of time and from one
year to the other. An Annual Report is produced, as well as an Executive Summary,
a Press Release and a Press File that are presented to the relevant partners in a Spe-
cific Annual Meeting as well as in a Press Conference. An annual discussion, under
a political perspective, about “the state of the country concerning drugs and drug
addictions” took place in the National Parliament in order to evaluate if the Natio-
nal Drug Strategy is being well implemented and if the goals defined in the Natio-
nal Action Plan – Horizon 2000 will be reached.
PROSPECTS ABOUT THE IMPLEMENTATION OF AN EIF IN PORTUGAL
Considering what was exposed in the former part of this report, it seems clearly
that a lot of information is already available, enabling some tracking of the deve-
lopments in drug phenomena. As referred before, last annual reports – the Natio-
nal Annual Report on the Situation of the Counrty concerning Drug and Drug
Addiction and the EMCDDA Portuguese Annual Report include specific chapters
on trends, at national level. 
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- IDT Dissuasion Department
Data about dissuasion processes;
- IDT Prevention Department
Data from “Drug Telephone Helpline” and about drug use 
in specific contexts; 
 National Emergency Institute (Ministry of Health)
Data about drug non-fatal emergencies;
 National Health Institute / Epidemiological Surveillance Centre on Transmissi-
ble Diseases 
(Ministry of Health)
Data about drug HIV/AIDS, hepatitis, and tuberculosis among drug users
 National Commission on Fight against AIDS (Ministry of Health)
Data about syringe exchange among problematic drug users
 National Medication Agency (Ministry of Health)
Data about drug properties
 National Directorate of Health (Ministry of Health)
Data about drug related deaths
 Criminal Police (Ministry of Justice):
- DCITE – Central Directorate for Narcotic Traffic Control 
Collects and analyse data from Customs (Ministry of Finance), Public Security
Police (Ministry of Home Affairs) and National Republican Guard (Ministry of
Home Affairs);
- Criminal Police Forensic Laboratory
Information about drug purity and characteristics of drugs 
and new drugs seized, etc.
- Europol National Unit
 General Directorate of Prisons (Ministry of Justice)
Data about drug use in prisons, treatment, etc.
 Criminal Courts (Ministry of Justice)
Data about drug court decisions
 National Forensic Institute (Ministry of Justice)
Data about drug related deaths
 National Statistical Institute (Presidency of the Council of Ministers)
Data about drug related deaths
 National Association of Pharmacies (private organization)
Data about syringe exchange among problematic drug users in pharmacies
 Research Units from Universities (public and private)
Qualitative and quantitative information about multiple indicators
These partners collect data from a variety of sources, from drug users in treat-
ment at the National Treatment Network (composed by public and private facili-
ties providing a variety of treatment programmes), to problematic drug users being
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However, the main objective of an EIF is not report trends, when they are already
“identifiable” through national statistics, but improve the sensibility of the exis-
ting Drug Information Systems in order to be able to “quickly identify, assess and
categorise Emerging Drug Phenomena in order to allow the production of relevant
information and its timely dissemination to target audiences”. In fact, “new deve-
lopments” usually do  nothappen at the same time in all a country. They
appear/emerge “somewhere” – one or more points – and, if they have potential to
survive, eventually spread to the neighbourhoods with more or less speed. 
Analysing the existing sources of information, methods and type of instruments
used in data collection, as well as the experts and institutions involved in the pro-
cess it is easy to conclude that the Portuguese Drug Information System is based
in data regularly produced – in a quite satisfactory schedule, and on very relevant
indicators – but obtained mainly through structured methodologies with few flexi-
bility and sensitivity to catch Emerging Drug Phenomena.
Nevertheless, considering the enormous potential resulting from the existence
of different networks (prevention, dissuasion, treatment, harm reduction) being
coordinated at national, regional and district levels, by IDT experts - that work in
close relation, at local level, with public and private organizations providing mul-
tiple kind of services to different target groups of drug users or potential drug users
– it seems not only desirable, but also not difficult, to develop a global methodo-
logy - according to what is proposed in the present manual - in order to be able to
properly address the appearance of drug emerging phenomena. Strong commit-
ment should then be placed in designing and develop a more qualitative approach
to this kind of phenomena, involving partners working in the field where “things”
happen.
Under a political point of view what seems more critic to that implementation,
is the problem of financial resources. All over Europe governments are deeply com-
mitted in reducing public funding of projects. Anyway, under a pragmatic per-
spective, perhaps it should be considered that, even when (or specially when) resour-
ces begun to scarce, is better to prevent than to repair. On other side, as the
Portuguese Drug Strategy is oriented to decentralisation, putting emphasis in inte-
grated projects based on communities - although with financial and technical sup-
port of IDT - it will depend very much on the ability to commit to the EIF Project,
local agents already working in other drug projects, in order to reduce costs.
Perhaps a good strategy to get support to this project would be trying to explain
to decision makers at different levels, what added value could be obtained with it.
Their commitment will be easier obtained if they can anticipate results with rele-
vance to their responsibilities in the community.
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SPANISH CONTRIBUTION
INTRODUCTION
The Government Delegation for the National Plan on Drug Abuse DGPND,
through the Spanish Drug Observatory, is responsible for the development on a
national scale of the data gathering and analysis and for the dissemination of infor-
mation concerning drugs and drug addiction (DGPND, 1998).
The Spanish participants in the Euro-TREND project are the Government Dele-
gation for the National Plan on Drug Abuse and the University of Valladolid. The
DGPND has acted as the national co-ordinator of the project and the University of
Valladolid has been responsible for carrying out the project project beneficiary.
Data from the Spanish Drug Information System will now be presented, with
special emphasis on those information systems which are closest to what has
been considered an EIF or Emerging Information Function by the current Euro-
TREND project.
THE EXISTING DRUG INFORMATION SYSTEM
Information system of the Spanish Drug Observatory
The information system of the Spanish Drug Observatory
(http://www.mir.es/pnd) is built up by the permanent state information system on
drug addiction (SEIPAD). This system is made up of the indicators of the former
State Information System on Drug Addiction (SEIT) and includes data from other
information sources.
The data supplied by all the information sources generate the indicators in the
Registration System of the National Plan on Drug Abuse.
The indicators chosen to make up the OED System of Indicators are:
 Sociological
 Consumption patterns
 Treatment
 Health
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The objectives of the “Rapid Surveys” are:
 Gather information in near-real time on various aspects related to drug traffic-
king and consumption (emergence of new substances or mediums, changes in
consumption patterns, emergence of new social or health problems related to
consumption, variations in welfare requests, etc.).
 Enrich and improve the quality of available epidemiological or quantitative
information.
 Identify new or emerging trends related to drug trafficking or consumption.
 Improve the applicability and practical utility of the information available on
drugs, so it can used as the basis of decision-making concerning policies to be
adopted on drug abuse issues.  
Frequency of information gathering: The information is transmitted when new
or emerging trends are observed.
Time lag: Only that which is strictly necessary to confirm that it is indeed a
new or emerging trend and not a simple fact.  The lag is not, in any case, very long.
Frequency with which results are released: It is not possible to determine regu-
lar frequency.
Reliability of data: Once the confirmation process is complete, reliability is
high.
Access to information: Not everyone has access to the information provided
by the surveys; it is selectively diffused to a network of key experts and institu-
tions, so that relevant decisions can be taken to prevent the consolidation of new
trends or the effects derived from drug trafficking and consumption, as quickly as
possible.  
Contact persons or institutions: The “Rapid Surveys” subsystem is supported
by a series of “watch-guard areas” designated using both functional and territorial
criteria.  In order to guarantee the internal coherence of the information provided
by the various surveys or correspondents in a given geographic area, it was esta-
blished that in each of the territorial coverage areas of the subsystem there would
be at least one “correspondent” or “key informant” from each of the chosen func-
tional fields, which are:
a) Drug abuse treatment centres.
b) Search or street centres (on-site social workers, mobile units, emergency
centres, etc.).
c) Health centres (Emergency medical services, regional services for epide-
miological monitoring)
d) Police units to control drug supply (operative services).
Besides these key informants operating in each of the predetermined geogra-
phic areas, there also exist a series of correspondents or informants located in per-
tinent institutions belonging to the Central Government such as:
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 Drug supply
 Police
 Prisons
 Law courts
 Mortality
 Prevention
 Rehabilitation
 Hospital Emergency
The indicators included in the OED System of Indicators have different degrees
of specificity, sensitivity and comparability. In short, they have different descrip-
tive powers or capacities. In spite of this, together, they provide adequate kno-
wledge of the current situation of drug consumption and addiction in Spain, of its
evolution through time and of the efficacy of the policies and programmes set up
to counteract it.
The nature of the information sources mean that close collaboration is neces-
sary with the Autonomic Information Systems of the Autonomic Plans on Drug
Abuse, collaborating hospitals, the National Toxicology Institute, the Documentation
Centre of the PNSD, the European Monitoring Centre for Drug and Drug Addic-
tion, etc.
Rapid Information Surveys
This system efficiently provides fast information concerning the existence of
new problems associated to drug abuse.
The system is made up of a series of health centres and surgeries selected for
their particular location, and of representatives from various collectives and insti-
tutions.
A network of “Key Centres and Informants” will be established for informa-
tion gathering. This information will then be sent, periodically, to the Spanish Drug
Observatory.
Description of “Rapid Information Surveys”:
http://www.mir.es/pnd/doc/sondas/index.htm
Brief description: Information subsystem used for quick, efficient gathering
of relevant ethnographic or qualitative information. 
The “Rapid Surveys” information subsystem is part of a larger information sys-
tem (Spanish Drug Observatory Information System) which handles the analysis
and comprehension of data gathered from other information sources (surveys, regis-
tration systems, etc.), which allows for a more coherent, more global view of the
current situation of drugs and drug abuse.  
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Further references and sources of information
Delegación del Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa-
ñol sobre Drogas. Informe numero 2. Madrid: DGPND, 1999. 
http://www.mir.es/pnd/observa/html/informe2.htm
Delegación del Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa-
ñol sobre Drogas. Informe numero 3. Madrid: DGPND, 2000. 
http://www.mir.es/pnd/observa/html/informe3.htm
Delegación del Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa-
ñol sobre Drogas. Informe numero 4. Madrid: DGPND, 2001.
http://www.mir.es/pnd/observa/pdf/oed-4.pdf
Delegación del Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa-
ñol sobre Drogas. Informe numero 5. Madrid: DGPND, 2002.
http://www.mir.es/pnd/publica/pdf/oed-5.pdf
http://www.mir.es/pnd 
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 National Toxicology Institute.
 National Epidemiological Centre of the Carlos III Health Institute.
 National AIDS Plan.
 Directorate General for Penitentiary Institutions.
 Ministry of Defence.
 National Central Narcotics Agency.
Target Audiences
Authorities from key Institutions:
- Drug Commissioners from the Autonomous Communities.
- Authorities from State Security Corps and State Security Forces.
- Authorities from the Healthcare System.
- Authorities from the Educational System 
- Other Institutions (Pharmaceutical Association, Medical Association, etc.)
PROSPECTS
The permanent state information system on drug addiction (SEIPAD) is conti-
nually being updated and is open to new ways of obtaining and analysing data. In
this sense, the Rapid Information Survey is the mechanism available in our coun-
try for detecting emerging trends, as referred to throughout the development of the
Euro-TREND project.
During the Euro-TREND project, a series of phases or procedures have been
established that are similar to those used by the Rapid Information Surveys. They
are not, however, exactly the same. That is, the establishment of a system of emer-
ging trends in our country would require the adaptation of the existing system of
Rapid Information Surveys, or the adoption of a new system.
On the other hand, these said emerging trends can occur at either a local, regio-
nal, national or even international level. The current situation of our country, with
great regional developments (the Autonomous Communities), would seem to require
greater involvement of the regional and local structures in the search for and detec-
tion of emerging phenomena in drug abuse.
BIBLIOGRAPHY
Delegación del Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa-
ñol sobre Drogas. Informe numero 1. Madrid: DGPND, 1998.
http://www.mir.es/pnd/observa/html/informe1.htm
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SWEDISH CONTRIBUTION
INTRODUCTION
The National Institute of Public Health (NIPH) has been the institution respon-
sible for carrying out the Euro TREND Project in Sweden. The institute is a state
agency under the Ministry of Health and Social Affairs working on a broad stra-
tegic scale to improve public health. Among these is the mission of operating as the
Reitox focal point towards the European Monitoring Centre for Drugs and Drug
Addiction in Lisbon. Also to guard and investigate whether there is a need for a sub-
stance to be regulated under the Penal Law on Narcotics1 or under the Act on the
Prohibition of Certain Goods Dangerous to Health. Linked to this assignment the
Customs, the Criminal Investigation Department of the National Police Board, the
Social Services and the Health and Medical care are in duty to the law obligated
to with no delay report to the NIPH if they in their work notice anything that indi-
cates changes in drug use or that a new substance is misused. These instances report
to the NIPH mainly through the Customs laboratory, the National Laboratory of
Forensic Science, the Department of Forensic Chemistry at the National Board of
Forensic Medicine and other smaller laboratories at hospitals and institutions who
carry out the analysis of the findings of the above mentioned units.
This chapter will give an overview of existing key partners and sources of infor-
mation being used in the line of work with detecting changes of drug use and drugs
in Sweden.
THE EXISTING DRUG INFORMATION SYSTEM
In Sweden there are a various range of instances involved in detecting and asses-
sing Emerging Drug Phenomena. The description below will focus on four of our
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1 The mission regarding the Penal Law on Narcotics is divided with the Medical Product Agency due to the fact that
some products are used only in addiction of narcotic drugs, which are due to the NIPH, and others can also be used
as medicine, which hence are due to the Medical Products Agency to guard and investigate. 
The National Consultation Working Group for Drugs Issues discusses and ana-
lyses the current drug situation on a general national and political level. Partners
of the networks are policy makers at the Ministry of Health and Social Affairs and
key informants from different professions, such as the NIPH, the Swedish Coun-
cil for Information on Alcohol and other Drugs, the Medical Product Agency, the
Office of the Prosecutor-General, the Police, the Customs, the National Labora-
tory of the Forensic Science and the Department of Forensic Chemistry at the Natio-
nal Board of Forensic Medicine.
The participants in the above mentioned networks have their own channels for
detecting, analysing and disseminating information. Thus, the networks include
networks themselves. Since these participants gather and detect different infor-
mation the important data will also derive from them and their line of work.
The main Swedish sources of information that gives access to data regarding
new drug phenomena are the forensic and toxicological departments, law enfor-
cement units, key informants (mainly health professionals and specific networks),
health, treatment and emergency facilities, correctional care, low threshold facili-
ties and youth welfare and prevention organisations, prevention of drug addiction
and counselling centres. Through these sources data on the following core indica-
tors are gathered:
 User: age, gender, geographical locality, methods of administration, quantity,
polydrug use, psychological effect and physical effects.
 Substance: chemical name, street name, physical appearance, logo/ brand name
and purity.
 Setting: belonging to a specific cultural area, retail price and perceived availa-
bility. 
Information of these core indicators is gathered on different occasions, with
different level of regularity and by diverse collection methods. Therefore, some of
the indicators are fed systematically while some are not. The main data collection
methods used in previous Drug Information System is quantitative epidemiologi-
cal studies, routine information systems and spontaneous notification. On special
occasion data is also collected trough focus groups.
PROSPECTS
Taking the results of the Euro TREND project into account some improvements
of the Swedish Drug Information System needs to be done to fulfil the needs of an
Early Information Function. Progress could be done regarding the data collection.
Previous structure lacks systematically collected data on some indicators. Espe-
cially on the user, e.g. on expected effects, the user’s opinion of the substance and
of his/her own use as well as on the users social and physical setting. The extrac-
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mayor networks concerning this issue. Behind each network are further functions
and networks with professionals that are collecting, assessing and disseminating
information.
Key partners involved in the existing drug information system in Sweden are:
 the Network for the Current situation of Drugs in Sweden (NADiS),
 the Swedish Council for Information on Alcohol and other Drugs system of
reporting about drugs (CRD-network),
 the Narcotic Network in Southern Sweden (NNSS),
 the National Consultation Working Group for Drugs Issues 
The NADiS network is administrated by NIPH with the aim to early detect,
collect and exchange information, knowledge and experience about new substan-
ces (with potential or record of drug abuse), old drugs that suddenly reappear on
the drug market and changes in drug use. The information exchange takes place on
a forum of discussion at a controlled website as well as at three meeting per year.
Each member evaluates their own data before putting it on the website and the data
is discussed and assessed by the group. NADiS consists of experts at national level
that, due to their profession, has an overview of their area of work. 
Members of the network are the Medical Products Agency, the Swedish Poisons
Information Center, the Swedish Council for Information on Alcohol and other
Drugs, the National Food Administration, the Customs and its Laboratory, the Cri-
minal Investigation Department of the National Police Board, the National Labo-
ratory of Forensic Science and the Department of Forensic Chemistry at the Natio-
nal Board of Forensic Medicine. The Social Services and the Health and Medical
care are represented by already mentioned laboratories but also by the CRD-net-
work, NNSS and other laboratories at hospitals and institutions.  
The CRD-network is aimed to examine trends and changes in the pattern of
substance abuse. Info is collected through a questionnaire twice a year from 225
reporters in 27 municipalities. Sources of information are the Social Services, the
Health and Medical care, the Correctional care, the Police and NGOs. The infor-
mation is analysed and disseminated to experts and the general public through a writ-
ten report. 
NNSS is a regional network aimed to discuss and analyse the drug situation in
southern Sweden. The network includes all different professions that somehow
come in contact with drug users or drug use. Information is collected, analysed
and disseminated and the information exchange takes place mainly at four meetings
per year. Members of the NNSS comes from e.g. the Health and Medical care
(including Needle exchange, Detoxification units and Treatment centers), Labora-
tories at Hospitals and Institutions, the Police, the Customs, the Social Services
(including Outpatient clinics) and the Correctional care. NIPH participates as 
observers.
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tion of information from existing sources of information also needs to be impro-
ved so that more data on new phenomenon that are, or could be, noticed by e.g. cor-
rectional care, low threshold facilities and the law enforcement units are taken into
account. Further, the system would advance with adding sources of information.
Data could be collected from users’ organisations and nightlife recreational cent-
res. It would also be interesting to introduce a cooperation that would give data
from drug users and their families/social environment. Internet would be a fruitful
source of information to cover, although it demands a lot of work doing so. 
There are no direct obstacles, either by policy makers or professional, for imple-
menting the theoretical model of an Early Information Function. A sufficient sys-
tem to quickly detect, assess and classify Emerging Drug Phenomena in order to
allow the production and dissemination of relevant information would be helpful
for Sweden as for any country. Nevertheless, the issue is more complex as there are
many aspects to take into account. There must be a balance between the resources
put in the system and the outcome. The Swedish Drug Information System has
been improved greatly the most recent years and is heading in the direction of an
Early Information Function. Sufficient information needed to fulfil the legislation
mentioned in the introduction is given through the existing Drug Information Sys-
tem, even though better information is always wanted. The implementation of an
Early Information Function is gradually on its way but will take time as effort will
be spent successively. 
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